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SAMENVATTING 
Ons onderzoek is gericht op de opbouw en afbraak van ATP in 
het hart en de mogelijkheid om deze processen medicamenteus te 
beinvloeden. Het hart is verplicht continu energie te leveren 
voor de contractie en ionenpompen. Voor de aanmaak van ATP is 
in het hart de oxydatieve fosforylering het meest belangrijke 
proces. Di t proces, dat o2 nodig heeft, wordt verstoord, 
indien de o2 vraag hager is dan het aanbod, zeals kan ontstaan 
bij een onvoldoende doorbloeding (ischemie). Dan kan ATP dalen 
door onvoldoende aanmaak, en adenosine en zijn catabolieten 
inosine, hypoxanthine, xanthine en urinezuur zullen in het 
effluent verschijnen. Het verlaagde ATP gehalte in de eel 
veroor·z.aakt verminderde contractie en verlaagde activiteit van 
diverse ionenpompen. Door dit laatste proces treden dan 
verstoringen op van de ionensamenstelling in de eel. Als 
gevolg daarvan wordt de stofwisseling gestoord en kunnen 
mernbraan beschadigingen ontstaan, met eventueel celdood als 
gevolg. 
In hoofdstuk 2 van dit proefschrift wordt een introductie 
gegeven met een literatuur overzicht betreffende het ATP 
metabolisrne in bet hart. Ook wordt aandacht geschonken aan de 
relatie ATP en celfunctie, 
huishouding. 
dit met betrekking tot de ca2+ 
In hoofdstuk 3 worden methoden en technieken ter bestudering 
van het ATP metabolisrne beschreven, met relatief veel aandacht 
voor een nieuwe techniek, de hoge druk vloeistof 
chrornatografie. Deze techniek maakt bet mogelijk om simultaan 
en geautomatiseerd myocardiale nucleotiden of nucleosiden en 
oxypurines in hartperfusaat te bepalen, dit in tegenstelling 
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tot de vroeger gebruikte enzymatische bepalingen. 
In hoofdstuk 4 wordt het ATP rnetabolisme beschreven, in 
relatie met de adenosinecatabolieten, die de celmernbraan kunnen 
passeren. Bepaling van deze stoffen buiten het hart kan dus 
een inzicht geven in het ATP rnetabolisrne binnen het hart. 
Specifieke aandacht wordt geschonken aan 
AMP-deaminase en xanthine oxydase/dehydrogenase. 
de enzymen 
In hoofdstuk 5 wordt een overzicht gegeven van de werking 
van ca 2+-antagonisten en beta-blockers op deze processen, zowel 
-ti jdens norrnoxie als ischemie. Het blijkt dat de 
ca2+-antagonisten nifedipine en diltiazem een ATP sparend 
effect hebben op het hart, wanneer deze toegediend worden voor 
of tijdens ischemie. In hoeverre dit te wijten (of te danken) 
is aan een negatief inotroop effect, wordt verder besproken. 
De beta-blokker DL-propranolol, toegediend voor ischernie in het 
geisoleerde rattehart, vertoont geen bescherrnende werking tegen 
ATP afbraak geinduceerd door ischemie, maar de cornbinatie van 
propranolol en nifedipine werkt nag effecttever dan nifedipine 
alleen. 
In hoo£dstuk 6 wordt de biosynthese van adenine- en 
guaninenucleotiden in het geisoleerde rattehart uiteengezet. 
Hypoxanthine wordt ingebouwd in adenine- en guanine nucleotiden 
en deze inbouw is versneld na ischernie en gedurende ribose 
infusie. Geconcludeerd wordt dat deze inbouw van hypoxanthine 
afhankelijk is van het fosforibosyl-pyrofosfaat (PRPP) gehalte 
in het hart. Inosine, de voorloper van hypoxanthine, wordt met 
gelijke snelheid omgezet in nucleotiden als hypoxanthine, 
hoewel de hoeveelheid inosine die door het hart wordt opgenomen 
twee maal zo groot is. Verrassend is echter het snelle hers tel 
van de lage ischemische ATP niveaus na perfusie met inosine. 
Dit snelle herstel kan niet verklaard worden uit de synthese 
snelheid van adenine nucleotiden uit inosine. Een verklaring 
hiervoor is nag niet gevonden. Een relatief grote hoeveelheid 
purines wordt in de GTP fractie ingebouwd (ca. 25% van die in 
de ATP fractie), hoewel de GTP concentratie ongeveer 30 rnaal 
lager is. 
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Het blijkt dat de concentratie van myocardiaal ATP een 
belangrijke parameter is voor de functie en overlevingkansen 
van de eel. ATP catabolisme tijdens ischemie kan verminderd 
worden door (voor)behandeling met calcium antagonisten, zoals 
nifedipine en diltiazern, en beta-blockers w.o. DL-propranolol. 
Verlaagde ATP spiegels na ischemie kunnen hersteld worden door 
toevoeging van een van de purines hypoxanthine en inosine, of 
ribose met een van de purines. Vooral het gunstige effect van 
inosine, hoewel even snel ingebouwd in ATP en GTP als 
hypoxanthine, 
de kliniek, 
lijkt veelbelovend en verdient verdere studie in 
omdat het naast farmacologische effecten 
(vaatverwijdend, positief inotroop) ook snel de verlaagde ATP 
niveaus in het hart kan herstellen. 
17 

SUMMARY 
The main points of interests of our research are the 
anabolism and catabolism of myocardial ATP and the 
possibilities to influence the processes pharmacologically. 
The heart cell is geared for continuous delivery of energy for 
contraction and ionic pumps. For the supply of myocardial ATP, 
oxidative phosphorylation is quantitatively the most important 
process. This process, which is fundamentally o 2-dependent, is 
disturbed, when o 2 demand is higher than 0 2 
hypoxia}. As a result, ATP levels will 
supply (ischemia or 
decrease, and the 
AMP-catabolites adenosine, inosine, hypoxanthine, xanthine and 
uric acid appear in the coronary effluent. The lowered ATP 
levels in the cell cause or reflect disturbances in contraction 
and the action of ionic pumps. Cellular ionic homeostasis is 
disturbed, 
dies. 
membrane damage can occur and ultimately the cell 
In chapter 2 of this thesis, a literature overview is gLven 
of the relation of ATP metabolism and cell function and 
survival. 
In chapter 3, methods and techniques, needed for the study 
of myocardial ATP metabolism, are discussed. Special attention 
is given to a technique, developed relatively recently: 
high-performance liquid chromatography. 
In chapter 4, ATP catabolism is discussed, in relation to 
adenosine and catabolite release into the coronary-venous 
system. 
fluid 
Determination of the purines in the extracellular 
gives continuously insight in intracellular ATP 
metabolism. Special attention is given to the enzymes 
AMP-deaminase and xanthine oxidase/dehydrogenase. 
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In chapter 5, the action of the calcium antagonists 
nifedipine and diltiazem is discussed. Also the role of the 
beta-blocker DL-propranolol on ischemic ATP catabolism and 
purine release in isolated perfused rat hearts is described. 
(Pre)treatment with the Ca 2+-antagonists protects the heart 
from ischemic ATP catabolism, while DL-propranolol shows no 
effect under the same conditions. The combination of 
DL-propranolol and nifedipine acts more effectively than 
nifedipine alone. 
ca2+_antagonists 
Whether this protective effect of 
(with or without propranolol) is due to their 
negative inotropic effect or to other mechanisms, is discussed. 
In chapter 6, the biosynthesis of adenine- and guanine 
nucleotides is discussed. Hypoxanthine is incorporated into 
adenine- and guanine nucleotides and this incorporation is 
accelerated after ischemia and during ribose infusion. We 
conclude from these observations that the hypoxanthine 
incorporation into myocardial nucleotides depends on the 
phosphoribosyl-pyrophosphate level in the heart. Inosine, as a 
precursor of hypoxanthine, is incorporated at the same rate as 
hypoxanthine, the uptake being twice as high. Ischemic ATP 
levels are restored much faster during reperfusion with inosine 
than could be accounted for by the measured incorporation rate. 
It seems that the level of myocardial ATP is an important 
parameter for cell function and survival. ATP catabolism 
during ischemia 
ca 2+-antagonists 
can be 
such 
diminished by 
as nifedipine 
(pre)treatment 
and diltiazem, 
with 
and 
beta-blockers such as DL-propranolol. Lowered ATP levels after 
ischemia can be restored by addition of the purines 
hypoxanthine and inosine. In particular the beneficial effects 
of inosine seem promising. It is incorporated into ATP and GTP 
at the same rate as hypoxanthine, but seems to restore 
post-ischemic ATP levels at a much higher rate. We suggest a 
further study of this compound in the clinical setting also 
because of its vasodilating and positive inotropic effects. 
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CHAPTER 1 AIM OF THE THESIS 
The heart is obliged to contract continuously. This 
implicates for a human with an average heart rate of 70 beats 
per minute in about 70 years more than 2.5 billions of 
contractions. For this contraction ATP is needed as the main 
substrate. As a consequence continuous ATP production by the 
heart is obligatory. This ATP is mainly produced by the 
oxygen-dependent oxidative phosphorylation. Disturbances of the 
oxygen delivery, such as that induced by partial occlusion of 
one or more coronary arteries can lead to a distortion of the 
balance between ATP production and consumption. As a res11lt, 
ATP is dephosphorylated, and subsequently the products 
adenosine, inosine, hypoxanthine, xanthine and uric acid pass 
the cellular membrane and appear in the coronary effluent. 
Because of the importance of adequate ~TP levels for the heart, 
the following 4 main ::.\'Venues have been investigated in this 
study, which forms the substance of my thesis. 
1. Assays have been developed for the 
high-energy phosphates in myocardial 
determination 
tissue and 
dephosphorylated degradation products adenosine and 
of 
its 
its 
catabolites inosine, hypoxanthine, xanthine and uric acid in 
the coronary effluent. The methods are based on a relatively 
new technique, high pressure liquid chromatography. 
2. Since ATP breakdown can continuously be monitored by the 
measurement of the release of adenosine and catabolites in the 
coronary effluent, the appearance of these catabolites has been 
evaluated as a biochemical marker of ischemia. 
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.3. Recently developed drugs have been shown to prevent or delay 
ischemic ATP breakdown. Studies with beta-blockers and calcium 
antagonists and their combination have been compared to 
elucidate their efficacy. 
4. It has been shown that diminished ATP levels after ischemia, 
due t,J release of adenosine and cataboli tes, can be restored by 
inosine or hypoxanthine infusion. 
been investigated. 
Regulatory mechanisms have 
In as much as the results of the experiments have mostly 
been published in the relevant literature, reprints of these 
papers are bundled in the appendix. In the following chapters 
of this thesis, these results are discussed and placed in a 
more general context. 
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CHAPTER.2 GENERAL INTRODUCTION: ATP METABOLISM IN THE MYOCYTE 
The function of the heart is to pump blood tbrough the 
organs of the body. The heart has to do this without a moment 
of rest. To achieve its task, a double-chambered hollow muscle 
propels the blood into the vascular system by means of 
contraction. The power needed for this function is evoked by 
shortening of striated muscle cells, the myocytes. The 
substrates and oxygen for these cells are provided by the 
coronary arteries, which are the first branches of the aorta, 
under a pressure of about 120 mm Hg in systole and about 70 mrn 
Hg during diastole. Removal of waste products occurs by way of 
the coronary venous system, which ends in the right atri1.1m, a 
low pressure system. The vasculature contains smooth muscle 
cells, whose tonus is regulated and which in turn determines 
the coronary flow. This is the most important mechanism for 
substrate provision to the myocytes. 
The substrates in the myocyte are oxidized to form ATP. 
Hydrolysis of this compound liberates and transforms chemical 
energy into mechanical energy, shortening of the fibers via 
actin/myosin interactions, as well as into electro-chemical 
energy for the ionic pumps, 
chemical bonds. 
or for the synthesis of other 
2.1 Energy metabolism of the myocyte 
In this paragraph a short review is given on ATP metabolism 
in the myocyte during three clinically important conditions, 
namely normoxia, ischemia and reperfusion. Special attention is 
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given to the significance of maintaining proper ATP levels in 
the heart. 
2.1.1 Normoxic metabolism 
In normoxic rnyocytes a balance exists between the production 
of ATP ;~nd its usage. About 90 % of the ATP is synthetized by 
oxidative phosphorylation in the mitochondria (see for a review 
[89]), and about 10% by anaerobic glycolysis [62]. Mitochondria 
are strictly dependent on o 2 [92, 93]; they mainly oxidize 
fatty acids and pyruvate, the latter arising from the anaerobic 
glycolysis of glucose, which takes place in the cytosol. A 
complex regulatory mechanism exists between fatty acid and 
carbohydrate metabolism [59, 60, 62, 63, 
adequate ATP supply. 
65, 83], to ensure 
ATP is used by the contractile apparatus; ionic pumps lil<e 
Na+ -K+ATPase and ca2+ATPase in sarcolemma aad ca2+;~TPase in the 
s:::~.rcoplasmatic reticulum (SR) and biosyntheti..c processes .. About 
80% of the ATP synthetized is used by the contractile 
apparat11s. This is about 1 p.mol per gram dry weight (1-J.mol/g 
dwt) AT? per beat [23, 61] or about 5% of the ATP content in 
each cell. It has been shown, by [ 31P]-nuclear magnetic 
resonance techniques, that ATP and creatine phosphate (CrP) 
levels fluctuate about 20% during the systole-diastole cycle in 
isolated, perfused rat hearts [18]. It has been postulated that 
the energy produced by the mitochondria is predominantly used 
by the contractile apparatus [34, 67, 72, 77]. This energy is 
transported from mitochondria to the contractile apparatus by 
CrP {for a review see [5]). The energy produced by anaerobic 
glycolysis is thought to be used by ionic 
phosphorylation reactions [65, 
schematically presented. 
83]. In 
pumps 
fig. 
In the normoxic cell, the respiratory 
and 
2.1 
rate 
membrane 
this is 
of the 
mitochondria is regulated by the ADP and Pi availability, i.e., 
the ADP and Pi genernted during con-traction regulates the 
respiratory rate of the cell. As a consequence ATP synthesis is 
in balance with its consumption [82]. 
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glycolysis 
........_ 
ADP ATP 
~ ....... 
[§] [§Q 
.......... 
.....,_ 
Cr CrP CrP Cr 
~ lilliltittiliJ' 
~ ~ 
.....,_ ........_ 
ATP ADP ADP ATP 
lilliltittiliJ' ....... 
contraction ionic pumps 
Fig 2.1. "Energy flows" in the myocyte during normoxia. 
In the left part of the figure, energy derived from the oxidative 
phosphorylation in the mitochondria is shown to be transported to the 
myofibrils, while the energy derived from the glycolysis is used by ionic pumps. 
CK-1, CK-II and CK-III are different forms of creatine kinase. 
Contraction is evoked by the amount of free ca 2+ in the 
cell. This amount is regulated by a voltage dependent ca2+-flux 
through the sarcolemma, a redistribution of intracellular ca 2+, 
and a removal of ca2+ by several ca 2+ pumps in sarcolemma and 
SR [14, 47, 56]. This ca 2+-dependent contraction is mediated by 
c-AMP through changed Ca 2+ sensitivity of the contractile 
apparatus [54, 75] and changed Ca 2+ influx by phosphorylation 
of several membrane proteins. Whether this last process is 
mediated by changes in the glycocalix, the glycoprotein coat of 
the sarcolemma, is still a matter of debate [48]. 
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2.1.2 Ischemic metabolism 
Ischemia can be defined as a situation, where coronary blood 
flow (and hence oxygen and substrate supply, and carbon dioxide 
and metabolite removal) cannot meet the tissue demand [30, 50]. 
As a consequence of this lower o 2 supply vs demand, 
mitochondrial function is restricted [93]. The balance between 
ATP production and usage is disturbed, CrP levels fall, 
followed by a decline in ATP [8, 10, 32, 35, 44, 68, 78]. 
Mitochondrial ATP production (fig. 2. 2) is impaired, the 
turnover rate declines and 
( Cr) , ADP, phosphate and 
contractility decreases. 
a+ levels increase [21, 
Creatine 
25, 27], 
glycolysis rate is enhanced [1, 61, 74] and lactate levels rise. 
The anaerobic ATP production, however, is insufficient to 
meet the amount of ATP needed for contraction [25]. Whether the 
fall in contractility is caused by a fall in ATP [25], an 
increase of a+ [6, 13, 41, 61] or a decrease in the phosphate 
potential (=[ATP]/[ADP][Pi]) [40] is unknown at the moment. One 
of the problems hampering this investigation relates to the 
compartmentalization of ATP and the interdependence of several 
parameters. For example, 
decrease in phosphate 
a fall in ATP or 
potential and 
CrP would 
an increase 
cause a 
of H+, 
therefore rendering the interpretation difficult. 
When ATP levels decrease, cellular ADP levels increase. ADP 
is converted to ATP and AMP, by the action of adenylate kinase. 
AMP is deaminated to IMP, or dephosphorylated to adenosine, 
which is further catabolized to inosine and hypoxanthine. These 
components pass the cell membrane (a.o [9, 11, 12, 36, 66, 80, 
84]), where adenosine acts as a vasodilator [4, 64, 80]. A 
slight decrease of ATP therefore results in an immediate rise 
in AMP-catabolites [86, 93]. This release can be used to 
monitor myocardial ATP-breakdowni this aspect will be discussed 
in more detail in chapter 4. 
As a result of, or paralleled by, the fall of ATP, 
intracellular ionic homeostasis is disturbed by impairment of 
ionic pumps. Cellular Na+ increases and K+ decreases [52, 71]. 
Oedema occurs, membranes are damaged and enzymes leak from the 
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Fig. 2.2. A schematic view of an ischemic myocyte. 
Due to impaired o 2 supply, mitochondrial function is disturbed. CrP levels fall, 
and Cr and H+ and Pi raise, since ATP demand of the myofibrils continues. 
Subsequently ATP decreases and ADP and AMP increase. The latter is broken down 
to adenosine and catabolites. Glycolysis can be enhanced, but will be slowed due 
to increased lactate or H+ levels (see also legends to fig. 2.1). 
cytosol and enter the blood stream. A slight increase in 
intracellular ca2+ is seen [58, 81]. Also the long-chain fatty 
acid ester [60] and the acyl-carnitine ester [68] concentration 
increase, which can further deteri..orate cellular function, with 
distortion of membrane structures [31, 42, 51] or inhibition of 
enzyme systems [46, 60, 65]. At a certain point the cell is 
irreversibly damaged, i.e., cellular functions are not restored 
during reperfusion and the cell dies. The onset of irreversible 
ischemic damage is associated with markedly depleted ATP 
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levels, cessation of glycolysis, depletion of glycogen and 
ultrastructural changes such as gaps in the sarcolemma, 
severely distorted mitochondria and a disorganized contractile 
apparatus [1, 20, 37, 44, 55, 71, 78]. 
2.1.3 Metabolism during reperfusion 
During reperfusion, cells are reoxygenated and waste 
products removed. 
induces an enhanced 
After reversible ischemia, reperfusion 
ca 2+ influx, mitochondria are activated and 
ATP and CrP are again produced [26, 33, 53]. The latter 
compound is transported to the myofibrils (fig. 2.3). Because 
glycolysis 
ADP ATP 
.....,... 
~ 
...... 
......... Cr CrP CrP Cr 
~ .....,... 
C§:Q ~ 
....., 
...... 
ATP ADP' 
• AMP 
ADP ATP 
~ 
contraction ionic pumps 
Fig 2.3. A schematic view of a reperfused myocyte. 
During reperfusion the o 2 supply is restored, and the mitochondria start to 
produce ATP. Because myofibrillar ATP consumption is still disturbed, CrP may 
increase to levels above normal {see also legend to fig. 2.1). 
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of ionogenic disturbances in the cell, contraction is still 
decreased at this 
concentrations in the 
stage probably due to disturbed ca2+ 
cell [69]. This can be demonstrated by an 
increased ventricular wall tension [2, 24, 49], indicating an 
increased ca 2+ level, and an increased CrP even to levels 
higher than the normal range [3, 17, 78 and appendix papers 6 
and 8]. This indicates that ATP consumption by contraction is 
at this state below ATP production. After activation of the 
ionic pumps, cellular homeostasis is restored and the cell 
starts beating again. ATP levels will remain subnormal, because 
of washout of the ill..MP-catabolites during ischemia and the early 
phase of reperfusion (as indicated in chapter 4 and 
demonstrated by others [9, 11, 12, 36, 70, 84, 85, 88, 90]). 
Although the cell is able to function, it seems that these low 
ATP levels cause an extra risk in as much as a critically low 
ATP level will be reached earlier during the next ischemic 
attac~ [7, 22, 45, 73]. 
After irreversible ischemia, a massive Ca 2+ influx parallels 
or causes an extension of ultrastructural damage, involving the 
development or intensification of contracture, activation of 
proteases and other hydrolases, disruption of myofibrils and 
sarcolemma, explosive cell swelling, rupture and loss of 
mitochondrial structure and the appearance 
intra-mitochondrial calciumphosphate particles [20, 
78]. 
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The amount of ca2+ influx during reperfusion is an important 
determinant for myocardial cell survival [15, 16, 43, 56, 57]. 
This influx is coupled to mitochondrial function [28, 76]. 
Reactivation of mitochondrial function restores the normal 
existing proton gradient over the inner membrane. It is likely 
that this triggers a cellular Ca 2+ movement, which causes 
sarcolemmal membrane damage. The precise mechanisrn{s) however, 
rernain(s) to be elucidated. There is a striking correlation 
between the cytosol Ca 2+ during reperfusion and the ATP levels 
at the end of the ischemic period [15, 57]. Whether changes in 
the basement membrane play a role as they do during the 
Ca-paradox [95], is also still unknown [19, 28]. 
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2.2 The significance of A.T? in the myocyte 
The importance of maintaining adequate ATP levels is 
indicated in several papers [29, 30, 38, 57, 74, 78, 87, 88, 
91], where a good correlation was found between myocardial ATP 
levels at the end of an ischemic period and recovery of cell 
function during the subsequent reperfusion phase. 
Ischemic ATP breakdown is a time-dependent process [27]. It 
is therefore of utmost importance to reperfuse the myocardium 
as fast as possible after ischemia. If the cell is completely 
devoid of ATP, cell death is inevitable. Because ischemia is a 
condition in which ATP levels are decreased, an important 
mechanism of maintaining ATP levels is to reduce ATP demand. 
ca2+-antagonists in particular, but also beta-blockers or their 
combination, seem suitable for this 
further discussed in chapter 5. Another 
purpose. This will be 
way of reducing ATP 
consumption can be achieved by lowering the myocardial 
temperature [57], thereby slowing down all biochemical 
processes, including ATP breakdown. 
At present there is no substantial evidence, that calcium 
antagonists restore cell survival by lowering the ca2+-influx 
during reperfusion~ this has been incompletely studied [79]. 
After reperfusion, reduced levels of ATP are restored by its 
biosynthesis. Several mechanisms are found to be involved as 
discussed in chapter 6. It is possible to enhance ATP synthesis 
with inosine [94 and appendix paper 8]. Current knowledge 
encourages future investigation on this topic in a clinical 
setting. 
2.3 Conclusions 
From this literature review, the following conclusions can 
be drawn: 
It is beyond doubt, that the concentration of ATP (and its 
catabolites) is an important regulatory factor in the myocyte. 
For instance, a lot of enzymes needed in the sequence of ATP 
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catabolism are inhibited by high levels of ATP. Due to 
ischemia, a fall in ATP causes or parallels several undesirable 
effects, such as a fall in contractility and disturbed ionic 
homeostasis. The direct correlation between ATP concentration 
and disturbed cellular function is hampered by ATP 
compartmentalization. However, linear correlations between ATP 
concentration at the end of the ischemic period and the 
possibility to restore the cellular function during reperfusion 
indicate its significance. As a consequence of the importance 
to maintain proper ATP levels in the heart, measures must be 
taken to reduce its catabolism and low ATP levels after 
ischemia must be restored as quickly as possible. 
CrP is thought to be the "energy carrier 11 from the 
mitochondria to the myofibrils. A fall in CrP and a rise in Pi 
indicate a disturbance of this transfer and probably precedes 
the fall in contractility. During reperfusion, it seems to 
indicate the restoration of the mitochondrial function and can 
therefore be used as a marker for the function and survival of 
the heart during the reperfusion phase. 
Because ATP and CrP have to be measured in the heart, a 
process which is difficult to realize in the clinical setting, 
any reflection of these myocardial compounds at the outside of 
the heart is desirable. Measurements of the dephosphorylated 
ATP catabolites adenosine, inosine, (hypo)xanthine and uric 
acid seem to fullfill this criterion. 
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CHAPTER 3 METHODS 
3.1. The Langendorf£ preparation 
To investigate myocardial ATP metabolism, the isolated rat 
heart has been studied. In the preparation, first described by 
Langendorf£ in 1895 [10], the isolated rat heart was attached 
to the perfusion apparatus at the aorta (see fig. 3.1) [3,12]. 
In our set up, the aorta was perfused retrogradely with a 
pressure of 72 rnm Hg. This pressure ensured sufficient 
perfusion of the coronary system in a normal direction. The 
perfusate fluid consisted of a salt buffer [13], enriched with 
10 ::n..rnol/1 glucose. The buffer was kept at a temperature of 37 
°C and was ventilated with an oxygen/carbon dioxide (95:5, v:v) 
mixture. The coronary effluent dripped from the heart and was 
collected continuously. In the perfusate, adenosine, inosine, 
hypoxanthine, xanthine, Uric acid and lactate were assayed 
[appendix paper 1]. The hearts beated at a spontaneous 
frequency between 240 and 320 bpm. As a st3.ndard procedure, the 
bundle of His was severed, and as a result the frequency fell 
to about 60 bpm. Thereafter the hearts were paced at a constant 
rate of 300 or 360 bpm. 
In this preparation the aortic valve was closed, so the left 
ventricle was (nearly) empty and did not deliver external pump 
work. According to Neely [16] and Opie [17], glucose metabolism 
and contractility is proportional with perfusion pressure, 
i.e., work delivered by this preparation is dependent on 
perfusion pressure. As an indicator of the mechanical behaviour 
of the hear-t, apex displacement was measured [14, 21]. In this 
preparation, the heart contracts isotonically. Starn and De Jong 
39 
H -... _, 
·• 
4 
... 
APEX Dl SPLACEMENT 
TENSION DEVELOPMENT 
+drug 
.,.._ TEMPERATURE 
CONTROL 
PACING 
Fig 3.1. Schematic diagram of a perfusion apparatus. 
The rat heart is attached to the canula via the aorta. H perfusion height. 
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Fig 3.2. The influence of the perfusion pressure on developed tension and apex 
displacement. 
Isolated rat hearts were perfused with a modified Tyrode solution, equilibrated 
with 95% o2 and 5% co2 . The hearts were paced at 300 bpm. Developed tension 
{upper panel) was measured with a pressure transducer, connected to the apex of 
the heart and monitored with a Brush recorder. Before ischemia the hearts were 
adjusted to a resting tension of about 12 g. Apex displacement (lower panel) was 
measured with a displacement transducer, fitted with a steel tampon, hooked to 
the apex of the ventricle and monitored on a Brush recorder. The values found at 
72 mm Hg were taken as 100% {x), n = 3. 
{Experiments were performed by Dr. J.W. de Jong and Mr. P.Ph. de Tombe.) 
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[21] had shown, that at a fixed perfusion pressure, a good 
correlation exists between apex displacement and left 
ventricular pressure. Apex displacement during normoxia, 
however, was slightly influenced by the perfusion pressure 
(fig. 3.2}. Increased perfusion pressure resulted in a decrease 
in apex displacement, while contractility is known to increase 
during this condition [16, 17]. 
In some experiments, developed tension was considered to 
reflect myocardial function [15]. In this situation the heart 
contracts isometrically. Resting tension is set at about 10 g~ 
a normoxic heart develops about 35 g. In fig. 3.2 is shown that 
during normoxia an increase in perfusion pressure gives an 
enhancement of developed tension. It seemed therefore that in 
experiments in which perfusion pressure had to be changed, 
developed tension is a more suitable measure for contractility 
than apex displacement. 
Ischemia in the Langendorf£ heart was induced by lowering 
the flow to about 20% of control flow, either by decreasing the 
perfusion pressure or by restriction of the flow. To ensure a 
good te~perature control, temperature of the perfusion buffer 
was measured in the canula. The temperature of the perfusion 
buffer was regulated by means of a feed-back control with a 
electric heating coil (fig. 3.1). This device gave us the 
possibility to keep the temperature fixed at 37 °c, even at 
a low flow rate. 
Coronary flow was determined by timed collection of the 
perfusate. At the end of the perfusion experiment, hearts were 
clamped between two alumina blocks (Wollenberger clamps}, 
precooled in liquid nitrogen. Nucleotides and CrP were assayed 
as described in appendix paper 2. 
3.2 High-performance liquid chromatography 
Chromatography is a separation technique, developed by 
Tswett in 1903, who used a chalk column to separate pigments in 
green leaves. The principle of chromatography is based upon 
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dynamic distribution of compounds 
moving phase (the column eluent) and a 
(from a sample) between a 
stationary phase {the 
column packing material). When flow rates, necessary to elute 
the column, produce a pressure exceeding 20 bare, it is called 
high-performance liquid chromatography (HPLC). This increase in 
pressure was needed because the particle size of the column 
ma·terial was decreased to obtain better separation 
characteristics. An HPLC system consists of one or more pumps 
to force the mobile phase through the column, an injector to 
apply the sample to the column, the stationary 
positioned in a column, one or more detectors, recorders and 
electronic integrators (see fig. 3.3). The type of column, in 
combination with the buffer( s), used for elu·t.ion, determines 
the separation of the compounds in the sample. The separation 
is a function of the particle size of the column packing, the 
composition of the elution buffer, and the flow. 
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Fig. 3.3. Schematic diagram of a high-pressure liquid chromatograph. 
A and B are elution buffers of different composition. 
B 
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We have used two types of columns. The first column is 
filled with apolar material 
10 pm). This type of column 
(particles with a diameter of about 
is suitable for separations of 
apolar compounds such as adenosine and other ca·taboli tes. The 
other type of column is filled with polar particles of a strong 
anion exchanger for the separation of the polar high-energy 
phosphates in the myocardium. 
3.2.1 Adenosine(catabolites) determination 
Adenosine, inosine, hypoxanthine, xanthine and uric acid 
were separated on a c18-~Bondapak reversed phase column. The 
eluent con·tained 3 to 10% methanol, with flow rates between 1 
and 3 ml/min [see appendix papers 1 and 5]. Samples must be 
deproteinized to maintain a proper column function [4]. Rat 
heart perfusates were directly injected onto the HPLC system 
(200 pl) and peaks were detected at 254 nm. The minimal 
detectable concentration of the adenosine(catabolites) was 
about 18 nM. Analysis time was 25 min and the whole system was 
automated. 
For determination of these compounds in blood, the procedure 
was more complicated. In appendix paper l we have shown, that 
during the preparation of plasma, hypoxanthine and xanthine 
levels increase 2 to 5 times. When serum was prepared, 
adenosine, inosine, hypoxanthine and xanthine levels increased 
up to 20 times (fig 3.4). This implies catabolism of ATP and 
GTP from erythrocytes and platelets during sample preparation 
[7,25]. This has recently been confirmed [2, 6]. We decided to 
deproteinize whole blood with cold perchloric acid as described 
by Remme et al. [19] to stop nucleotide breakdown. Nucleotides 
interfered with the HPLC separation and were removed by alumina 
oxide (appendix paper 1). Minimal detectable concentrations of 
purines in whole blood are 100 nM, with a sample loop of 200 
~1; HPLC analysis time is about 1 h. Per column, 200-500 
analyses can be performed. 
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Fig 3.4. Concentration of adenosine and catabolites in human blood, plasma and 
serum. 
The purines were measured by HPLC as described in appendix paper 1. Data 
represent mean values :± SE of 5-6 non-resting volunt-eers * P<O.Ol vs blood, 
•P<O.QS vs plasma [21]. 
3.2.2 High-energy phosphate determination 
Myocardial high-energy phosphates were determined on a 
Partisil SAX-10 column. Because of large differences in 
polarity between AMP and ATP, gradient elution was necessary. 
Within 30 min AMP, ADP, ATP, GMP, GDP, GTP, Cr, CrP, and NAD+ 
can be separated and quantitated in heart extract as described 
in appendix paper 2. Fifty to 250 analyses can be performed per 
column. We have also used this technique for the determination 
of nucleotides in liver, kidney and adipose tissue. We adapted 
this system for determination of adenine nucleotides and CrP in 
heart biopsies as small as 5 mg wet weight(= about l rng 
protein). In this case about 1 pmol nucleotide/ g protein can 
be detected, detection limits were about 1 pmol nucleotide/g 
protein. Control values of ATP in pig heart biopsies were found 
to be comparable with the values found in isolated rat hearts, 
which were freeze clamped [22]. 
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3.2.3 Special applications of HPLC 
1. Radiolabeled compounds have been injected onto the HPLC 
system, subsequen·tly the separated products were collected 
after detection. [20 and appendix paper 1]. 
2. Enzyme reactions have been followed by monitoring decreasing 
substrate concen·tration and increased product concentration [9, 
20]. 
3. It proved possible to collect an eluent fraction after 
ion-exchange HPLC and inject it onto a reverse phase column. If 
this fraction was collected in a sample loop, it could directly 
be injected to an other column ("column cutting"). An example 
for this technique is the assay of S-adenosyl-hornocysteine [1]. 
4. Application of the fluorimeter as a detector gave the 
possibility to selectively detect compounds in a complex 
mixture [5, 8]. 
For example, direct injection of 100 pl urine onto a reversed 
phase column, with fluorescence detection at 440 nm (excitation 
260 nm) resulted in only 2 peaks within 5 min, one being 
riboflavine. Concentrations of 1 nM could easily be detected 
[De Tombe, personal communication]. Detection of riboflavine in 
urine is important, for instance when riboflavine is used as a 
tracer compound in drugs to test the compliance. 
5. Detection of drugs in plasma can easily be achieved with 
minor sample preparation [8]. 
verapamil [24], nifedipine [18], 
For example, HPLC assays for 
diltiazem [23], propranolol 
and catabolites [11] in plasma have been published. 
3.3. Conclusions 
The isolated rat heart, perfused according to Langendorf£, 
provides a system to study metabolic processes. Although no 
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pump work is performed, the preparation contrac·ts and therefore 
ATP is used by myofibrils. Contractility, however, is difficult 
to measure. Apex displacement can easily be obtained and during 
constant perfusion pressure a good correlation was shown 
between apex displacement and left ventricular pressure. When 
differences in contractility during changes of the perfusion 
pressure must be established, the measurement of developed 
tension seems more appropriate. 
HPLC is a flexible technique to determine several compounds 
in biological matrices. The system is easily automated, several 
compounds can be detected within one run, and also parts of the 
chromatogram which are not used for compound quan·titation, can 
be used as a visual check in the course of the analysis. 
Commonly samples must be purified, in which case one makes sure 
that the compounds to be determined are indeed recovered. 
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CHAPTER 4 MYOCARDIAL ATP CATABOLISM 
In this chapter, the literature about the enzymes which are 
involved with the catabolism of ATP in the heart is reviewed. 
Furthermore, some experiments are discussed, which show the 
relation between ischemia and the dephosphorylated ATP 
catabolites, recovered in the perfusate. Subsequently, the 
adequacy of purine release as a marker of ischemia in humans is 
discussed. 
4.1 Introduction 
During ischemia the balance which exists between ATP 
formation and ATP breakdown is disturbed. Mitochondria consume 
oxygen. When the p0 2 is lowered, mitochondria may conserve all 
o 2 available, and oxidative phosphorylation stops. Anaerobic 
glycolysis is enhanced and lactate is produced, but this 
pathway does not produce enough ATP. As a consequence, a fast 
decline in CrP is observed, concomitant with a slower decline 
of ATP. Simultaneously, P1 , ADP, AMP and IMP accumulate in the 
heart [1, 9, 17, 33, 41, 42, 86]. This process is schematically 
depicted in fig. 4.1. The rnononucleotides AMP and IMP are 
dephosphorylated to adenosine and inosine, respectively [9, 28, 
63, 84]. These purines are released into the venous coronary 
system [10, 19-22, 31, 44, 46-48, 53, 77-79]. Further breakdown 
of these purines to hypoxanthine, xanthine and uric acid can 
also take place in the heart [9, 20, 58, 67, 68, 76, 78, 81, 82 
and appendix papers 5-8]. In the next paragraph a discussion of 
the enzymes is presented, which are intimately involved in the 
catabolism of ATP up to uric acid or allantoin. 
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1 = adenylate kinase, 2 = AMP-deaminase, 3 = 5' nucleotidase, 4 adenosine 
deaminase, 5 nucleoside phosphorylase, 6a = xanthine oxidase, 6b = xanthine 
dehydrogenase, 7 = uricase. These enzymes are discussed in chapter 4. A 
ATP-consuming process~s, such as contraction and ionic pumps. B = ATP-forming 
processes, such as oxidative phosphorylation and glycolysis. C PPi-forming 
enzymes (for instance, PRPP synthetase or adenylate cyclase). D = SAH-hydrolase. 
4.2.1 Adenylate kinase 
The enzyme adenylate kinase (AdK) 
equilibrium: 
catalyzes the 
2 ~DP <====> ATP + AMP 
following 
A rise in ADP levels during ischemia or hypoxia will shift the 
equilibrium towards the formation of ATP and AMP. Two AdK 
isoenzymes have been reported for heart, one in the 
mi tochond:cia, the other in the cytosol [61, 92]. Disturbances 
of oxidative phosphorylation will increase ADP levels near the 
mitochondrion, where the first AdK might function to lower the 
raised ADP concentration [29]. This reaction is thought to be 
one of the major cellular reactions which stabilize and 
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maximize the so-called energy charge, (ATP + 0.5 ADP)/(ATP + 
ADP + AMP) [7]. Arch and Newsholme [6] attribute to AdK the 
role of biological amplifier, because a relatively small ATP 
decline will bring about a manifold rise in AMP concentration. 
This is important in, 
glycolysis. 
for example, the regulation of 
The cytosolic AdK form is thought to play a role in the 
reve~se reaction, to transfer AMP into ADP. This isoenzyme is 
inhibited by high AMP concentrations ( > l rnM) and thereby 
spares the use of ATP during this condition. Only after severe 
ischemia or hypoxia, can high AMP concentration be expected [39 
and appendix paper 2]. 
4.2.2 AMP-deaminase 
AMP which is formed by way of AdK can be dearninated to IMP 
by the enzyme AMP-deaminase [AMP-D]. NH 3 is released in this 
reaction. 
AMP ~ IMP + NH 3 
IMP is the common point between the de novo nucleotide 
synthesis and hypoxanthine salvage; both reactions are involved 
in ATP and GTP biosynthesis (see 
important regulatory properties 
chapter 6) and may have 
[30]. The NH3 formed may 
stimulate the glycolysis [45]. AMP-Dis another enzyme which 
elevates the energy charge of the cell. Although by this 
reaction total adenine nucleotide levels are decreased, the IMP 
formed is not lost from the heart and can eventually be 
reincorporated into the adenine nucleotide pool. 
Currently, controversy exists about the exact mechanism 
which regulates AMP-D activity. ATP, ADP, K+, Mg 2+ and CrP may 
all play a role in this context [14, 43]. 
We have purified the enzyme AMP-D from pig skeletal and 
heart muscle, to get an insight into the importance of this 
enzyme, especially in heart tissue [appendix paper 3]. In 
skeletal muscle we found AMP-D to be present in a larger 
amount, more active and with a higher Vmax and a lower Km than 
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the pig heart enzyme. In skeletal muscle a low molecular weight 
inhibitor is present, which can be removed by Sephadex column 
chromatography. This may indicate the relative importance of 
the enzyme in skeletal muscle compared to myocardium. Both 
purified enzymes are found to be regulated by the energy charge 
[see appendix paper 3]. From this study we conclude, that in 
the heart the enzyme is present, but during norrnoxia it will 
not play an important role. During ischemia or anoxia, however, 
this enzyme is activated and a substantial part of the AMP can 
form IMP, which in turn can be be deaminated to 
deQbosphorylated to inosine. This is in accordance with 
findings of Achterberg and De Jong [2], who stated that part of 
the inosine released by the heart is not derived from 
adenosine. 
4.2.3 5'-Nucleotidase 
Apart from deamination to IMP, AMP can be broken down to 
adenosine by dephosphorylation according to the following 
equation: 
AMP ~adenosine + Pi 
Dephosphorylation of AMP by aspecific phosphatase plays a minor 
role in this process [79]. This process also increases the 
energy charge, but in this case the end product can leave the 
heart. Two forms of 5' nucleotidase (S'N) exist, namely ecto-
and endo-S'N. Ecto-S'N is a membrane-bound enzyme. AMP is the 
preferred substrate; the enzyme exerts its action on the 
outside of the cell. Extracellular AMP probably is produced by 
breakdown of extracellular c-AMP and/or ATP, the last compound 
being released by the heart in minute concentrations (< 50 nM) 
as a physiological vasodilator [16, 69, 79, 83]. The 
extracellular adenosine formed by ecto-5 1 N is thought to be 
taken up by the heart and rephosphorylated by adenosine kinase 
into intracellular AMP [25, 32, but see 73]. 
Endo-S'N is a cytosolic and soluble enzyme. It shows less 
substrate specificity than the ecto-form. It dephosphorylates 
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AMP, IMP, GMP and XMP to their nucleosides. Endo-5'N has a low 
Krn for AMP (between 20 and 30 ~M), is Mg 2+ dependent and 
inhibited by ATP [79]. It is thought that AMP formed by anoxic 
ATP breakdown, is predominantly broken down by endo-5'N [51, 
55, 79]. 
Recently, Lamers et al. [50] purified two 5'N isoenzymes 
from rat heart sarcolemma, one having the characteristics of 
the ecto-S'N, the other having endo-S'N characteristics. 
The metabolic fate of cytosolic AMP is dependent on the 
relative activity of endo-S'N and AMP-D. In the myocardium from 
several species, a tremendous variation between the activities 
of these two enzymes can be found [55]. Burger and Lowenstein 
[14] stated that in rat heart AMP is predominantly 
dephosphorylated. However, studies in our laboratory seem to 
indicate the importance of deamination [2]. In control and 
ischemic rat hearts IMP concentrations remain low [38, 66, 84]. 
It is likely that IMP formed from AMP is directly converted to 
AMP or GMP, or dephosphorylated to inosine. 
Adenosine, formed by AMP dephosphorylation, is transported 
from the cytosol to the extracellular space and the coronary 
venous system. Adenosine is a strong vasodilator and is thought 
to be involved in the autoregulation of the heart [10, 44, 54, 
62, 79]. Autoregulation is a process, by which a larger 0 2 
demand of the heart is reflected by an increase in coronary 
flow. In this respect, the papers of Nutinen et al. [60] and 
Thompson et al. [85] are interesting. They describe the 
relation between the o 2 need of the mitochondria and the 
adenosine production in the heart. However, recently conditions 
were found, in which increased flow is not correlated with 
increased adenosine concentration [23, 49]. These a11thors 
conclude from their studies that adenosine is not the only 
metabolic factor responsible for coronary vasodilation. 
Adenosine influences c-AMP dependent processes, either by 
direct modulation of the adenylate cyclase system or by way of 
purinergic receptors. Adenosine also inhibits the 
voltage-dependent ca2+-influx, which could explain the 
cardia-depressant effects of high doses of adenosine [27, 71]. 
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4.2.4 Adenosine dearninase 
The enzyme adenosine dearninase (ADA) is widely distributed. 
It is found in myocytes, interstitium, epithelial cells, blood 
and blood cells and catalyzes the following reaction [18, 57, 
70, 72, 88]: 
adenosine ~inosine + NH3 
Because of of ADA activity in the above mentioned compartments, 
adenosine concentrations are low. Olsson et al. [64] speculate 
that in normoxic hearts, most of the cellular adenosine is 
bound to the enzyme BAH-hydrolase. 
4.2.5 Nucleoside phosphorylase 
Nucleoside phosphorylase 
equilibrium: 
(NP) catalyzes the following 
pi 
inosine ~ hypoxanthine + ribose-1-phosphate 
NP is found in epithelial cells, blood and blood cells [57, 70, 
7 2, 88]. It is not found in myocardial cells. Therefore the 
production of hypoxan-thine mainly occurs in the vessel walls 
and the blood. Hypoxanthine can be reutilized by the cells to 
form IMP, while inosine cannot (see chapter 6). 
4.2.6 Xanthine oxidase/dehydrogenase 
The enzyme wich catalyzes the conversion of hypoxanthine to 
uric acid appears in two different forms. One form uses 0 2 as 
an electron acceptor and produces radicals (xanthine oxidase 
( XO) ) , the other form uses NAD+ as electron acceptor and forms 
NADH (xanthine dehydrogenase (XD) [8, 76]). 
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The enzyme is found in large amounts in the liver but also 
in small amounts in the heart [51, 76], probably situated in or 
on the epithelial cells [12]. It exists mainly in the 
dehydrogenase form [8, 76], but can be converted to its oxidase 
form under certain conditions [74]. 
Surprisingly, XO is also found in large amounts in bovine 
milk. In 1950 Oster claimed that drinking of homogenized milk 
increases blood XO activity. These increased levels of blood XO 
are thought to cause epithelial damage in the coronary 
arteries, which could start the atherosclerotic process [for a 
review, 15]. Although this theory is highly speculative, we 
found in our laboratory that milk XO can be absorbed from the 
intestinal tract in the blood. Also, incubation of heart 
homogenates with XO produces depletion of plasmalogen, a 
phospholipid constituent of cell membrane [75]. Production of 
superoxide radicals by XO, eitheL derived from milk or from 
conversion of heart XD, may also lead to membrane damage [74]. 
Most investigators ignore the existence of XO/XD in heart 
tissue, and assume that hypoxanthine is the end product of 
myocardial ATP 
1961, Benson 
breakdown [10, 66, 77]. However, already in 
et al. [9] detected xanthine in the myocardium. 
Furthermore myocardial xanthine and uric acid release is shown 
by several authors [1, 20, 38, 68, 76 and appendix papers 5-8]. 
We found that in a normoxic rat heart over 70% of the purine 
release consists of uric acid. During ischemia this percentage 
falls to about 20% (see fig 4.2). 
4.2.7 Uricase 
In primates, including man, and in the dalmatian dog, uric 
acid is the end product of nucleotide catabolism [26]. It is 
excreted by the kidneys [35]. In all other mammals uric acid is 
converted to allantoin. In rat heart no allantoin release is 
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Fig. 4.2. Myocardial nucleoside release during normoxia, ischemia and 
reperfusion. 
Isolated rat hearts were retrogradely perfused with a modified Tyrode solution, 
gassed with 95% o 2 and 5% co2 , pH ~ 7.4. Heartrate = 300 bpm, perfusion pressure 
during normoxia and reperfusion = 70 mm Hg, and during ischemia 15 mm Hg. 
Nucleosides were determined in the coronary effluent by HPLC. •---• 
concentration in the coronary effluent (pmol/1). o---o =amount released by the 
heart (nmol/min/g dwt). In the right part of the figure are plotted the 
oxypurines hypoxanthine (Hx), xanthine (X) and uric acid (UA) and in the left 
part of the figure the nucleosides adenosine (Ado) and inosine (Ina). 
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Myocardial nucleoside release during normoxia, ischemia and 
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gassed with 95% o 2 and 5% co2 , pH= 7.4. Heartrate = 300 bpm, perfusion pressure 
during normoxia and reperfusion = 70 mm Hg, and during ischemia 15 mm Hg. 
Nucleosides were determined in the coronary effluent by HPLC. •---• 
concentration in the coronary effluent {~mol/1). o---o =amount released by the 
heart (nmol/min/g dwt). In the right part of the figure are plotted the 
oxypurines hypoxanthine (Hx), xanthine (X) and uric acid (UA) and in the left 
part of the figure the nucleosides adenosine (Ado) and inosine (Ino). 
59 
detected, even after perfusion with 20 pM 14c-inosine or 
-hypoxan·thine [38 and appendix paper 8]. We canclude that this 
enzyme is either absent or inactive in rat heart. 
4.3.1. Purine release as a marker for ischemia 
In the previous paragraphs it 
of ATP ultimately results in 
is described that catabolism 
the appearance of adenosine, 
inosine, 
4.2). It 
hypoxanthine, xanthine and uric acid (see fig. 4.1 and 
was also established that a decrease of myocardial 
adenine nuc.leotides during ischemia is recovered as the amount 
of AMP-catabolites in heart and coronary effluent [1, 41, 72]. 
Becrtuse of the fast transport mechanisms between intra- and 
extracellular nucleosides and oxypurines [65], it seems 
plausible that adenosine catabolites in the coronary effluent 
reflect the myocardial ATP breakdown [see also 17, 20, 82 and 
appendix paper 7]. In fig. 4.2 an increase of perfusate 
adenosine and catabolites is demonstrated within the first 
minutes of ischemia. Lactate, the end product of anaerobic 
glycolysis, is also used as a biochemical marker for ischemia 
[3-5, 17, 19, 40, 46-48, 52, 90, 91 and appendix papers l and 
5 J. 
4.3.2 The use of purine release as a marker for ischemia in the 
clinical setting 
From 1960 on, several studies have discussed the release of 
purine components during ischemia or anoxia (see table 4.1) .. A 
close correlation has been found between purine- and lactate 
release from animal and human hearts. [18, 19, 22, 46-48, 67, 
91]. Lactate as a marker of ischemia, however, has several 
disadvantages. During normoxia, lactate is preferentially taken 
up by the heart [24]. In fact, lactate released from a local 
ischemic area 
tissue [5]. The 
influenced by 
60 
can be metabolized by the surrounding 
formation and removal of lactate 
blood fatty acid levels, acidosis 
normoxic 
is also 
and by a 
Table 4 .1. 
AMP-catabolites in blood and urine as marker for myocardial ischemia in 
patients. 
Purine Body fluid Clinical Ref. 
situation 
Adenosine A-CS plasma APST [31] 
Uric acid Serum AMI, IHD [37, 53] 
Hypoxanthine A-CS blood APST [app. 1' 67] 
Hypoxanthine Peripheral ischemia, 
venous plasma AMI,AP [34, 56] 
Adenosine, 
inosine, A-CS plasma CABS [31] 
hypoxanthine 
Inosine, 
hypoxanthine A-CS plasma APST [46-48] 
Hypoxanthine, 
xanthine, Urine Cardiac arrest 
uric acid AP, AMI [13] 
Adenosine, 
inosine, A blood CABS [11] 
hypoxanthine, 
xanthine 
Hypoxanthine, A-CS blood 2 X APST [22] 
A ~ arterial; CS ~ coronary sinus; APST = atrial pacing stress test; AMI = acute 
myocardial infarction; IHD ischemic heart disease; CABS = coronary-aorta 
bypass surgery; AP = angina pectoris; app. l = appendix paper 1. 
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diabetic condition [for a review, see 89]. In appendix paper 1, 
fig. 4, the myocardial hypoxanthine and lactate release are 
plotted from patients with a coronary stenosis larger than 50%, 
during an atrial pacing stress test. Thirty min after the end 
of the pacing period, hypoxanthine is still being released by 
the heart, while lactate release is converted to uptake. Selwyn 
et al. [80] have shown, that even 30 minutes after an atrial 
pacing stress test, the Na+K+-ATPase activity is still 
disturbed. They conclude that during that post-pacing period 
the heart has still not recovered from the provoked ischemia. 
This observation is in agreement with the prolonged 
hypoxanthine release found after the pacing period. 
4.3.3 Problems with the use of purine release as a marker of 
ischemia 
1. It is important to determine those purines in blood which 
are released by the heart and not those originating from other 
tissues. Therefore, paired arterial and coronary-venous samples 
must be drawn. 
2. When one ischemic event is relatively quickly followed by a 
second one, purine production during the latter period is 
substantially lower. Therefore, an experimental animal or a 
patient cannot serve as its/his own control during a study of 
drug efficacy under these conditions [81]. 
4.4 Conclusions 
Myocardial purine production is a direct result of ischemia 
and therefore a promising biochemical indicator of ischemic 
heart disease. Because purine production can take place in many 
other tissues, the arterio-venous differences across the heart 
must be assessed, to assure that indeed purine release from the 
heart is measured. 
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CHAPTER 5 PHARMACOLOGICAL PREVENTION OF ISCHEMIC ATP BREAKDOWN 
5.1 Introduction 
During ischemia, intracellular ATP levels decline as a 
resul-t of the disturbed balance between production of ATP and 
its usage as detailed in chapter 4. As a result of low ATP 
levels, the ionic pumps are disturbed [54, 100], ionic 
homeostasis will be changed and ul tirnately, perhaps via action 
of activated lipases and proteases [49], membranes are damaged 
and finally the cell dies [54, 63]. This process is depicted in 
fig. 5.1. Whether the decrease in ATP is the main cause in this 
sequence to cell death is still a matter of debate [9, 23, 
42-44], but ATP levels at the end of the ischemic period are 
inverse related to the damage during reperfusion [33, 43, 45, 
63, 79]. From any point of view, it seems advisable to maintain 
high ATP levels by preventing or delaying ATP catabolism during 
ischemia. 
In principle, 4 different methods can be used to achieve 
this: 
1. Myocardial flow can be increased. Higher flow rates will 
resul-t in a higher substrate and oxygen supply and hence 
accelerate myocardial ATP production. ca 2+-antagonists can 
achieve this, provided tha·t a stenosis is not the permanently 
restricting factor [17, 36, 37, 104, 114]. 
2. Cardiac work can be decreased. When ATP production is 
limited by flow, reduced usage of ATP can restore the disturbed 
ATP balance. This is achieved by negative inotropic agents such 
as beta-blockers, ca2+_antagonists [10, 11, 29, 82], or by 
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LOSS OF STRUCTURE AND FUNCTION 
Fig. 5.1. Schematic representation of some events, precipitated by inadequate 
flow {ischemia}. 
The inhibition of certain pathways by ca 2+-antagonists and beta~blockers (B) is 
indicated. 
CF = coronary flow, cathechol. = cathecholamine, mitoch. = mitochondrial. 
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peripheral vasodilators (ca2+-antagonists and adenosiner cf. 
[8, 29]). In the clinic its usefulness is limited as the heart 
has to continue beating and contractile power can be reduced 
only to a certain degree. 
3. Stimulation of ATP-producing processes. "Extra" A'rP can be 
produced by stimulation of the anaerobic glycolysis (with a 
mixture of glucose-insuline-potassium, see for a review [99], 
but wit0 the restrictions described by Apstein et al. [3]). 
4. The rate at which ATP is hydrolysed can be slowed down by 
hypothermia [6, 44, 79]. 
In the context of this thesis, treatments 1 and 2 are 
discussed. Especially the ATP-sparing effects of the 
ca 2+-antagonists nifedipine and diltiazem and the beta-blocker 
propranolol have been investigated. A short introduction on the 
cellular activators ca 2+ and c-AMP is now given, since these 
are centrally placed regulators in this context. 
5.1.1 The influence of ca 2+ on the myocyte 
The coupling between the voltage-dependent membrane changes 
and mechanical contraction is called the exitation contraction 
coupling (for a review see, a.o., [10, 29]). Contraction is a 
proceSS 1 which results from tlle interaction of the contractile 
proteins myosin and actin. In the absence of cf+, this 
interaction is inhibited by the configuration of the 
actin/troponin/tropomyosin complex. Myosin/actin interaction 
occurs by the configuration change induced by the binding of 
ca2+ to troponin. To achieve this, a relatively high 
intracellular ca2+ concentration is needed, an increase from 
10-7 to 10-5 M, [65]. This c~ 2+ increase is primarily caused by 
a (voltage-dependent) ca2+-influx through the sarcolemma (fig. 
5.2), which is estimated to be only 10% of the total amount 
needed for contraction. It 
voltage-dependent ca2+_influx 
is currently thought that this 
triggers an intracellular ca2+ 
pool which resides in the sarcoplasmatic reticulum (SR), from 
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Fig. 5.2. Function of ca 2+ and c-AMP in the myocyte. 
A = sarcolemmal Na+/ca2+ antiporter. B = Voltage dependent slow ca 2+ channel. c 
ca 2+ pump, D = beta-adrenergic receptor, E = ca 2+ uptake and release by the 
sarcoplasmatic reticulum. F = ca 2+-uptake and release by the mitochondria. SR 
sarcoplasmatic reticulum, [±] = ca2+ stimulated, B = ca2+ inhibited, & c-AMP 
stimulated, e = inhibition. 
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which additional ca 2+ is liberated. Cytosolic free ca2+ not 
only causes actin and myosin to interact but also stimulates 
the myosin-ATPase [65, 82]. Under experimental conditions the 
influx is dependent on the 
concentrations [29, 30]. 
Relaxation of the myocyte occurs, 
ca2+_levels are reduced. Part of this 
sarcoplasmatic reticulum (via a ca 2+- and 
pump)i remaining ca 2+ is removed from the 
extracellular ca2+ 
when the cytosolic 
ca2+ is removed by the 
Mg 2+-dependent Ca 2+ 
cell by a ca2+-ATPase 
in the sarcole@na. Other pumps may play additional roles. As a 
consequence 
dissociates, 
of the lowered cytosolic ca 2+, 
the binding between actine and 
ca2+-troponin 
myosin is 
disconnected and relaxation takes place [10, 65]. 
ATP is needed as substrate for the various ca 2+ pumps, 
involved in the removal of the cytosolic free ca2+, but it is 
also necessary for relaxation [56]. When the ATP levels are 
below a certain level, no relaxation can take place and the 
heart remains in a contractile state (hypoxic contracture or 
rigor 1 [42, 
ca 2+ overload 
43, 70]). When, during reperfusion, an excessive 
occurs, it may cause an abrupt contracture. This 
inability of the cell to adequately remove the excessive ca 2+ 
leads to reperfusion contracture [40, 41, 59, 60, 70, 78]. 
In the sarcolemma a Na+/ca2+ antiporter (which exchanges 
extracellular Na+ for intracellular ca2+ or vice versa) is 
situated together with the ca 2+-ATPase. The former also plays a 
role in the maintenance of intracellular ca2+ levels [10, 56, 
58, 122]. This antiporter is responsible for the coupling 
between intra- and extracellular ca 2+ and Na+. No ATP is needed 
for that process. The distribution of the two ions across the 
sarcolemma is dictated by Nernst's Law. 
The role of mitochondria in the maintenance of ca2+ 
homeostasis is still a matter of debate. The transfer of ca2+ 
across the inner membrane of the mitochondria consists of 
separate uptake and release processes [13, 14, 27, 66, 91, 95, 
108]. The influx process is driven by the 
chain and is modulated by, a.o., 
energy of the 
ATP, Pi and Mg2+. respiratory 
ca2+ lowers the mitochondrial ATP production. The mitochondrial 
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ca2+ efflux is mediated by a ca 2+/Na+ exchange. Increased ca2+ 
levels cause mitochondrial swelling and impairment of function. 
It is thought that the mitochondrial ca 2+ functions as a buffer 
for ca2+ in the cell, and "tunes" the free ca 2+ in the cytosol 
[27]. Whether this process is important for ca2+ variations to 
regulate contraction is still a matter of debate [13]. 
In conclusion, ca2+ is the main regulating factor of 
contraction and it plays a critical role in the activation of 
phosphorylases, phosphokinases, lipases and proteases (fig. 
5 .1) . The phosphokinase reactions are of utmost importance for 
enzymic activations and membrane processes. Finally ca2+ per se 
plays an important role in stabilizing the membrane structure 
[19, 32]. 
5.1.2 The influence of c-AMP in the myocyte 
ca2+ is considered as the "beat to beat" regulator in the 
myocardial cell, while c-AMP can be regarded as the global 
cellular activator, which reacts to influences from outside the 
cell via several recep-tors in the sarcolemma. Stimulation of 
beta-adrenoceptors activates adenylate cyclase and as a result 
c-AMP is formed [1, 23, 24] (fig 5.2). Increased c-AMP levels 
in turn s·timulate several phosphorylation 
(phosphokinases). This causes activation of enzymes needed for 
glycogenolysis [56]. Also the proteins myosine and/or troponine 
are phosphorylated, which makes the system more sensitive to 
ca 2+ [74, 101]. Several membrane structures are phosphorylated, 
which lead to activation of the voltage-dependent ca2+ influx 
[2, 89] concomitant with augmented ca 2+ binding of the 
sarcolemma [110]. C-AMP causes a shift £rom glycolysis to fatty 
acid oxidation and the cell becomes more dependent on o 2 [87]. 
Higher c-AMP levels, as a result, increase the contractility of 
the myocyte. 
5.2.1. Calcium antagonists 
In 1964, Fleckenstein and Kronenberg discovered that 
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verapamil, a vasodilator which has cardiodepressant activities, 
selectively inhibits the cardiac exitation-contraction coupling 
without a major change in the action potential [10, 29, 81]. 
This effect could be counteracted by increasing the 
extracellular ca2+ concentration, beta-adrenergic 
catecholamines or cardiac glycosides. They suggested the name 
"Ca2+_antagonists" for drugs with this action. These compounds 
cause negative inotropy in the myocardium, while the vascular 
cells are relaxed and vasodilation occurs (but see ref [113]). 
In 1969, it was found that ca2+-antagonists specifically 
interfere with the slow trans-sarcolemmal ca 2+ inward current, 
without affecting the fast-channel mediated transmembrane Na+ 
influx, hence the name "slow-channel blockers" [30]. Since 
skeletal muscle does not need extracellular ca 2+ for its 
contraction, Ca 2+-antagonists do not seem to affect this type 
of muscle [80]. 
If one follows Fleckenstein•s definition of ca2+-antagonists 
(inhibitors o£ the voltage-dependent transmembraneous 
ca 2+-influx), ~great variety of this type of compounds exists 
[28, 29, 64, 80]. Nayler [80] has tried to classify them. She 
distinguishes two main groups, the relatively unspecific group 
of inorganic compounds and the more specific group of organic 
compounds. The organic compounds are divided into three classes 
on the basis of their organ specificity: Class I consists of 
compounds, which primarily act on cardiac tissue (for example, 
diltiazem). Class II compounds mainly influence vascular cells 
(nifedipine, niludipine, nitrendipine, nimodipine), while class 
III compounds mainly act upon cardiac nerve tissue (veraparnil, 
gallopamil). Compounds in the last class also seem to exhibit 
some influence on the fast Na+-current. However other 
classifications are also feasable. Rodenkirchen et al. 
suggest a classification on their specificity of modes of 
action. 
The binding characteristics of these compounds to 
sarcolemmal- or sarcoplasmatic reticular membranes differ 
considerably [22, 78, 80, 84, 92, 94]. 
It is important to note, that the action of (at least some) 
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ca2+_antagonists can be pluriform [46]. For example, diltiazem 
at low concentrations blocks the voltage-dependent slow ca2+ 
channelr while at 
ca2+_pump in the 
higher concentration it also halts the 
general sarcolemma [15, 102]. However, 
agreement exists about the dominant inhibitory action of 
ca2+-antagonists on the voltage-dependent channel. The nature 
of this channel is not clearly defined at this moment, although 
some speculation about models exists [10, 57]. Organ to organ 
diversity seems likely, which could explain the different 
specificity of the various compounds. At this moment, other 
actions of ?+ . ca~ -antagonlsts apart from inhibition of the slow 
Ca2+-channel cannot be excluded. 
We became interested in 
ca2+_antagonists as claimed 
the 
by 
ATP-sparing 
Fleckenstein 
effect of 
[28] and 
subsequently (partly) documented by Nayler et al. [83], and not 
found by Geary et al. [34]. We have investigated the 
ATP-sparing effect of the Ca 2+-antagonists nifedipine and 
diltiazem in the isolated rat heart [appendix papers 5-7]. 
In normoxic hearts, addition of nifedipine or diltiazem 
causes vasodilatation and negative inotropy. The maximal 
vasodilatory effect for both drugs is found at a lower 
concentration than that which is necessary for the maximal 
negative inotropy, which could indicate a higher sensitivity of 
t'he vascular cell than the myocytes [28, 35, 84]. To produce 
equipotent effects, about 30 times more diltiazem than 
nifedipine must be used. 
During ischemia two observations have been made: 
1. In hearts which have been pretreated with nifedipine (up to 
0.3 pM [appendix paper 5]) or diltiazem (up to 100 pM, 
[appendix paper 7]), ischemic purine release was found to be 
depressed by both drugs in a dose-dependent manner. In the 
non-treated hearts, apex displacement fell 60-80% during 
ischemia, due to the flow reduction. When hearts were 
pretreated with the ca2+_antagonist, the apex displacement 
during ischemia was comparable to that of the non-treated 
hearts (with the exception of the 100 pM diltiazem dosage, 
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which completely arrests the heart during norrnoxia, ischemia 
and reperfusion). Ischemic purine release, however, was 
diminished in a dose-dependent way with a concomitant better 
preservation of myocardial ATP levels. The ischemic purine 
release correlated with the negative inotropic effect of the 
drug before the ischemic period [appendix papers 5-7]. 
2. When ca2+-antagonists are presented to the heart during 
ischemia (diltiazem [appendix paper 7]), the reduction of 
purine release is paralled by a reduction in apex displacement 
{negative inotropy). 
The ATP-sparing effects of the ca2+-antagonists administered 
before or during ischemia confirm the results claimed earlier 
[28, 46-48, 83, 96, 119-121]. The explanation for this effect 
is not yet known. Fleckenstein [28] stated that the ATP sparing 
effect of Ca 2 +-antagonists is only due to their negative 
inotropic properties. Nayler et al. [83] postulated enhanced 
preservation of mitochondrial function 
preventing mitochondrial ca2+-overload. 
during ischemia, by 
Ichihara et al. [53] 
found a nifedipine induced shift from fatty acid to glucose 
oxidation, suggesting another intracellular action, while 
Church and Zsoter [15] and Henry and Wahl [48] did not find 
diminished myocardial ca2+-influx during ischemia, when they 
treated hearts with ca 2+-antagonists. 
In apppendix papers 5 and 7 we speculated about an 
intracellular action of nifedipine and diltiazem. This 
speculation, however, cannol be fully proven yet, and the 
following mode of action of the two drugs appears to be the 
most 1 ikely at present: 
In the isolated rat heart, treatment with diltiazern during 
ischemia, showed a correlation between the negative inotropic 
effect of the drug and the ATP sparing effect. This could be 
due by a reduction in cardiac work. Hearts pretreated with 
nifedipine and diltiazern 1 however, do not show any relation 
between purine release and apex displacement during ischemia. 
On the other hand the correlation between purine release during 
ischemia and the change in apex displacement during normoxia is 
striking. In the diltiazern-treated hearts, a correlation 
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coefficient of 0.84 is found between these parameters for the 
concentration range 
ca2+-antagonists will 
used. Pretreatment of the heart with 
reduce cardiac work and therefore ATP and 
o2 demand before ischer:tia. Subsequent flow reduction will 
induce ischemia of which the severity is dependent of the work 
of a heart before ischemia. In other words, ca 2+-antagonists 
can reduce the severity of ischemia by pre-ischemic action. 
This effect is dose-dependent and is directly achieved by 
inhibition of the voltage-dependent Ca 2+-influx. Although this 
explanation seems satisfactory in our experimental set-up, an 
additional intracellular action of these drugs cannot be 
excluded [38, 48, 76, 93, 116, 119]. 
An important 
ca2+-antagonists 
question which remains is the effect of 
when 
phase of reperfusion, an 
applied after ischemia. 
excessive Ca 2+-influx 
In the early 
takes place, 
particularly when ischemia has been present long enough to lead 
to low ATP levels at the end of the ischemic period [98, 109]. 
This ca2+-influx is probably mediated by Na+/ca 2+ exchange, and 
ca2 + len.:.::s across the damaged sarcolemma [35, 66]. In this 
case, no effect of ca 2+-antagonists can be expected [112, 118]. 
Schols et al. [103], however, have shown that the so-called 
ca2+_antagonist lidoflazine applied within the first 5 min of 
reperfusion can still protect the myocardium. This compound 
exhibits besides ca2+-antagonistic properties, also an effect 
on the sarcolemmal transport of adenosine. Part of the 
beneficial effect of adenosine might be explained by increased 
adenosine phosphorylation (see chapter 6). Also after the 
ca2+-paradox [44, 123], some protection by ca2+-antagonists was 
found [5]. 
5.2.2. Beta-blockers 
Beta-blockers protect the heart against the deteriorating 
effects of ischemia [11, 26, 68, 69] primarily by blockade of 
the beta-adrenoreceptors. As a result, the normal augmentation 
of c-AMP by beta-adrenergic stimulation is inhibited, which has 
a beneficial effect via reduction of tissue energy demand [62]. 
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Fig 5.3. Influence of D- and L-propranolol on beta-adrenergic stimulation. Rat 
hearts were perfused with a modified Tyrode solution, equilibrated with 95% o 2 
and 5%' co2 , pH= 7.4. Five min after the start of the perfusion pressure, apex 
displacement was set at 100 %. D (e---0) and L-propranolol {0---0) were solved 
in the perfusion medium at a concentration of 150 pg/1. Isoproterenol (Isuprel) 
is added between t = 10 and t = 14 min (shaded area) at a concentration of 15 
pg/l. 
Values are means of 4 perfusion experiments, performed by Dr. J.W. de Jong and 
Mr. P.Ph de Tombe. 
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Propranolol, as one of the most commonly used beta-blockers in 
the clinic, has also a "membrane stabilizing" effect [4]. 
However, this last effect is of no clinical importance. 
As is shown in appendix paper 6, DL-propranolol, added to 
the perfusion medium in concentrations of 30 or 150 pg/1, does 
not show any protective action on ischemic ATP levels and 
purine release in an isolated heart. However, preliminary 
studies with D- and L-propranolol indicate that in this 
concentration range, L-propranolol effectively inhibits the 
beta-adrenergic stimulation of isoproterenol (see fig. 5. 3). 
the same stimulation has no D-propranolol, 
beta-adrenergic 
during 
blocking properties. Probably, the 
catecholamine release in an isolated rat heart is of minor 
importance during ischemia. This is in accordance with the 
experiments of Edoute et al. [25] and Lubbe et a1. [71]. 
However, Nakazawa et al. [77] found in isolated rat hearts a 
normalization of the ischemic myocardial pH during 
DL-propranolol treatment. They concluded that DL-propranolol 
had a protective effect. Nayler et al. [85], Conway and Weiss 
[18] and Manning et a1. [72] had found, after application of 
propranolol in the intact animal, a protective effect when 
these hearts were perfused and then made ischemic. In intact 
animals, however, circulating catecholamines are expected to 
play a more important role than in isolated, perfused hearts, 
so that the effect of these drugs would be more likely to show 
up. 
5.2.3. Combined effects of ca 2+-antagonists and beta-blockers 
In the previous paragraphs, the ATP-sparing effec-t of 
ca 2+-antagonists during ischemia was demonstrated, while 
propranolol under the same conditions showed no protective 
effects. In contras·t, the combination of these drugs showed a 
better protection than either drug alone [20, 21, 117 and 
appendix paper 6]. Apex displacement and flow were not 
differen·t before or during ischemia during the combined therapy 
in our experiments [appendix paper 6], compared with the action 
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of nifedipine alone. Therefore it seems that this synergistic 
effect is independent of contractility and flow and some 
intrncellular action of the combination must be assumed. Nayler 
et al. [85] suggest an effect of propranolol on ca2+-transport, 
while Katz et al. [58] found an influence of propranolol on 
microsomal 
both ca2+ 
ca2 +-binding. Several 
and c-AMP regulated. 
ATP-consuming processes are 
Whether a (molecular) 
compensatory mechanism exists in the myocyte comparable with 
the baroreflex activation in the intact system [86], is not 
known at the present. If 
ca2+-antagonists in their action 
so, it is conceivable 
alter the ca 2 +-balance in 
that 
the 
cell which leads to a compensatory stimulation of c-AMP, which 
in turn could be blocked by propranolol. However, no increase 
in c-AMP is found after addition of nifedipine or verapamil in 
isolQted rat hearts [39, 111], which makes this explanation 
less plausible. Clearly, much further work on the efficacy of 
this combination must be done to elucidate its mechanisrn(s). 
5.3. Clinical importance of ca 2+-antagonists and beta-blockers 
The main action of ca2+_antagonists administe-ced 
intravenously to patients, is coronary and peripheral arterial 
vasodilation [37, 104]. The peripheral vasodilatory effect 
results in reduction of the systemic resistance, thereby 
relieving the workload of the heart 
application of ca2+-antagonists 
[29, 67]. 
results 
Intracoronary 
in coronary 
vasodilatation and negative inotropy [55, 106, 107, 115]. These 
drugs are therefore used as powerful anti-anginal drugs [50, 
51] and are especially recommended when angina pectoris is 
caused by increased vasomotor tone of the coronary arteries 
[7]. Protection is also found during cardiac arrest induced for 
open heart surgery [12, 16] and during transluminal angioplasty 
[lOS]. 
The protective effect of beta-blockers has been recognized 
for years, both for the reduction in the ischemic sequela of 
myocardial infarction and for treatment of anginal attacks 
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[11]. They act mainly by inhibition of the catecholamine 
response. Beta-blockers are therefore well suited for the 
treatment of patients with stable angina pectoris, as they 
reduce cardiac frequency. 
Since several years the combination of the two drugs is 
employed and an additive protective response is found [20, 52, 
90]. Beta-blockers block the baroreflex response which induces 
tachycardia [67]. In many cases of angina pectoris, both drugs 
are indicated instead of either of the drugs alone [51]. Due to 
their additive (or even synergistic) effect, the dosis of each 
drug can be lowered, thereby lowering the side effects [20, 31, 
97]. 
However, one serious side effect of this combination deserves 
special attention [75, 88]: Through blockade of the baroreflex 
induced catecholamine release, severe bradycardia and excessive 
fall in blood pressure may lead to shock, underperfusion of the 
heart, acute myocardial infarction and even death. In 
particular the combination of verapamil (which slows the 
conductive system and leads to A-V block) with propranolol is 
dangerous [88]. However, Kieval et al. [61] found no negative 
side effects with this combination in patients with ischemic 
heart disease, provided initial cardiac function was normal and 
cardiomegaly absent. 
5.4. Conclusions 
From studies in isolated perfused rat hearts it can be 
concluded that: 
1. Administration of nifedipine or diltiazem to the heart 
before ischemia, prevents or delays ATP breakdown. We propose 
that this effect is in a large part due to the negative 
inotropic properties of the drugs during normoxia by 
diminishing the normoxic ATP demand and therefore decreasing 
the severity of the ischemia due to the subsequent (fixed) flow 
reduction. As a consequence of this lower ATP demand, ATP 
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levels remain normal, ionic homeostasis is longer preserved and 
mitochondrial function is less disturbed. However, additional 
intracellular actions of ca2+-antagonists are not excluded by 
our experiments. 
2. Administration of diltiazem during ischemia decreases ATP 
brea"kdown, which parallels the negative inotropic effect, 
observed in the isolated rat hearts. 
3. No appar:=:mt difference is found between the action of 
nifedipine and diltiazem. However, for a given dosis of 
nifedipine, 30 times more diltiazem must be given to achieve 
the same protective effect. 
4. DL-propranolol is an effective beta-adrenergic blocker, but 
it do~s not protect the (isolated) heart from ATP depletion. 
However, in combination with nifedipine it reinforces the 
ATP-sparing effect of nifedipine. In this case, no correlation 
bet·ween contractility and purine release 
with nifedipine alone. 
intracellular mechanism. 
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CHAPTER 6 MYOCARDIAL ATP BIOSYNTHESIS 
6.1. Introduction 
In chapter 2 1 the importance of adequa·te myocardial ATP 
levels is indicated, while in chapter 4 i·t can be read that due 
to :nitochondrial impairm·'.:!nt (caused by lack of ox:ygen) ATP 
levels decrease. Dephosphorylated catabolites such as adenosine 
and inosine pass the cell membrane and leave the heart. 
Restocation of o2 supply after reversible ischemia is followed 
by restoration of mitochondrial function. ATP levels, however-, 
remain low because of washout of the aa.enos ine and its 
catabolites [a.o., 1, 6, 21, 27, 55 and appendix P·"3-.: . J~Cs 2, 6 
and 8]. 
Low ATP levels have two important consequences: 
1. A reperfused heart cell with a lowered ATP level is more 
vulnerable during a next ischemic period, because t'ne critical 
limit between reversible and irreversible damage is sooner 
reached {supposedly in patients with frequent anginal attacKs 
and subsequent purine release} [5]. 
2. Recovery of heart function after an ischemic period is 
thought to be proportional to recovery of ATP levels. This has 
been shown in patients with acute myocardial infarction and 
those undergoing caLdiac surgery. Fast recovery of ATP levels 
is followed or paralleled by a fast recovery period [27, 55]. 
In this chapter, several pathways are described for the 
biosynthesis of AMP. The AMP formed can be used by adenylate 
kinase and transferred to ADP (see chapter 3). ADP can be 
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rephosphorylated to ATP by oxidative phosphorylation or 
anaerobic glycolysis. 
6.2 Nucleotide biosynthesis 
The differen·t biochemical pathways for cellular ATP and GTP 
biosynthesis are summarized in fig. 6.1. 
GTP PRPP--···RIBOSE ATP 
t l3 t GOP ADP t t 7 6 4 5 
GMP ...,.._ XMP ...,.._ IMP .. AMPS ._....._ AMP 
t" ? I PRPP 2 
10 .10 9 8 
UA ...,.._ X ...,.._ HX 7 INO ...,.._ ADO ' 
' Rl BOSE--'------- -RIBOSE-1 P 
Fig. 6.1. Enzymes involved in the biosynthesis of ATP and GTP. 
1 ~ adenosine kinase, 2 - hypoxanthine phosphoribosyl transferase, 3 = de novo 
synthesis (a 10-step synthesis), 4 adenylosuccinate synthetase, 5 
adenylosuccinate lyase, 6 = IMP-dehydrogenase, 7 ~ GMP-synthetase, 8 = adenosine 
deaminase, 9 = nucleoside phosphorylase, 10 = xanthine oxidase/dehydrogenase. 
ADO = adenosine, AMPS = adenylosuccinate, HX = hypoxanthine, INO = inosine, PPi 
pyrophosphate, PRPP = phosphoribosyl pyrophosphate, X = xanthine, UA uric 
acid. ? indicates the possibility, that xanthine can be converted to XMP. 
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6.2.1 Adenosine phosphorylation 
Adenosine is directly phosphorylated to AMP by adenosine 
kinase (AK). 
.Adenosine + ATP ~ AMP + ADP 
In 1957, Goldwaith [16] was the first to show the existence 
of this process in heart homogenates and since that time 
adenosine kinase has been demonstrated in hearts of several 
species [7, 20, 34, 48, 
l rM for adenosine and 
pmol/min/g protein [8, 
58]. The enzyme has a (low) Krn of about 
a 
60 
specific activity of 
and appendix paper 
about 6-8 
4]. Several 
isoenzymes are found, all with a molecular weight of about 
40,000. In rat heart, it is predominantly located in the 
cytosol [7]. Together with S'N, it forms a so-called futile 
cycle. According to Arch and Newsholm [2] this cycle has a 
specific task in adenosine regulation (see also chap-ter 4}. At 
the cost of 1 mol ATP per turn, this cycle provides a direct 
and fast production of adenosine, which is of utmost importance 
for flow regulation [3, 38, 42]. In appendix paper 4, the 
purification of AK from rat heart is described. With a fast, 
relatively simple two column-step procedure, this enzyme is 
purified to apparent purity. The enzyme is inhibited by the 
adenosine deaminase inhibitor dipyridamole [8]. The maximal 
incorporation rate of adenosine found in isolated rat heart is 
50 nrnol/rnin/g dwt [48], which is about 1500 times less than the 
maximal reported enzyme activity. 
6.2.2 Purine salvage 
The purine bases adenine, guanine and hypoxanthine are 
converted to their respective 
phosphoribosyl-pyrophosphate (PRPP, 
ribose-5-phosphate). 
monophosphates, using 
a diphosphorylated 
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A.der1ine + PRPP -----------> AMP + ppi 
Guanine + ?RP? ----;. GMP + ppi 
Hypoxanthine + PRPP ----> :U1!? + ppi 
:-Iypoxanthine and guanine are phospl1orylat-e.d. by hypoxanthine 
phosphoribosyl transferase (HPRT), while adenine is converted 
by adenine phosph:::n_-ih.)·:;yl -transferase [18] . 
.J:\ccording to Murray [37] and Fox [13] more than 75% of all 
purine bases in the body {formed by nucleotide- or nucleic acid 
breakdown or derived from the food) are transformed into 
i_ntr::tcellular nucleotides by these enzymes. The other 25% is 
converted to uric acid (or allantoin) and excreted. 
The salvage enzymes play an important role in nucleotide 
metabolism; however, the precise regulatory mechanism remains 
to be elucidated. The importance of the salvage pa-thvTa.y is 
stressed by the folowing exa:nple: a HPR'r deficiency results i!l. 
the so-called Lesch-Nyhan syndrome. This disease is associated 
:::tnd rnen t.n.l vvith several severe neurological disturbances 
retardation, resulting in very aggressive behaviour and a 
tendency to self mutilation. Also massive deposition of uric 
acid in the kidneys is found with resulting renal failure [32]. 
This increased uric acid producti.e>n is not only derived from 
"non-salvaged" hypoxanthine but predominantly from the 
accelerated de novo synthesis. 
In hear-t tissue, HPRT and APRT enzyme activities have been 
detected [35]. Normally, adenine levels are not detectable in 
blood, whereas hypoxanthine is p.c,:o:sent in rnicromolar amoun·ts. 
the precursor of hypoxanthine, is often used as a 
cardioprotective agent and cannot be directly incorporated into 
myocardial nucleotides [34]. 
Incorporation of hypoxanthine and inosine into myocardial 
~TP has been reported by several authors [16, 20, 26, 39, 45, 
51, 57, 58]. Ho> . re\/f;r, till now, no regulatory mechanism for 
this process has been found in heart. 
In appendix paper 8, we described the incorporation of 
hypoxanthi!l.e in isolat:::>.d_ Lat hearts. The ATP biosynthesis from 
hypoxan·thine was 0.4 nmol/min/g dwt under normoxic conditions. 
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A.bout 0.2 nmol/min/g dwt hypoxanthine was incorporated in the 
AMP and ADP fraction, so that the total adenine nucleotide 
synthesis in rat heart fr.-orn hypoxanthine is about 0.6 
nmol/min/g dwt. The GTP biosynthesi_s is 0.1 nmol/min/g dwt, 
which aLso constitutes ab01_1t 75% of total guanine nucleo-t i.d.e 
synthesis. The latter findi..ng was unexpected, becaus(~ GTE' 
levels in heart are about 5% of the ATP levels [17, 54, 55 and 
appendix paper 8], while GT~ biosynthesis is about 25% of that 
of the ATl? biosynthesis. The total ,~TP and GTP concentrations 
are not significan·t altered after the incorporation period. The 
biosynthesis rates of ATP and GTP were increased when 0.5 mM 
ribose is infused together with the hypoxanthine solution 
[appendix paper 8]. 
During reperfusion (after a 20 min period of mild ischemia 
induced by a flow reduction of 70%), the ATP biosynthesis rate 
from hypoxanthine is doubled. The maximal synthesis rate is 1 .. 5 
nrnol/rnin/g dwt, which amounts to 2.0 nmol/rnin/g dwt synthesi:s 
of total adenine nucleotides. GTP biosynthesis in all cases 
parallels ATP biosynthesis, the maximal t:)tal guanine 
nucleotide synthesis rate being 0 .. 5 nmol/min/g dwt (fig. 6.2). 
'The uptake of the hypoxanthine was comparable in all sets of: 
experiments. We es-timate the intracellular hypoxanthine 
concen-tration to be be-t..;een 15 and 20 pM, which is reflected by 
its concentration in the perfusate. Inosine uptake is about 
tHice the hypoxanthine uptake, while conversion to hypoxanthine 
maxim-:tlly amoun·ts to 15%. This indicates a lower cellular 
hypoxanthine concentration than during perfusion with 
hypoxanthine, while hypoxanthine and inosine incorporation 
rates are comparable in normoxic and reperfnsr~d hearts. From 
these observations, we conclude an intracell11lar factor to be 
responsible for the regulation of the salvage rate, presumably 
PRPP. 
According to Zimmer et al. [62, 64], PRPP is supplied by the 
hexose monophosphate shunt (see fig. 6.3}. The first step in 
the oxidative part of the pentose cycle by the enzyme 
glucose-6-phosphate dehydrogenase (G-5PD) is the rate-lirnit,ng 
step and is regulated by the NADP+/NADPH ratio. After ischemia, 
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2.0 
ATP 
1.0 
0.0 
0.5 
GTP 
0.25 
0.0 
H R 
Fig. 6.2. Biosynthesis of ATP and GTP. 
Isolated hearts were perfused with a modified Tyrode solution, gassed with 95% 
o 2 and 5% co2 . Twenty min after the start of the perfusion, hearts were made 
ischemic by flow reduction for ~0 min (about 25% of control flow). Thereafter, 
the hearts were reperfused for another 20 min. The experiments were terminated 
by freeze-clamping the hearts. In the last 15 min of the experiments 20 pM 
[B-14c]hypoxanthine {H), with 0.5 mM ribose (R) or 20 pM [s-1 4c]inosine (I) is 
applied to the hearts. From the freeze-clamped hearts, ATP and GTP were 
extracted, and 14c was counted. The open bars represent the normoxic values, the 
shaded bars the reperfused values + SEM. (Data were taken from appendix paper 
8.) 
this ratio is decreased, the inhibition of G-6PD is abolished, 
and the PR~P synthesis is increased. It is possible to bypass 
this cycle, by infusion of ri..bose 1 which can be directly 
converted via ribose-5-P to PRPP [47, 63]. All these conditions 
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Fig. 6.3. Phosphoribosyl-pyrophosphate (PRPP) synthesis . 
1 = Glucose-6-phosphate dehydrogenase, 2 = ribokinase, 3 = PRPP synthetase, 4 
hypoxanthine phosphotransferase. 
indeed stimulated hypoxanthine inco-rporation, 
PR~P dependency of the process. 
confl.r;ning the 
Inosine 
hypoxanthine 
(0.7 and 2.0 
inc:>rporation 
incorporation 
nmol/:uin/g dwt, 
in t·:> ATP is crJmparable with 
in normoxic and reperfused hearts 
respectively: see appendix paper 
8). Inosine cannot directly be inco-rporated into IMP [34], but 
is first catabolized to hypoxanthine and ribose-1-phosphate. 
The last compound can be used as a precursor of PRPP (see fig. 
6.1). The increase of total adenine nucleotides after 
reperfusion with inosine is surprising. After ischemia, total 
adenine nucleotides fall to about 23 )lmol/g dwt. Fifteen 
minutes of reperfusion with inosine restores total adenine 
nucleotides levels to about 27 ~mol/g dwt, an increase of about 
·'I ,umol/g dwt. Total adenine nucleotide 
inosine during that period is no more than 30 
biosynthesis 
nmol/min/g 
from 
dwt, 
as measured by the incorporation of 14c-inosine. The reason for 
this discrepancy between these data is not clear at the moment.. 
It seems that inosine can restore ATP and total adenine 
nucleotides levels by another pathway than salvage, 
far unknown mechanism. 
via a so 
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ATP and GTP synthesis involves conversion of IMP to AMP and 
GMP, respectively (see fig. 6.1). The enzymes adenylosuccinate 
synthetase and -lyase, needed for AMP synthesis, have been 
detected in heart homogenates, the first enzyme being rate 
limiting [18, 35]. The enzymes needed for GMP forrnation, 
IMP-dehydrogenase and GMP synthethase have not yeL been 
tissue, but the incorporation of determined in cardiac 
[8-14c]hypoxanthine into myocardial ATP and GTP makes it a lmt.)st 
certain that -these enzymes exist in rat heart. 
IMP concentrat i..ons in heart are low { <0 .1 pmol/ g dwt) [17, 
48, 54, 55]. This suggests that conversion of IMP to AMP and 
GMP is not res-tricted by the enzymes needed for AMP and GMP 
synthesis, but that the first step, conversion of hypoxanthine 
and PR:?P to II>1P, is rate limi. Li..ng bee~ use of the 1 imi ted 
availability of ?RPP. 
6.2.3. De novo synthesis 
IMP is formed from PRPP in a ten-step synthesis. As 
precursors glutamine, ~lanine, aspartate, co2 and ac·~tic ~cid 
(see fig. 6.4), are needed, plus 4 molec11les of A.TP (4-P) per 
molecule IMP formed fig. 6 .4). The first step 
( PRPP-transferase) is thought to be rate 1 i_mit ing. This enzyme 
is PRPP dependent and inhibited by ATP [64]. Also high levels 
of hypoxanthine and inosine are found to inhibit this step. 
~co2: 
: C ' --- glycine\ 
,----- ------~- -~"-<:..--N -------:as_Par~a~e __ N) -- ( C (---'§_ __________ _ 
_ _ _ _ _ _ t ! II : :C formate,: 
( tormate C~-----~C.,i..---1:------ " 
----------->~N/\ ·----':'-N '-
,_ -
--
glutamine ' / 
Fig. 6.4. Precursors for de novo synthesis of the purine ring. 
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Whether this is by direct inhibition [53] or by competition for 
the available '?RPP [61] is unclear at the moment. 
In isolated normox_i,~ rat hearts, total adenine nucleotide 
synthesis rate in ti1'=' d·~ novo pat11.way amounts to 0.1 nmol/min/g 
dwt [64], whicl-1 can be accelerated after ischemia and during 
.ci'.Jose infusion to about 2 nmol/min/g dwt. 
6.3 The relative importance of adenosine phosphorylation, 
hypoxanthine salvage and de novo synthesis 
In sect .. i.0.:.1. 0.2. de novo synthesis, hypoxanthine salvage and 
adenosine phosphorylation in the myocardium have been 
described. Adenosine phosphorylation tal<'·~~3 pl.3.ce at the highest 
rat~ und. is -e.nergr-~l:i..cally the most economical [48]. However, 
free adenosL1e concentrations are low in heart and blood [43 
and appendix paper 1]. During ischemia, the adenosine 
concentration increases in heart. This nucleoside is 
predo1ninant ly washed out ')f the cells and catabolized in the 
blood as shown in chapter 4. For this reason, adenosine 
phosphorylation may be rest.cicted. 
The de novo synth8si.s rate in rat heart is 0.1 nmol/min/g 
dwt. This rate is stimulated after ische,nia and during ribose 
iofusion to about 2 nmol/min/g dwt. Also A.ICA-ribose 
(5-amino-4·-imidazole:-.. >i.:c.-boxamide-ribose), an intermediate of the 
de novo pathway, has been shown to accelerate this process [50, 
55]. 
The hypoxanthine salvage rate in normoxic heart is about 0.7 
n:mol/min/g dwt whec:-1 20 pM hypoxo.nthine or inosine is supplied 
to the l1eart [39 and appendix paper 5]. This rate is increased 
after ischemia and ribose infusion to about 3 nmol/min/g dwt. 
All the above mentioned processes are slow, compared with 
isc''l.emic purine release. However, their importance can be 
indicated by the following example: 
When 20% of ATP is depleted during (moderate) ischemia and 
has tv be resynthet ized in the following rept:'!·cfusion phase, it 
will take two hours to restore normoxic ATP values, provided 
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adenosine supply is aJ.equate with concentrations Clbove 20 JJ.M. 
When only de novo synthesis is activated (which is stimulated 
after ischemia), it takes about G days for the heart ATP 
content to recover. With 20 }-1M hypoxanthine, .A.TP rest:)ration 
will take place within 
this process accomplish 
probably lea(1~ 
("within 15 min, 
2 days. Addition of O.S ITh\1 ribose will 
within 1 day. Twen-ty IJ.!v1 inosine 
~~ven 
see 
hypoxan-thine, although 
faster to recovery of proper A..TP lev<-:l~; 
appendix papec 8), compared to 
thei c incocporation rates are in the 
same order of magnitude. 
It must. be stressed that these recovery times are estimated 
from data. derived from isolated rat hearts. Zirrunet· et al. [64] 
have found that myocardial de novo synthesis r-::1te in the intact 
ani-mal is about 5 times faster than in isolated perfused heart. 
Presumably, in 
active than 
intact animals, glucose 
in isolated hearts [40, 
,rhJre 
44]. flowever, the 
calculation in the above described example shows, that after an 
ischemic event, restoration of i\TP levels can be improved 
drastically, and will probably decreasG the "time at risk", 
especially when inosine is used as precllrsor. 
6.4 Relevance of ATP biosynthesis in the intact animal and in 
the clinical setting 
A-ddition of Persantin (dipyridamole, an adenosiQe transport 
inhibitor) during ischemia and rr3perfusion diminishes thr~ 
adenosine washout from the heart.This adenosine can be used for 
the resynthesis of ATP [4, 11, 12, 28, 49]. Infarct size has 
been limited in dogs as a result of this treatment [49]. 
Furthermore, loss of function 
crossclamping and reperfusion was 
caused by 20 
inhibited [ll, 
min 
12]. 
aortic 
.A.lso, 
addition of erythro-hydroxy-nonyl-adenine (EHNA), an adenosine 
deami..nase inhibitor, plus adenosine increased r'=cdvery of 
function [19]. All factors, which increase adenosine 
concentration, cause peripheral- and coronary vas.odilatation. 
This also can exert a beneficial effect on the heart. 
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Allopurinol, a xanthine oxidase inhibitor, decreases the 
hypoxanthine breakdown to uric acid. In animals, it shows 
cardioprotective properties [14, 31, 33, 36, 46]. It is thought 
that at least part of the beneficial effect is 1uediated by the 
stimulation of ATP synthesis, 
hypoxanthine availability. 
caused by an increased 
Inosine has also been used as a cardioprotective agent [15, 
25, 52, 59]. It provides hypoxanthine and ribose-1-phosphate 
and also shows some interesting phar;nacological properties, 
such as vasodilatation, although it is at least 100 times less 
potent as adenosine [9, 22, 23, 59]. Furthermore, in contrast 
with adenosine, it act .. s as a positive inotropic agAnt [9, 24, 
29, 52, 56, 59] and can stimulate the glucose upta\:e and the 
glycolysis rate [29, 30, 52]. !?art of the posi-tive inotropic 
effect of inosine is beta-adrenergically mediated, although 
inhibition of the Na+-K+-pump cannot be excluded. Infarct si."?.e 
was limited and scar formation accelerated after acute 
experimental myocardial infarction by inosine treatment [ 9, 
41]. Data of DeWitt et al. [10] indicate that application of 
inosine during cardioplegia decreases ATP breakdown and loss of 
fuQ<:: l i_on. 
6.5 Conclusions 
The three processes which restore diminished A.'TP levels 
adenosine phosphorylation, hypoxanthirle sal-vaJe and de novo 
synthesis - all take place in cardiac tissue. Magui.ce et al. 
[35] concluded from enzyme activity measuremen-ts, that 
hypoxanthine incorporation would be by fa.c the most important 
of the three pathways. Literature data and data from our 
laboratory on direct incorporation sb1dies do not support thi..8 
view [7, 39 and appendix paper 3]. When high concentrations of 
purines are supplied to the heart, adenosine incorporation is 
the most predominant process. Adenosine, however, is quickly 
catabolized to inosine and hypoxanthtne. Treatment with 
adenosine must be combined therefore with inhibitors of 
adenosine catabolism. 
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Hypoxanthine salvage and de novo synthesis ."ire much slower 
than adenosine phosphorylation. These two processes produce ATP. 
and G'['·=>. Al th:Jngh the significance or: the relatively high GTP 
synthesis ra-te i..s not clear at the moment, this relatively high 
rat~ could indicate its relevance. Both processes are limited 
by ?RPP availability, i.e., synthesis of PRPP is rate-limiting. 
~RPP concentration is increased after ischemia and during 
ribose infusion, resulting in higher r:ab:::!S of de novo synthesis 
and salvage. "ifuen hypoxanthine is present, PRPP is 
pcefe·rentially used by the salvage process, while delaying or 
in1libi. t ing de rhJ'F) synthesis. 
Inosine is also incorporated into ATP and GT?, via 
conversion to hypoxanthine. Besi·les direct incorporation and 
the a,~li..very of ribose-1·-l?, inosine seems a direct 
action on ?\'I'? concentration. The mechanism of this action is 
unknown at the momen-t. Besides this favorable action on ATP 
levels, it also has desirable pharmacological properties. 
Inosine acts as a peripheral- and coronary vasodilator and has 
positive inotropic propecties. It can also stimulate the 
glycolysis. 
For clinical purposes, ribose and inosine infusion would 
seem to be tlu~ most important for patients who nave suffered 
fr01n -nyocardia l ischemia (angina pectoris, myocardial 
infarr::t.ion, post-operative patiec1ts). ~specially inosine may 
have beneficial effects as a cardioprotective agent during and 
after isc"1F"<JL1ia 1 for instance in cardioplegic solutions during 
open heart surgery. 
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CHAPTER 7 FINAL CONCLUSIONS 
It is of utmost importance for the myocyte to maintain 
adequate A..TP levels throughout its lifecycl(~, Most of the ATP 
needed for contraction is synthetized by the 1nitochondria via 
oxidative phosphorylation, an o2-dependent process. However, o2 
cannot be stored in the cytosol in sufficient amounts and 
therefore must be supplied continuously by the coronary 
arterial system. Lack of oxygen caused by inadequate 511pply of 
arterial blood, ischemia, leads directly to a decreased ATP 
prod11ction. Ulti..mately, as a consequence of this low i\TP 
production, the dephosphorylated purine compounds adenosine, 
inosine, hypoxanthine, xanthine and uric acid leave the heart 
and enter the coronary venous system. Appearance of adenosine 
and catabolites in the venous blood therefore directly 
indicates ATP catabolism as a consequence of impairment of o 2 
supply. For thLs ceason, these cataboli tes are ideal markers 
for ischemia as discussed in chapter 4. 
HPLC has proven to be a good technique to study the above 
described processes. From an analytical point of view, it is a 
sensitive technique, and within onB r11r1. several compounds can 
be determined. The process can be automated and used 
quantitatively to separate radiolabeled compounds. 
The effectiveness of anti-ischemic drugs can be tested by 
their ability to reduce ischemic ATP breakdown, and hence to 
reduce ischemic purine release. ca 2+-antagonists are able to 
reduce ischemic ATP breakdown, when applied to the heart before 
or during ischemia. Substantial controversy exists about their 
mechanism of action. Our results with these drugs can be mainly 
explained by their negative inotropic properties as discussed 
111 
in chapter 5. By their negative inotropic properties, ATP 
demand will be decreased, which makes the cell more capable to 
maintain proper ATP levels and ionic homeostasis. 
The combination of calcium antagonists and beta-blockers has 
been shown to have a synergistic effect in prevention of 
ischemic ATP breakdown. The mechanism of this synergism remains 
to be elucidated. In contrast to application of either drug 
alone, this ATP saving effect is not due to their negative 
inotropic action, and some intracellular action must be 
assumed. Numerous phosphorylation reactions are regulated by 
c-AMP and ca2+ and are probably partially inhibited by combined 
beta-blockade and calcium antagonism. 
After ischemia, reduced myocardial A.TP levels are found, due 
to washout of the purine catabolites. These low ATP levels make 
the heart more vulnerable during a next. ischemic attack and 
must be replenished as quickly as possible. The salvage 
mechanism, i.e. r incorporation of hypoxanthine into ATP, is a 
promising pathway. We have shown, that this pathway is PRPP 
dependent and can be stimulated after ischemia and during 
ribose infusion. This last compound can be used clinically, in 
combination with hypoxanthine and a xanthine oxidase inhibitor. 
The precursor of hypoxanthine, inosine, deserves special 
attention in this context. This compound is able to restore ATP 
levels at a high rate, which cannot be explained by the 
incorporation of inosine via the salvage mechanism alone. It 
also shows some beneficial hemodynamic effects, such as 
positive inotropism and vasodilatation, which makes it 
clinically very a·ttrac·tive. Further research in this direction 
would seem urgently required 1 if the con·tribution of modern 
cardiac biochemistry must have significance for the clinic. 
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Hypoxanthine production by ischemi_c heart 
demonstrated by high pressure liquid 
chromatography 
of blood purine nucleosides and oxypurines 
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Summary 
An isocratic high pressure liquid chromatographic system was developed for the 
estimation of purine nucleosides and oxypurines in blood. Use was made of a 
reversed-phase column. Nucleotides derived from erythrocytes affected the separa-
tion; these compounds were removed with Al 20 3 . The recovery of the whole 
clean-up procedure exceeded 75%. and the lower detection limit of the assay for 
blood metabolites was 0.1 l'moljl. In 6 healthy volunteers, non-resting, the follow-
ing blood concentrations (mean values-+- S.D. in l'moljl) were observed: adenosine 
( < 0.1), inosine (0.2-+- 0.1), hypoxanthine (2.2-+- 1.3) and xanthine (0.2-+- 0.1 ). In 
plasma and serum the total amount of these compounds was 1.9 and 5.4 times 
higher, respectively, presumably due to nucleotide breakdown during blood process-
ing. The myocardial arterial-venous differences of blood purine nucleosides, 
oxypurines and lactate were subsequently measured in blood samples from 13 
patients with angiographically documented ischemic heart disease, undergoing an 
atrial pacing stress test. No significant release of adenosine, inosine and xanthine by 
the heart was detectable in this study. The myocardial arterial-venous difference of 
lactate changed from 0.01-+- 0.03 mmoljl (mean-+- SEM) at rest, to -0.10-+- 0.04 
mmoljl during pacing ( p < 0.002). Relatively larger changes were observed for 
hypoxanthine: pacing increased the arterial-venous difference from -0.01-+- 0.05 to 
- 0.51 -+- 0.17 i!IDO!jl ( p < 0.02). We conclude that the high pressure liquid chro-
matographic assay of blood hypoxanthine is a useful tool in the diagnosis of 
ischemic heart disease. 
* To whom sorrespondenc.e should be addressed. 
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Introduction 
During and after hypoxia or ischemia, there is in the heart, as well as in other 
muscles, excessive ATP breakdown. This degradation of ATP causes an efflux of 
breakdown products, which are able to pass through the cell membrane, and are 
released into the blood. The purine derivatives adenosine, inosine and hypoxanthine 
are thought to be markers for ischemia (for a review, see ref. [!]). Because of high 
activities of adenosine deaminase (EC 3.5.4.4; ADA) and nucleoside phosphorylase 
(EC 2.4.2.1; NP), and low or non-detectable amounts of xanthine oxidase (EC 
1.2.3.2; XO) in the heart and blood, hypoxanthine seems very promising as marker 
for myocardial ischemia [2,3]. Enzymatic purine determinations [ 4,5] are time-
consuming and do not differentiate between hypoxanthine and xanthine. Recently 
high pressure liquid chromatography (HPLC) came into use for the determination of 
nucleosides and purine bases in urine, plasma and serum [6-8]. We have developed a 
method to determine these compounds in blood, and have compared the levels of 
adenosine, inosine, hypoxanthine and xanthine in blood, plasma and serum. With 
the assay we demonstrated the myocardial release of hypoxanthine in patients with 
angiographically documented ischemic heart disease, undergoing an atrial pacing 
stress test. 
Materials and methods 
Enzymes (XO, 13 U jml; NP, 10 U jml; ADA, 140 U jml) were purchased from 
Boehringer-Mannheim, F.R.G.; CHpH (Uvasol), NH 4 H 2 P04 , KOH, K 2C03 • 
adenosine, hypoxanthine and uridine from Merck (Darmstadt, F.R.G.). Uric acid 
was supplied by Sigma (Saint Louis, MO, U.S.A.), and the other standards by 
Koch-Light (Colnbrook, Bucks., U.K.). Al 20 3 came from Desaga, Heidelberg, 
F.R.G. [U- 14 C]nucleosides and oxypurines were obtained from The Radiochemical 
Centre (Amersham, Bucks., U.K.; spec. act. 50-60 Cijmol). HC104 was supplied by 
Merck, and used as a 1.3 moljl dilution. Water was purified with the Milli-
Ro4jMilli-Q system (Millipore Co., Bedford, MA, U.S.A.). 
Blood sample treatment 
Blood (2.0 ml) was deproteinized immediately with an equal volume of HC104 as 
described by Remme et al. [2]. Plasma was prepared by adding 3 ml blood to a 
heparinized tube and immediate centrifugation for 15 min at 3000 X g (4°C). Serum 
was prepared from 3 ml blood which had been allowed to clot at room temperature 
for 30 min and subsequent centrifugation. Plasma and serum were also deproteinized 
with equal volumes of HC104 . After centrifugation, the supernatant fluids were 
stored at -20°C. The acid extracts were brought to pH 5-7 at 0°C with an 
automatic titration device (Radiometer, Coperthagen) using 150-200 1'1 6 moljl 
KOH +I moljl K 2C03 . KCI04 was spun down for 10 min at 12000 X gat 4oc. For 
plasma and serum 200 1'1 of these extracts were directly injected onto the HPLC 
column. For whole blood extracts, removal of nucleotides appeared to be necessary. 
We used the method of Chatterjee et al. [9], with some minor differences. We applied 
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1.5 ml of the deproteinized, neutralized blood sample onto a pre-washed column of 
Al 20 3 (0.6 g) in a Pasteur pipette, and eluted it with 5.0 ml 10 mmoljl TrisjHCl, 
pH 7.4. For faster elution, a vacuum was applied; with a 1225 sampling manifold 
(Millipore Co.) 12 samples were treated at the same time. With standards (about 10 
ILmoljl oxypurines and nucleosides, and about 5 mmoljl nucleotides), we found 
recoveries exceeding 90%, whereas the nucleotides were fully retained. These values 
are in close agreement with values in the literature [9]. 
Recovery studies for blood treatment 
To carry out recovery studies, it is necessary to inactivate first the purine 
metabolizing enzymes in the blood. We achieved this by rapid mixing of blood with 
cold HCl04 . This procedure is comparable to the determination of recoveries after 
inactivation of enzymes by freeze-clamping heart tissue, or removal of cells from 
blood, and subsequent addition of standards [4,5,7,8,10-12]. If radioactive standards 
were used 10 ILl 14 C-labelled hypoxanthine, xanthine, inosine or adenosine were 
mixed with 10 ml HCl04 . For the determination of radioactivity 50 ILl aliquots were 
mixed with 10 ml Insta-gel (Packard Instr. Co., Downers Grove, IL. u.S.A.) and 
counted with a Packard Tricarb 2650 liquid scintillation counter. 
High pressure liquid chromatography 
A Varian 8520 high pressure liquid chromatograph (Varian, Palo Alto. CA, 
U.S.A.) was used with a pneumatic sampling device (Valco Instr. Co., Houston, TX, 
U.S.A.), an autosampler (Varian), a Model 440 fixed wavelength UV -detector 
(Waters Assoc .. Milford, MA, U.S.A.) and a chromatographic data system C-111 
(Varian). A 4 mm I. D. X 30 em prepacked ILBondapakjC 18 column (Waters Assoc.) 
was used in these studies. The packing material has an average particle size of l 0 IL m 
and consists of porous silica to which a monolayer of octadecyltrichlorosilane is 
chemically bound. Chromatographic conditions were adapted from earlier work [13]: 
200 ILl samples were eluted from this column with 10 mmoljl NH 4 H 2 P04 /CH 30H 
(10: l, v jv), pH 5.50. The flow rate was 60 ml/h ( p = 80 bar). 
Lactate assay 
Lactate was determined in acid supernatants in duplicate with an AutoAnalyzer 
II (Technicon, Tarrytown, NY, U.S.A.) as described by Apstein et al. [14]. 
Statistical analysis 
Statistical analysis in Table II was performed with a two-group comparison test 
based on Student's t distribution, and those in Table III and Fig. 5 by Student's 
paired t test. p-values < 0.05 (two-sided) were considered significant. 
Results 
HPLC 
Fig. I represents the separation of several nucleosides and purine bases. The lower 
detection limit with a 200 ILl sample loop is 0.01 ILmoljl; the method is linear up to 
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200 l'moljl (Fig. 2). The standard deviation at the 10, I and 0.1 l'mol/1 level is 
< 0.12%, < 5% and < 9%, respectively (n = 9). Identification of the compounds in 
pre-purified blood samples was achieved by retention times (Fig. Ja). co-
chromatography of standards (Fig. Jb) and enzyme shifts (Fig. 3c). as described by 
Hartwick et al. [7]. The clean-up procedure of the blood samples causes a 9-fold 
dilution, which increased the lower detection limit in blood to 0.1 I' moljl. 
A254 
0.01 X 
6 
H 5 
2 
3 
A 
4 
0.005 
0 
0 5 10 15 20 
retention time (min) 
Fig. I. bocratic HPLC separation of nuclcosidcs and purine bases (2-4 )lilloljl). Column: J.LBondapak 
C 1:;; (4X300 mm). Buffer: 10 mmoljl NH 4 H 2 P04 jCH 30H (10: L vjv), pH 5.50. Flow rate: 60 ml/h. 
Injected sample volume: 200 p.l. I, uric acid; 2. uraciL 3. uridinc: H, hypoxanthine: X, xanthine: 4, 
xanthosine; L inosine; 5, guanosine; 6, adenine: A, adenosine. 
Recoveries 
With radioactive standards the recoveries for the whole clean-up procedure 
exceeded 75% (Table I). With non-radioactive standards, assayed by HPLC, we 
found comparable recoveries in the concentration range of our interest (Fig. 4). 
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Fig. 2. Calibration curves for HPLC of hy-poxanthine ( 0--- 0) y= 2.16x- 0.09. r= 1.000: xanthine 
(II 8) _v=0.73x+O.Ol. r=0.999; inosine (11---11) y=l.59xT0.02, r=l.OOO: adenosine 
(0--0) v=2.23x-OOS. •·=O 999. 
Purine derivatives in blood, plasma and serum 
Six healthy non-fasting, non-resting volunteers donated venous blood. In their 
blood, plasma and semm. hypoxanthine, xanthine, inosine and adenosine were 
TABLE I 
RECOVERY OF PURINE NUCLEOSIDES AOID OXYPURIKES DURIOIG SAMPLE PREPARA-
TION 
(Data represent mean values of 6 experiments± S.E.M.) 
Clean-up stage 
Acidified human blood ( = \00%) 
Acid supernatant 
Neutralized extract 
Alumina eluate 
Adenosine 
dpm added 
50000 
recovery (%) 
96±3 
88±2 
79=2 
Inosine 
330000 
106±1 
101 ±2 
91±4 
Hypoxanthine Xanthine 
230000 44000 
101=1 93=4 
92±2 99±4 
86± 1 76=6 
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0.012 H 
0.003 H 0. 008 
0.004 
0 
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0. 002 retention time (min) 
0.001 
X 
0 5 10 15 20 
retention time (m'ln) 
Fig. 3 (a, b and c). Chromatogram of blood from a normal donor. (a) Blood was deprotcinized and 
purified as described under "Materials and methods''. Conditions. see Fig. \. (The upper panel rcpresenb 
the same chromatogram with a 4 times lower detector sensitivity.) H, hypoxanthine~ X, xanthine: I, 
inosine: A adenosine. 
TABLE II 
CONCENTRATION OF ADENOSINE, INOSINE AND (HYPO)XANTHINE IN HUMAN BLOOD, 
PLASMA AND SERUM 
(Data represent mean values in p.moljl of 5~6 volunteers±S.D.) 
Preparation Adenosine Inosine Hypoxanthine Xanthine 
(~mol/!) (~mol/!) (~mol/1) (~mol/!) 
Blood <0.1 0.2±0.1 2.2± 1.3 0.2±0.1 
Plasma <0.1 0.2±0.2 3.6±0.8 1.1±0.7* 
Serum 0.9±0.2 *.A. 1.0±0.4 *"' 5.6±1.9* 6.6±2.1 *it. 
* p<O.OS vs. blood,"' p<O.OS vs. plasma. 
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retention time (min) 
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Fig. 3(b). Chromatogram as in (a), after co-injection of a solution containing hypoxanthine, xanthine, 
inosine and adenosine. 
determined. The results are listed in Table II. As can be seen plasma shows 1.6 times 
higher levels of hypoxanthine and 5.5 times higher levels of xanthine than blood. 
Serum has significantly higher values of the AMP-catabolites. Here the values are 2.5 
times (for hypoxanthine) to 33 times (for xanthine) higher. compared to blood. 
Determination of blood purine nucieosides, oxypurines and lactate of patients with 
ischemic heart disease 
Thirteen patients with angina pectoris were catheterized as described by Remme 
et al. [2]. The patients were fasted overnight and 36 h before catheterization all 
medication was stopped. Before catheterization 50 000 IE of heparin were infused. 
The diagnosis, ischemic heart disease, was established by angiography (obstruction 
of at least one coronary artery >SO%). Before angiography an atrial pacing stress 
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A 2541 (c) 
0 0041 
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0 002~ 
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0 001 
X 
A 
.---~r----,----.-----,-----, 
0 5 10 15 20 25 
retention time (min) 
Fig. ~(c). Chromatogram as in (a), after 30 min incubation with XO. NP and ADA. 5 t-tl each. 
test was performed. During a control period, maximal pacing, and 5 and 20 min 
after pacing, arterial and coronary sinus blood samples were taken. At rest no 
significant myocardial arterial-venous hypoxanthine or lactate difference was seen 
(Fig. 5). During maximal pacing, a rise in coronary sinus hypoxanthine (from 0.83 to 
1.43 l'moljl, p < 0.01) and lactate (from 0.87 to 0.98 mmoljl, p < 0.005) was 
observed, which fell off after pacing. The arterial levels of these compounds 
remained constant. The myocardial arterial-venous difference of hypoxanthine 
changed from -0.01 l'moljl at rest to -0.5 I l'moljl ( p < 0.02) during pacing 
(Table Ill). We showed in earlier work [2,15] that patients with anginal pain, but 
with patent coronary arteries (<50% obstruction), did not produce myocardial 
hypoxanthine. Relatively smaller changes were observed for lactate: pacing in-
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Fig. 4. Recoveries determined by HPLC. Standards were dissolved in HC104 . before blood was added. 
H)'poxanthine: (0 --- 0) y=0.72x+ 0.77, r=0.997: xanthine: (8---fJ) y=0.68x _.,._ 0.01, r::: 0.999; 
inosine: (lllil---ll)y=0.72x-0.03, r=0.993: adenosine: (D---C:)y=0.77x+0.20. r=0.995. For 
conditions. sec legends to Figs. I and 3. 
Fig,. 5. Arterial (0---0) and coronary sinus (8---fl) hypoxanthine and lactate levels during, an 
atrial pacing sucss test of 13 patients with ischemic heart disease. C 1, control period: P1, maximal pacing: 
C~ and C3 • 5 and 20 min after maximal pacing,, respectively. Mean values are given \vith l S.EM. 
(* p<0.05 vs. arterial levels). 
TABLE III 
MYOCARDIAL ARTERIAL-VENOUS DIFFERENCES AND EXTRACTIOI' VALUES OF HYPO-
XANTHII'E AND LACTATE DURI);G AN ATRIAL PACING STRESS TEST OF PATIENTS 
WITH ISCHEMIC HEART DISEASE 
The extraction value is defined as the arterial concentration minus coronary' sinus concentration divided 
by the arterial concentration, time." I00'7f .. Mean \·alues arc given::: S.E.M. ( n= 13) 
Heart rate Hypoxanthine Lactate 
(beats/min) 
A-CS Extraction A-CS Extraction 
(~moljl) (%) (mmoljl) (Sf) 
c, 79±4 -0.01 =0.05 -6± 6 0.01 ±0.03 4=4 
P, 144:.:±:::4 * -0.51=0.17' -68± 18 * -0.10=004. -9=6 * 
c, 7R"' 4 -0.33=0.14. 49:::±:::14* 011~±003 13=6 
c, R0±·4 -0.15=11.118 .~35:±:14 0.12±0.04 * 19=6 * 
* p<o.os vs. C 1. 
A-CS. arterial-venous difference: C 1, control period: P1, maximum pacing; C 2 , 5 min after pacing: C~. 
20 min after pacing. 
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creased the arterial-venous difference from 0.01 to -0.10 mmoljl ( p < 0.002, see 
Table III). Significant production of lactate, calculated either as arterial-venous 
difference or extraction, only took place during maximal pacing, but significant 
hypoxanthine release was also present 5 min after pacing was stopped (Table III). 
The coronary sinus levels of adenosine, inosine and xanthine during the control 
period were 0.17-+- 0.04, 0.53-+- 0.11 and 0.20-+- 0.14 l'moljl, respectively. No 
significant arterio-venous differences were observed throughout the test. 
Discussion 
Hypoxanthine, xanthine, inosine and adenosine levels in human blood (or plasma 
or serum) have been measured in normal adults [7-11,16], patients with gout [17], 
immunological disorders [ 18], ischemic heart disease [2,3, 19,20]. pregnant women 
[21], and children [21]. The values reported show considerable variation, which could 
be caused by: 
(I) Differences in assay methods. The enzymatic determination of hypoxanthine, 
for instance, does not differentiate between hypoxanthine and xanthine. 
(2) As we have shown in Table II, large differences occur in the levels of these 
compounds when these are measured in blood, plasma or serum from the same 
person. These diff~rences can be explained by the enzymatic degradation of ATP, 
deri.ved from blood cells, and ADP, released from platelets during clotting [7,8]. 
Furthermore xanthine, as the end-product of guanine nucleotide catabolism, can be 
expected to occur in higher concentrations in plasma and serum than in blood. For 
instance, blood xanthosine, guanosine and guanine are rapidly converted to xanthine 
[22]. For this reason instant inactivation by acid seems indicated, when one wants to 
determine the nucleoside and oxypurine concentration in the blood. 
(3) Physical activity also influences the levels of these AMP catabolites in blood. 
Sutton et al. [23] showed that the plasma levels of oxypurines are twice as high 
during and after physical training compared with control levels. Although they did 
not measure inosine levels in the plasma, urinary inosine during excercise is elevated 
tenfold, possibly indicating increased inosine levels in the blood. Therefore, if one 
wants to measure normal values, it is also important to define the physical state of 
the group under study. 
We feel that measuring myocardial arterial-venous differences of blood hypo-
xanthine levels could give insight into the metabolic state of the heart; the method 
described here makes it possible to measure a number of purine metabolites in 
blood. The observations on the patients undergoing an atrial pacing stress test 
indicate that hypoxanthine is a more sensitive parameter for myocardial ischemia 
than adenosine, inosine, xanthine or lactate, because hypoxanthine release is more 
pronounced and of a longer duration than that of the other compounds. 
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ATP is one of the most important substances for the proper functioning of 
the heart [1]. Creatine phosphate (CrP) serves as an ''energy buffer", and could 
also play a role in the rapid transport of energy between cell compartments 
[2]. Separations by high-performance liquid chromatography (HPLC) of 
nucleotides on an ion-exchange column with detection at 254 nm have been 
carried out [ 3, 4] . Recently, determinations of nucleotides on reversed-phase 
columns [ 5], with or without ion-pairing [ 6, 7], have also been made. CrP, 
however, cannot be detected at 254 nm. Juengling and Kammermeier (6] 
detected CrP at 210 nm, but their HPLC system could not separate adenine 
nucleotides. Heldt et al. [ 8] used a phosphate analyzer as a detector and were 
able to detect CrP in one run with nucleotide quantitation. We modified the 
separation and detection conditions of Edelson et al. [ 9] . Analysis time was 
decreased by a factor of two and detection at 210 nm was introduced. We 
obtained sufficient resolution to quantitate CrP and adenine nucleotides within 
30 min. 
EXPERIMENTAL 
Reagents 
Hexokinase (EC 2.7.1.1, 140 U/ml), creatine kinase (EC 2.7.3.2, 25 Ujml), 
and adenylate kinase (EC 2.7.4.3, 360 Ufml) were purchased from Boehringer, 
Mannheim, G.F.R.; AMP-deaminase (EC 3.5.4.6, 30-60 U/mg) was obtained 
from Sigma (St. Louis, MO, U.S.A.). KH 2 P04 , H3P04 , KOH and HCl04 were 
from Merck (Darmstadt, G.F.R.), the nucleotides and CrP were from 
Boehringer and creatine was from Technicon (Tarrytown, NY, U.S.A.). Water 
129 
was purified with the Milli-Ro4jMilli-Q system (Millipore, Bedford, MA, 
U.S.A.). 
High-performance liquid chromatography 
A Varian 8520 HPLC system (Varian, Palo Alto, CA, U.S.A.) was used, 
which consisted of two positive displacement pumps, a variable-wavelength UV 
detector (Varichrom) set at 210 nm, a pneumatic sampling device, and a chro-
matographic data system (CDS-111) connected with a chart recorder. Buffers 
were prepared on the day of use and filtered through a 0.45-f.lm filter 
(Millipore). Buffer A consisted of 0.01 M H 3P04 , adjusted to pH 2.85 with 
KOH; buffer B consisted of 0.75 M KH 2 P04 , pH 4.40. The column (Partisil-10-
SAX, 0.4 X 25 em, particle size 10 f.lm; Whatman, Maidstone, Great Britain) 
was eluted with buffer A at a flow-rate of 2.0 ml/min. Five minutes after in-
jection, a gradient started with an increase of 4% B per minute until 100% B. 
Rat heart perfusions and sample treatment 
Isolated hearts from male rats (Wistar strain, 300-400 g) were perfused 
retrogradely for 30 min and quickly frozen as described before [10]. After 
weighing, cardiac tissue was ground in a mortar, precooled with liquid nitrogen. 
One half of the sample (about 0.5 g) was freeze-dried for determination of 
percentage dry weight; the other half was extracted with 3.0 ml of 0.8 M 
HCl04 . After thawing and centrifugation, 2.0 ml of the supernatant fluid were 
neutralized at O'C with about 200 Ill of 6 N KOH and the KClO. was spun 
down at 4 'C. A 20-f.ll volume of this supernatant was applied to the HPLC 
column. 
RESULTS AND DISCUSSION 
Chromatograms 
Fig. 1 shows the separation of a standard mixture of thirteen nucleotides and 
creatine compounds. Fig. 2A gives the separation of the adenine nucleotides 
and CrP in an extract of an oxygenated rat heart. 
Linearity, recovery and sensitivity 
The lower detection limit with a 20-f.ll sample loop varies between 20 pmol 
for AMP and 100 pmol for CrP, and the determination is linear up to 400 nmol 
for all compounds indicated. Recoveries, determined in a model system (high-
energy phosphates added to a 1 gjml albumin solution), after deproteinization 
and neutralization, exceeded 95%, with a standard deviation of <3% for the 
adenine nucleotides and <6% for CrP (n ~ 5). 
Peak identification 
Fig. 2A gives the chromatogram of a rat heart extract. The main peaks in the 
extract are creatine, NAD, CrP, ADP and ATP. Peak identification was made by 
comparing retention times with standards and by enzymic peak shifts [3]. Fig. 
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Fig. 1. Separation of standard nucleotides and creatine (Cr) compounds (0.2-0.5 mmol/1). 
Injection volume, 20 J..Ll; flow-rate, 2.0 ml/min; eluents, A = 0.01 I'v! H 3P04 , adjusted to 
pH 2.85 with KOH, B" 0.751VI KH,PO, (pH 4.40); column, Partisil-10-SAX. 
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Fig. 2. Chromatogram of a rat heart extract and peak identification by enzymic conversions. 
HPLC was carried out with a 20-~..d extract, prepared as described in the text. For HPLC 
conditions, see Fig. 1. Panel A gives the chromatogram of untreated extract. Enzymic peak 
shifts were carried out according to the method of Brown [ 3 J. An aliquot of the extract was 
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incubated for 30 min at 37°C with 0.7 mU hexokinase and D-glucose to convert ATP: 
ATP + glucose __,. ADP + glucose-6-phosphate (panel B). Subsequently CrP was broken down 
by addition to the extract of 0.1 mU of creatine kinase and MgC1 2 • Under the influen<:e of 
creatine kinase and hexokinase, the overall reaction is: CrP +glucose --~o creatine+ glucose-6-
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phosphate (panel C). In a similar way ADP was converted with 1.8 mU of adenylate kinase: 
2ADP + glucose -+ 2AMP + glucose-6-phosphate (panel D). Finally, the AMP peak was 
shifted with 0.4 mU of AMP-deaminase: AMP- IMP+ NH, (panel E). 
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2B-E shows chromatograms after subsequent incubation with hexokinase (B), 
creatine kinase (C), ader,ylate kinase (D) and AMP-deaminase (E). Complete 
removal of ATP, CrP and AMP was observed, with a concomitant increase of 
the conversion products ADP, creatine and IMP. ADP in the chromatogram 
shown in Fig. 2D is not completely removed, presumably because of an unfavor-
able equilibrium of the adenylate kinase reaction. After addition of AMP-de-
aminase, which removes AMP, all ADP is converted (Fig. 2E). 
Rat heart concentrations 
In Table I concentrations are given for adenine nucleotides and CrP, 
measured in normal and anoxic rat hearts. These values are in the same range 
as found in the literature [1, 11, 12]. 
TABLE I 
CONCENTRATION OF ADENINE NUCLEOTIDES AND CREATINE PHOSPHATE IN 
RAT HEART 
Hearts were perfused retrogradely (Langendorff perfusion) for 30 min with a modified 
Tyrode solution, equilibrated with 95% 0 2-5% C02 (normoxia), or for 15 min perfused 
with 95% 0 2-5% C0 2 and 15 min with 95% N 2 -5% C02 (anoxia). Heart extracts were 
prepared as described in the text. For HPLC conditions and peak identification, see Figs. 1 
and 2. 
Condition "mol/g dry weight(± S.E.M.) 
ATP ADP AMP CrP 
Normoxia 20.9 ± 0.5 7.3 ± 0.4 0.2 ± 0.1 29.3 ± 2.8 
Anoxia 9.9 ± 1.9* 9.5 ± 2.2 5.1 ± 1.6* 7.4 ± 1.8* 
*p< 0.005 vs. normoxia, n = 5-7. 
Conclusion 
We conclude that the method presented here is a quick and accurate way to 
determine myocardial high-energy phosphates. Within 30 min the concentra-
tion, energy charge [13] and ATP/CrP ratio can be read from the chromato-
gram. 
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Abstract---!. Cytosol from pig skeletal muscle. but not heart. contains an inhibitor of AMP-deaminase 
(AMP-D. EC 3.5.4.61 which reduces AMP-0 activity 8-fold. 
2. Heart and skeletal muscle AMP-D have been purified to apparent homogeneity by cellulose 
phosphate and DEAE-Sephacel chromatography. 
3. AMP-0 from skeletal muscle is inhibited more severely than the heart enzyme by an increase in 
adenylate energy charge to levels exceeding 0.4. Nevertheless both enzymes seem to be regulated by the 
energy charge. which contrasts with reports for rabbit heart AMP-D. 
IYfRODLCTIO!\ 
AMP-deaminase (AMP-D. EC 3.5.4.6) catalyzes the 
hydrolytic deamination of AMP to IMP and NH 3 . 
The enzyme seems important in the regulation of the 
adenylate energy charge {ATP + 0.5 ADP)... 
(ATP + ADP +AMP) and the adenine nucleotide 
pool. together 'lvith 5'-nucleotidase (EC 3.1.3.5) and 
adenylate kinas<:: (EC 2.7.4.3) (see review: De Jong. 
1979). Relatively little is known about AMP-D in 
heart. In vie\\' of the presence of tissue specific iso-
zymes of AMP-0 (Ogasawara er ol., !978; 1982), it 
seems likel-y that the physiological role of this enzyme 
may vary from tissue to tissue. 
AMP-D has been purified to homogeneity from 
skeletal muscle of rabbit (Smiley et al.. 1967; Stan-
kiewicz er ol., 1979). rat (Coffee & Kofke, 1975: 
Ranieri-Raggi and Raggi. 1976; Ogasawara er a/., 
1978: Shiraki era/ .. 1979: Stankiewicz et a/.. 1979) and 
man (Stankiewicz, 1981: Ogasa\vara eta/., 1982). The 
heart enzyme has been purified only partially from a 
number of mammalian sources: rabbit (Chung & 
Bridger. 1976: Solano & Coffee. 1978: Barsacchi eta/., 
1979), rat (Ogasawara eta/., 1975: Kaletha & Sklada-
nowski, 1979). pig (Purzycka-Preis eta/ .. 1978). beef 
(Skladanowski er a/ .. 1981) and man (Kaletha et a/., 
1979: Ogasawara et al.. 1982). Because of our interest 
in pig purine metabolism {De Jong & Goldstein, 
1974; DeJong era/ .. 1977) we decided to purify por-
cine heart and skeletal muscle AMP-D to homogen-
eity and studied the response of the enzymes to 
various adenylate energy charges*. 
:VIATERIALS AI"\D METHODS 
;Vuclwtidr>s 
These were purchased from Boehringer, Mannheim. 
GFR. 
* Part of this study has been presented at the 4th Inter-
national Symposium on Human Purine and Pyrimidine 
Metabolism. Maastricht, The Netherlands (Verwoerd era/., 
1982). 
AMP-D assay (see Smiley et al .. 1967} 
The enzyme was incubated at JO'·C with 50 mM imida-
zole.HCI, 20mM sodium cacodylate. 0.5M KC\. 1 mM 
2-mercaptoethanol and 5 mM 5'-AMP (except for the ex-
periments shown in Fig. 1 ). The pH was 6.5 and the final 
volume 1.0 ml. IMP formation was detected at 285 nm with 
a Gilford 2600 spectrophotometer (Gilford. Oberlin. OHI. 
Protein determination 
The Coomassie Brilliant Blue (Biorad Laboratories, 
Munich. GFR) assay was used with bovine serum albumin 
(Sigma, St. Louis. MO) as the standard. 
Purification of" AMP-D (see Coffee & Kofke, 1975: Pur· 
zycka-Preis et al .. 1978) 
Each buffer contained I m\.1 2-mercaptoethanol. All 
steps were performed at 0-5'C. Heart or white skeletal 
muscle (100 g) from piglets (Sus .lcrofa. about 25 kg) was 
homogenized with 3 vol (v/w) of 0.18 M KCl-0.054 M 
KH 2 P04-0.035 M K1 HP04 (pH 6.51. The homogenate 
was centrifuged for 30 min at 25.000 g. and the supernatant 
fluid passed through Nuova filter material (Hoffmann. 
Overath-Eulenthal. GFR). The eluate was stirred with 
30 ml washed cellulose phosphate Pll (Whatman, Maid-
stone. UK: 5 g) for I hr. The slurry was then transferred to 
a glass column (1.5 x l2cm) and washed with the extrac-
tion buffer until the effluent had an absorbance at 280 nm 
below 0.01. The enzy'me was eluted with I M KCI (pH 6.5) 
Fractions with the highest specific activity were pooled and 
dialyzed against 0.045 M potassium phosphate (pH 7.2). 
The dialyzate was applied to a DEAE---Scphacel column 
(Pharmacia. Uppsala. Sweden: 1.5 x 15 em), v,.-hich had 
been equilibrated with this phosphate buffer. and washed 
with 100 ml buffer. The enzyme was eluted with a linear 
gradient consisting of 100 ml each of 0.045 and 0.45 \1 
potassium phosphate (pH 7.2). 
Generatio11 of" energr charge ratio" 
AMP and A TP were incubated with adenylate kinase as 
described by Coffee & Solano (1977). The concentrations of 
AMP. ADP and ATP were determined by high perform-
ance liquid chromatography (Harmsen et al .. 1982). The 
individual nucleotide concentrations were found to be 
within lO'_J~ of the calculated ones. 
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Table 1. AMP-deaminase activity (U,img protein) of pig 
heart and skeletal muscle cytosol 
Treatment 
None 
Gel filtration 
Heart 
0.099 ± 0.006 
0.104 ± 0.010 
Skeletal muscle 
0.340 ± 0.018*t 
2.74 ± 0.038* 
Mean values of 3 to 4 experiments + SEM Student's 
r-test: *P < 0.001 vs heart. tP < 0.001 vs treatment with 
Sephadex G-25 gel. 
RESULTS 
Acririty 
Table 1 shows that the activity of AMP-D in the 
cytosol of skeletal muscle could be increased 8-fold 
(to 2.7 U/mg protein) by removal of endogenous in-
hibitors. This treatment did not influence the heart 
enzyme, which had an activity of 0.10 U/mg protein. 
Purification 
In Table 2 data of the purification of AMP-D from 
heart and skeletal muscle are presented. With cellu-
lose phosphate and OEAE-Sephacel chromatography 
they were purified 426 and 526 times, respectively. 
Disc electrophoresis on polyacrylamide (10% acryl-
amide. plus sodium dodecylsulfate) gave only one 
band. The cardiac enzyme did not show 5' -nucleoti-
dase or adenosine deaminase (EC 3.5.4.4) activity. It 
was quite labile: 10% of enzymic activity disappeared 
when the preparation was kept overnight at -20°C. 
Repeated freeze-thawing caused the activity to disap-
pear completely. Purified skeletal muscle AMP, on 
the other hand, remained active. when treated like 
this. 
Properties of the purified enzymes 
The apparent K, of purified heart and skeletal 
muscle AMP-D was 3.8 and 1.2 mM, respectively. The 
Hill constant, nH, was comparable for the two 
enzymes: LO (heart AMP-D) and 1.1 (skeletal muscle 
AMP-D). 
Effect of energy charge 
Skeletal muscle AMP-D was inhibited by increas-
ing adenylate energy charge {Fig. 1). Heart AMP-D 
showed a biphasic response. At energy charges which 
are probably physiological ( > 0.5), skeletal muscle 
AMP-0 is inhibited 1.5-2.7 times more than heart 
AMP-D. The effects were most pronounced at lower 
(5 mM) total adenine nucleotide pool sizes. 
OISCliSSIOI\ 
The activity of AMP-Din pig skeletal muscle cyto-
sol increased 8-fold, when low molecular weight com-
ponents were removed (Table 1). It is of interest that 
Fishbein et a/. (!981) found a specific inhibition of 
muscle AMP-DIn serum and plasma of humans and 
animals. Apparently pig heart cytosol did not contain 
inhibitors which could be removed by gel filtration 
(Table 1 ). The Vmo• is 25 times lower than that in 
skeletal muscle cytosol (after gel filtration). Ogasaw-
ara eta/. (1982) did a similar observation in human 
tissues. 
Skeletal muscle AMP-D has been purified to hom-
ogeneity from a variety of species. However, the heart 
enzyme has only been completely purified from duck 
(Pekke\' and Kirker, 1979), but not from the mam-
malian heart. Purzycka-Preis et a/. (1978) obtained 
AMP-0 from porcine heart by cellulose phosphate 
chromatography. but their preparation was presum-
ably impure. We found it necessary to use DEAE-
Sephacel chromatography after the cellulose phos-
phate step to obtain an apparently homogeneous 
preparation. Our procedure is considerably simpler 
than the one used by Pekkel' & Kirkel' (1979). 
Purzycka-Preis eta/. (1978) found a half-saturating 
substrate concentration for porcine heart AMP-0 of 
5 mM. This is comparable to our value (3.8 mM). For 
pig skeletal muscle AMP-0 we found the Km to be 
3·fold lower. This contrasts findings by Ogasawara et 
a/. (1975) who reported that rat skeletal muscle 
AMP·D has a K, which is 3-4 times higher than that 
of heart. 
Purzycka·Preis et a/. (1978) reported cooperative 
binding of AMP for pig heart AMP-D (nH = 2.35). 
This value decreased to about 1 on addition of ATP 
and liposomes. In our hands nH = 0.96 was found for 
the purified enzyme without any addition, which is 
similar to the value reported for rat heart AMP-0 
(Kaletha & Skladanowski, 1979). We conclude from 
our studies that the number of binding-sites for AMP 
on AMP-D from pig heart and skeletal muscle is the 
same. 
Solano & Coffee (1978) reported that rabbit heart 
AMP-D was unaffected by energy charges below 0.9. 
in contrast to the skeletal muscle enzyme which in-
creased gradually in activity when the energy charge 
was decreased from 1.0 to 0. We observed that pig 
skeletal muscle enzyme AMP-0 behaved comparably 
to that from rabbit (Fig. 1). Although the inhibition 
observed with physiological energy charges was less 
for the heart enzyme (Fig. 1 ~ AMP-D from porcine 
heart seems to be regulated by the energy charge, 
whereas rabbit heart AMP-D always seems to be in 
Table 2. Purification of pig heart and skeletal muscle AMP-deaminase 
Specific activity Purification Yield 
(Ujmg protein) I x) i%1 
Purification step Heart SM Heart SM Heart SM 
Supernatant fluid 0.10 0.30 Ill Ill (100) (100) 
Cellulose phosphate 20 75 208 252 20 62 
DEAE-Sephacel 30 156 426 526 ll 42 
SM, skeletal muscle. 
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5 mM nucleotides 10 mM nucleotides 20 mM nucleotides 
• 50 
0 
~ 
~ 
0. 5 
energy charge 
1.0 
.5 
energy charge 
1.0 0. 5 1.0 
energy charge 
Fig. l. Response of AMP-D to variation in the adenylate energy charge at different total adenine 
nucleotide pool sizes. Purified enzyme of pig skeletal muscle (SM. 3/lg) and heart (H, 10 pg) were tested 
in triplicate. Maximal activities (!-!mol/min) observed at 5 mM nucleotides: 0.39 (S\1) and 0.12 (H): :.~t 
10 mM nudeotides: 0.53 (SM) and 0.30 (H); at 20 mM nucleotides: 0.49 (SM) and 0.38 (H). 
the activated state (Solano & Coffee, 1978: Barsacchi 
eta/., 1979). 
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>\NALYTI(AL BIOCHEMISTRY 101,407-4\2 (]980) 
Further Purification of Adenosine Kinase from Rat Heart 
Using Affinity and ion-Exchange Chromatography 
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Adenosine kinase {EC 2.7.1.201 in a cytoplasmic fraction of rat heart was wbjected to 
5 -AMP-Sepharose 48 chromatography. The enzyme showed affinity for the column in 
contrast to adenosine deaminase, and was eluted with adenosine plus MgATP. Fractions 
containing adenosine kinase were put on a column of DEAE-Sephacel and eluted with a 
gradient. The enzyme was purified up to 3000-fold (yield IO'ir}. The specific activity ex-
ceeded 8000 units per gram of protein and ':>Odium dodecyl sulfate-polyacrylamide gel 
electrophoresis showed only one band. We conc.lude that the method presented i':> a simple. 
quick. and elegant way of purifying myocardial adenosine kinase to virtual homogeneity. 
Relatively little work has been published 
on myocardial adenosine kinase (A TP: 
adenosine 5 '-phosphotransferase, EC 
2.7.1.20). Nevertheless this enzyme may 
play an important role in the maintenance 
of adequate adenine nucleotide levels in the 
heart ( 1-3). Purification of myocardial 
adenosine kinase is useful for kinetic meas-
urements (4-6), assays of adenosine (7), 
and the study of the effect of drugs, for 
instance, dipyridamole 1 (6,8,9). In an earlier 
publication we showed that rat heart 
adenosine kinase could be purified up to 80-
fold with Sephadex G-100 and DEAE-
Sephadex A-50 chromatography (4). Sub-
sequently we reported briefly (8) on the use 
of 5'-AMP-Sepharose 4B affinity chroma-
tography to separate adenosine kinase and 
adenosine deaminase (EC 3.5.4.4). In this 
paper we describe a combination of affinity 
and ion-exchange chromatography for the 
purification of adenosine kinase. A purifica-
tion factor of 3000-fold can be reached with 
1 Abbreviations used: dipyridamole. 2.6-bis(di-
ethanolamino -4.8 -dipiperidinopyrimido -!5.4 -( + }]pyrim-
idine: EH~A. erylhm-9-(2-hydroxy-3-nony!Jadenine: 
T ric ine, /'-./ -tri s( hydroxymeth y 1 )meth y lglyci ne. 
a yield of about 10%. A preliminary report 
has been published as an abstract. 2 
MATERIALS AND METHODS 
Adnwsine kinase asso:,··. See Ref. (1). 
Incubations were carried out at 30°C in a 
volume of 100 ,ul in closed micro-test tubes 
(Eppendorf. Hamburg). Incubation condi-
tions were: 40 mM potassium phosphate, 
pH 7.0, 1.0 mM potassium guanosine 5'-
triphosphate, 1.0 mM MgCI2• 10 I'M 
[U-"C]adenosine (Radiochemical Centre, 
Amersham; specific activity about 50 Ci/ 
mol). and bovine serum albumin (0.1 
mg/ml). Reactions were initiated by the 
addition of adenosine kinase (up to 10 
l'g protein!. After 10-20 min 25-1'1 aliquots 
of the reaction mixture were distributed on 
squares of DEAE-cellulose ( 1.5 x 1.5 em 
Whatman DE81) which binds nucleotides. 
The squares were washed with l mM am-
monium formiate, water, and ethanol. A 
detailed description of the washing and 
:: Uitendaal. M.P., DeJong, J. W., Harmsen, E .. 
and Keijzer. E. (1979)1. C!in. Clwn. Cfin. Biochem. 
17, 446. 
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counting procedure can be found else-
where I I). 
Adenosine as.wy. Proteins were de-
natured by heating the assay mixture to 
!OOoC for 3 min. After cooling on ice the 
samples were filtered (Millipore filters, 1.2 
,urn). Analysis of adenosine (and inosine) 
was performed by automatic high-pressure 
liquid chromatography iLC 8500. Varian. 
Palo Alto. Calif.) on a I'Bondapak C" col-
umn (Waters. Milford. Mass.: 0.39 x 30 
em). The column was eluted with 10 mM 
ammonium phosphate at pH 5.5/methanol 
(87/13) at a rate of 1.0 ml/min and a pressure 
of 60 bar. Peaks were detected at 260 nm 
(VariChrom. Varian) and peak areas cal-
culated automatically with a Chroma-
tography Data System Ill( (Varian). The 
concentration of standard solutions was de-
termined according to Olsson ( 10). 
Adenosine d<!omin(l.\'e octiFity, chloride 
concentrations. und protein contenT. Aden-
osine deaminase activity was measured 
(4) at room temperature (22°C). Er.rthro-
9-(2-Hydroxy-3-nonyl)adenine ( EHN A: 2 
,uM) inhibited the enzyme completely. 
Chloride concentrations were determined 
titrimetrically (II I with N aCI as standard. 
Protein content was measured according to 
Bradford (12) using the Bio-Rad (Richmond. 
Calif.) protein assay with bovine serum 
albumin as standard. No interference was 
noted between the Coomassie blue reagent 
and P,. Tris. or GSH. We found that the pres-
ence of these compounds in our samples 
made it impossible to use the Folin-
Ciocalteu reagent ( 13). 
Gel electrophoresis. Gel electrophoresis 
was carried out as described by Weber and 
Osborn ( !4) with P, buffer containing 
sodium dodecyl sulfate and bromphenol 
blue as the tracking dye. The separation 
took 2 h (constant current 16 rnA). Gels 
were stained for 1.5 h with Coomassie 
brillant blue in methanol/acetic acid (91/9) 
and destained overnight with methanol/ 
acetic acid/water (50/75/875). 
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Concentration (dsomple.\·. Concentration 
of samples after ion-exchange chroma-
tography was necessary for the measure-
ment of protein content and for gel elec-
trophoresis. We used the single hollow fiber 
method for fast concentration described by 
Rommerts ct a/. ( 15). 
/v!aterio!s. Coenzymes were purchased 
from Boehringer-Mannheim, agarose de-
rivatives from P-L Biochemicals (Mil-
waukee. Wis.). and methanol (Uvasol) from 
Merck (Darmstadt). Adenosine, hypox-
anthine, and uridine were also supplied by 
Merck, uric acid by Sigma (St. Louis. Mo.). 
and the other standards by Koch- Light 
(Colnbrook. Buckinghamshire. U.K.). 
Pur(fication. Male rats of the Wistar strain 
(200-250 g) were killed by cervical fracture 
and subsequent bleeding. Hearts were re-
moved and kept at -25oC until used. A 57r 
myocardial homogenate was prepared with 
a Virtis homogenizer in 0.25 M sucrose con-
taining 10 mM Tricine-KOH and 1.0 m:'vl 
Na,EDTA (pH 7.4). Homogenization and 
further purification steps were performed 
at 0-8cC. The homogenate was centrifuged 
at 7500g for 10 min. The supernatant 
fraction was centrifuged at IOO,OOOg for 
I h. The cytoplasmic fraction. 10-80 ml 
(which could be stored at -25°(, if 
necessary), was applied at a rate of I ml/ 
min to a column of 2 g /\'"1'(6-aminohexyi-)-5'-
AMP-Sepharose 4B (Pharmacia. Uppsala: 
1.6 x 5 em) and washed with 20 mM potas-
sium phosphate containing I mM GSH at 
pH 7.0. The absorbance of the eluate was 
monitored with a Uvicord Ill (LKB. 
Stockholm). When this absorbance was 
minimal, the buffer was changed to 20 mM 
Tris-HCI/1 mM GSH. pH 7.0. Adenosine 
kinase was eluted from the column with 10 
ml I mM ATP/1 mM MgCI,/0.1 mM aden-
osine in Tris/GSH buffer. The combined 
fractions containing adenosine kinase were 
applied to a column of DEAE-Sephacel 
(Pharmacia: 1.6 X 15 em) equilibrated with 
20 mM Tris-HCI/1 mM GSH, pH 7.0 (I 
0 
0 
' 
0 8 
.; 
9 
_"---- \ 
retenl10n 11me lnw>l 
A 
'" 
B 
adenos•ne 
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\ 
0 \ J 
" retent10n l1me (m,~l 
Fl(,. 1. High-pres~ure liquid chromatography of nucleo~ides and derivatives. iAl Chromatogram 
ohtained Vvith the following standards (2-." nmol): I, uric acid: 2, uracil: 3, uridine: 4, hypoxanthine: 
5, X<tnthine: 6, xantho~ine: 7, inosine: 8. guanosine: 9. adenine: HI, adeno~ine. (8) Determination of 
adenosine concentration in :-.ample from 5 ·-AMP- Sepharose 48 column eluted with MgA TP,..adenosine. 
A~,;., ~ Absorhance at 260 nm. 
ml/min). After elution of adenosine. a 
linear gradient of 75 ml 20 mM Tris-HCI!i 
mM GSH, pH 7.0. and 75 ml 100 mM Tris-
HCI/1 mM GSH, pH 7.0. was started. 
RESULTS AND DISCUSSION 
Assuy <!{Adenosine Kinase 
The assay of adenosine kinase is based 
on a sensitive radiometric determination in 
which the formation of [ 1-lC]AMP is meas~ 
ured (I A). We changed the incubation buffer 
from Tris-maleate. pH 5.6, toP,, pH 7.0. 
because the pH of the chromatographic 
eluate was 7 .0. This change made certain 
that adenosine kinase was assayed at a 
well-defined pH. even when a relatively 
large amount (50 ;d) of eluate was assayed. 
Second. GTP replaced A TP as phosphate 
donor which allowed us to work without 
an ATP-regenerating system and oligomycin. 
GTP, which is superior to ATP as a phos-
phate donor (4). gave an optimal activity 
at a I to 5 mM concentration. Third. we 
omitted dipyridamole (used as an inhibitor 
of adenosine deaminase), because it has an 
effect on adenosine kinase per se {4). 
EHNA. 2 f.LM. which completely inhibited 
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rat heart adenosine deaminase (cf. Ref. 
(16)), influenced adenosine kinase activity, 
and was not used in the assay. However, 
only if the adenosine deaminase activity in 
the sample exceeds that of adenosine kinase 
many times does care have to be taken for 
depletion of adenosine (unpublished ob-
servations). This is presumably due to the 
fact that we used 10 J.LM adenosine which 
saturates adenosine kinase (K 111 0.5 p_M: 
Ref. (4)), but gives suboptimal activity of 
adenosine deaminase ( K 111 72 p_M, Ref. ( 17)). 
We found the activity of adenosine kinase 
measured with the modified system de-
scribed above comparable to the value ob-
tained with the more complex system (I). 
Assay qf AdC!nosinC! 
If an adenosine kinase sample contains 
unknown amounts of adenosine, the method 
described above is inaccurate because the 
radioactive substrate is diluted. Therefore 
we developed a high-pressure liquid chro-
matographic procedure to assay adenosine. 
Figure I A shows the separation of l 0 
nucleosides and derivatives. The retention 
times of inosine and adenosine were 5.5 and 
11-11.5 min. respectively. We used the 
system to measure the concentration of 
adenosine in the eluate of the AMP-
Sepharose column (see Fig. !B). Nucleotides 
and GSH showed retention times of less 
than 5 min. When a 2-p_l sample was used 
in the assay mixture for adenosine kinase. 
the specific activity of [14C]adenosine de-
creased up to 20r1r-. We found the high-
pressure liquid chromatographic system 
also useful to check our adenosine kinase 
and adenosine deaminase measurements. 
For this. purpose incubations and sub-
sequent denaturations were performed as 
described under Materials and Methods. 
Preparation r~f C.vtop/asmic Fraction 
Myocardial adenosine kinase is a cyto-
plasmic enzyme ( !). We therefore started 
the purification with the preparation of a 
high-speed supernatant fraction. The yield 
of adenosine kinase activity usually ex-
ceeded 1 000(.. which could indicate that an 
inhibitor is removed by this step. The 
specific activity increased six-fold. The 
cytoplasmic fraction also contains the 
adenosine deaminase activity ( 17). 
Affinity Chronwto(.?raphy 
Adenosine kinase and adenosine deaminase 
can be separated by affinity chroma-
tography. Adenosine deaminase does not 
bind to the column and virtually all of the 
activity is eluted with P/GSH buffer. Most 
of the adenosine kinase. on the other 
hand. shows affinity for AMP- Sepharose. at 
least when the sample applied to the column 
is prepared in sucrose/Tricine/EDTA (see 
Materials and Methods). If P/GSH buffer 
is used for the preparation of the homoge-
nate, binding of adenosine kinase is poor. 
Adenosine kinase activity is eluted from 
TABLE I 
Pt;RIF·ICATION OF RA1 HEAR"r AD~_r-;oslr-;E KI:-.JASE" 
Volume Protein Activity Specific activity 
Purification step (mil (mgl (mUJ I Uigl 
Cell-free extract 79 230 631 2.74 
5'-AMP~Sepharose 4B 30 3.5 I 13 I 37.3 
DEAE-Sephacel 
(fractions 39 to 4!) !5.2 0.0071 60 8280 
''The activity of the enzyme is given in nmol/min {mUJ: the specific activity is expressed per gram of protein. 
"Cell-free extract'' refers to the !00,000;: ~upernatant fraction. 
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Sepharose-AMP. when MgATP and aden-
osine are present in the eluting buffer, either 
P,!GSH or Tris/GSH. ATP can be re-
placed by GTP, but omission of magnesium. 
A TP, or adenosine results in minimal 
recovery. 
Larger amounts of cytoplasmic fraction 
lead to overloading of the column and 
consequently a lower yield in the MgA TP/ 
adenosine eluate. However, in the last step 
of the purification. ion-exchange chroma-
tography, larger amounts result in a higher 
yield and specific activity, possibly be-
cause less denaturation takes place. 
Results. similar to those given in Table I. 
were obtained when N(;-(6-aminohexyi)-
5'-AMP-agarose was used. although the 
number of AMP molecules per gram matrix 
was twice as high as in the case of 5'-
AMP-Sepharose 48. C-(Hexyl)-adenosine-
agarose and C '-(hexyl)-5' -AMP- Sepharose 
could not replace the N''-(6-aminohexyl)-
derivatives of 5'-AMP-Sepharose or 5'-
60 
30 
0 
) \I\ 
I 
\ 
. J ' 
\ 
....... ';-. I . ' . ' 
20 
AMP-agarose for the purification of aden-
osine kinase. 
The preparation is relatively stable at this 
stage, and can be stored at - 2SOC. 
Ion-Exclwnge Chromatography 
The enzyme could be further purified by 
ion-exchange chromatography. Figure 2 
shows the elution pattern of adenosine 
kinase on DEAE-Sephacel. Gel electro-
phoresis of the pooled fractions 39 to 41 
shows one band. The yield of the purified 
enzyme is IO'ir· and the specific activity 
exceeds 8000 units per gram of protein 
(Table 1 ). The preparation does not con-
tain detectable activity of adenosine de-
aminase, adenylate kinase (EC 2.7.4.3). 
nucleoside phosphorylase ( EC 2.4.2.1 ). or 
AMP deaminase (EC 3.5.4.6). The enzyme 
loses its activity rapidly at - 25°(. A similar 
finding has been reported for (partially) 
purified yeast and liver adenosine kinase 
( 18, 19). 
" adenOSine k1nase (U 1·' 1 .Y 
chlor<de (mM 1 
wo 
50 
0 
40 fraction number 
FIG. 1. Ion-exchange chromatography of adenosine kina:-:.e on a DEAE-Sephacel column. 
Fractions containing the partly purified enzyme after affinity chromatography (.~ee Materiah and 
Methods) were pooled and put on the column. The column was eluted with 20 mM Tri~-HCI./1 mM 
GSH, pH 7.0, until the absorbance at 260 nm was minimal. Fractiom of 5 ml were colkcted. The 
fir~t peak contained protein and adenosine. but no adenosine kinase. With a Tris-HCI gradient the 
enzyme could be recovered from the column. 
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Concluding Remarks 
The purification described here is simple 
and the purification factor (3000-fold) much 
higher than obtained by other methods 
(4-7). Only a few rat hearts are needed 
and within a few hours the enzyme is ob-
tained free of adenosine deaminase. The 
preparation and assay of adenosine kinase 
described in this paper should prove useful. 
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An A TP-sparing effect has been demonstrated for a number of calcium antagonists. I\ ifedipine probably has a ~imilar action. but 
data supporting this view are limited. Therefore we decided to study the effect of nifedipine on high-energy phosphate (and 
carbohydrate) metabolism in the ischemic rat heart. Langendorf[ preparations were made ischemic for less than 1 S min. The reduction 
in coronary Oow was 60 or 70%. Ape>< displacement during ischemia, a measure of contractility. was comparable for nifedipine-treated 
and untreated hearts. hchemia caused a considerable release of the AMP catabolites adenosine, inosine and (hypo)xanthine. and of 
lactate. Nifedipine ( 10-100 !-l.g/1) prevented this in a dose-dependent way. The highest dose reduced the release of purines and lactate 
by 90% (P<O.Ol) and 60% (P<O.OOl), respectively. The drug acted in a similar way during reperfusion. Due to ischemia. the 
adenylate energy charge (ATP+O.S ADPl/(ATP+ADP+AMP), decreased 15% (P<O.OOl): nifedipine at a concentration of 100 
f-[g/1 prevented this decrease (P<0.05). We conclude that nifedipine exerts a benificial eff.:ct on myocardi::tl adenine nucleotide 
metabolism during ischemia and reperfusion. 
Calcium antagonist Purine nucleoside Oxypurinc Lactate 
1. Introduction 
N if edipine [ 1.4~dihydro-2,6-dimethyl-4-( o-nitro-
phenyl)-pyridine-3,5-dicarboxylic acid dimethyl 
ester. Adalat~"l is a blocker of slow calcium chan-
nels (Fleckenstein et al.. 1972; Nayler and Poole-
Wilson, 1981). The drug has negative inotropic, 
dromotropic and chronotropic properties and is a 
powerful vasodilator ( cf. review by Henry, 1980). 
It is presently used in patients for the treatment of 
angina pectoris and hypertension (see, for in-
stance, Antman et aL, 1980: Serruys et a!., 1981, 
Hugenholtz et al., 1981). 
Calcium antagonists are thought to block trans-
membrane Ca2 - transport through slow channels 
or deplete Ca2 + stores in the sarcolemma (Fleck-
enstein, 1980). They prevent the mitochondrial 
To whom all correspondence should be addressed: Cardia-
chemical Laboratory, Thoraxcenter CVR, Ee 2371, Erasmus 
Vniversity Rotterdam, P.O. Box 1738, 3000 DR Rotterdam, 
The Netherlands. 
Energy charge Reperfusion 
accumulation of calcium ions during ischemia and 
reperfusion (Nayler et al., 1980). Nifedipine. like 
other calcium antagonists, is thought to have an 
ATP-sparing effect (Fleckenstein. 1980: Hugen-
holtz, 1980: Magovern eta!., 1981) but data sup-
porting this view are limited. Nayler eta!. (1980) 
showed a beneficial effect of nifedipine on high-
energy phosphate metabolism in rabbit heart which 
had been totally ischemic for 90 min. Further-
more, Higgins eta!. (1980) demonstrated this drug 
to increase the ATP content of anoxic cultered 
neonatal rat heart cells. On the other hand. Ichihara 
and coworkers ( 1979) were unable to measure an 
effect of nifedipine on the ATP concentration in 
ischemic dog heart. 
We decided to study the effect of nifedipine on 
nucleotide metabolism in the isolated perfused rat 
heart. The preparation was made ischemic for less 
than 15 min. We used release of adenosine and 
its catabolites as a sensitive indicator for nucleo~ 
tide breakdown. This had proved useful in the 
isolated rat heart (Starn and De Jong, 1977), the 
open-chested pig heart (DeJong eta!., 1977) and 
147 
patients undergoing an atrial pacing stress test 
(Fox et aL 1974; Remme et al.. 1977). The present 
report shows that nifedipine decreased the release 
of purine nudeosides, oxypurines and lactate dur~ 
ing ischemia and reperfusion. 
2. Materials and methods 
2.1. Prepararion of the ischemic heart 
Male Wistar rats [291 =51 (S.D.) g], fed ad 
libitum, were anesthetized with an intraperitoneal 
(i.p.) injection of 0.5 ml sodium pentobarbital (60 
gjl, Abbott, Saint-Remy sur Avre, France). Hearts 
were rapidly removed and cooled in ice-cold 0.9% 
NaCI. Retrograde perfusion of the aorta according 
to Langendorf£ was immediately started with a 
modified Tyrode solution (Meyler et al.. 1958; De 
Jong, 1972), containing 10 mM glucose and equi-
librated with 95% 0 2 + 5% C02 . The perfusion 
pressure was 72 mmHg (Statham pressure trans-
ducer. model P23D6, Gould Inc., Oxnard, CA). 
The temperature was measured in the canula tip 
with a telethermometer (temperature module: 
Gould Inc .. Cleveland, OH: with model 511 probe: 
Yellow Springs Instr. Inc .. Yellow Springs, OH) 
and maintained at 37.0:::; 0.5°C. Ventricles were 
paced at 4 V with 2 ms duration. In Experiment I. 
hearts were paced at 300 beatsjmin and ischemia 
was induced by lowering the perfusion pressure to 
17 mmHg. This resulted in an ischemic flow of 
about 4 mljmin. In Experiment 2, the heart rate 
was 360 beatsjmin and during ischemia, flow was 
restricted with a model 2132 peristaltic pump 
(LKB, Stockholm. Sweden) to about 2.5 mljmin. 
2.2. Chemicals 
Ail chemicals were analytical grade. Water was 
purified with the Milli-Ro4/Milli-Q system (Milli-
pore Co., Bedford, MA). Bayer AG (Leverkusen, 
FRG) supplied ampoules with a 0.1 g/1 solution 
of nifedipine or solvent alone ('placebo', etha-
noljpolyethylene glycoljwater, IS: 15: 70). Care 
was taken to keep the nifedipine-containing fluid 
in the dark (Clark et al., 1981). 
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1.3. Apex di.lplac(:'nu:nr 
Apex displacement wa~ u~ed as a mea.~ure of 
contractility (Starn and De Jong, 1977). It was 
measured with a displacement transducer (model 
7-DCDT-1010. Hewlett-Packard. Palo Alto. CA). 
fitted with a steel tampon hooked to the apex of 
the ventricle. and monitored with a Bru~h 2~00 
recorder (Gould. Cleveland. OH). The displace-
ment. observed 5 min after the ~tart of the perfu-
sion, was taken as 100%. 
2.4. Protocol 
Hearts were allowed to equilibrate with the 
perfusion nuid for 5 min plus an additional 10 min 
with medium containing nifedipine or solvent 
(preperfusion). Collection of perfusate was then 
started. Two series of experiments were carried 
out. In Expt. L hearts (300 beats/min) \vere per-
fused for a control period of 10 min, followed by 
14 min ischemic period. Reperfusion for another 
14 min only took place in this experiment. In 
Expt. 2. with hearts at 360 beats/min, control 
perfusion was also 10 min with severe ischemia for 
an additional 10 min. The hearts were freeze-
clamped at the end of the control or the ischemic 
period in this second series of experiments for 
analysis of adenine nucleotides. 
2.5. Coronary flmv· 
Coronary flow was measured by timed collec-
tion of perfusate. Two-min fractions were col-
lected in Expt. 1. Only two 10 min fractions were 
collected in Ex pt. 2: control and ischemic. 
1.6. Assay of purines 
Purines were assayed in a slightly modified 
version of the high-performance liquid chromatog-
raphy (HPLC) described by Harmsen eta!. (1981). 
The ,u.Bondapak C 1H column was eluted at a rate 
of 3 mljmin with 0.07 M K-P04 buffer, pH 4.5. to 
which methanol (30 mljl) had been added. Sam-
ples of perfusate were collected on ice. NaN3 
(0.02% final concentration) was added to prevent 
bacterial purine breakdown. Analysis took place 
within 24 h. 
J 7. A1w~vsis of m_vocardial adenine nucleotides 
Analysis of myocardial adenine nucleotides was 
also done by HPLC {see Harmsen et aL 1982). 
The elution profile of ATP, ADP and AMP from 
the ion exchange column was used to calculate 
adenyl ate energ:;' charge (ATP + 0.5 ADP)/{ATP 
+ ADP + AMP). Freeze-clamped hearts were 
stored in liquid N 2 until analysis. 
2.8 Assay of lactate 
Lactate was assay .. ed enzymaticall~' in the per-
fusates ~ccording to Apstein et a\. { 1970) 'A'ith the 
AutoAnalyzer II (Technicon, Tarrytown, NY). 
2. 9. Sratisrical anaZvsis 
Statistical anaJ;rsis was performed \vith Student's 
Hest: P > 0.05 (two-sided) was considered not sig-
nificant (NS). Results are given as mean values 
±S.E.M. 
3. Results 
3. 1. Coronar_r flmt' 
Fig. I shows the coronary flow in the first ex-
periment. Kifedipine at 10 ,u:g/1 concentration in-
TABLE I 
100 
D 
JDD . APEX DISPLACEMENT 
• 
. 
~-'-'-~- .. :-.J.l.li"Il: -!:111: z " 50 
30 !'I!N 40 
ISCHE~11A 
Fig. 1. Coronary flow (ml;min per gr<lm dry weight} and apo; 
displacement(%} during control. is<.:hemia and reperfusion in 
Expt. 1. The displacement measured before the addition of 10 
11g/l nifedipme (el or solvent (0) was uken as 100%. The 
heart rate was 300 beat~;min. Fourteen minutes of ischem1a 
were induced by lowering the perfusion pre~sure from 72 to 17 
mmHg. :vl~an~ :>:S.E.M. (n""5},!::. P<O.OS vs. solvent (un-
paired !-lest}.* P<0.02 vs. control (paired H~~t with value~ at 
t=9 min). 
creased the control flow from 40 to 100 mljmin 
per g dwt (P<O.OOI). When the perfusion pres-
sure was lowered from 72 to 17 mmHg, coronary 
Dose-dependent dfect of nifedipin~ on coronary flow and apex displacement in Expt. 2. Additwn of \Oin~nt alone to the perfw,ion 
fluid had no significant innucnce on flow and contractility. Ap~x displac~ment bdore the addition of drug wa~ taken ~s \Ooc;_ Heart 
rate was 360 beatsjmin. After a control period of 10 min. flow was reduc~d wtth a pump forth~ sam~ paiod of time. 
:-Jifcdipin~ Coronary flow (ml; 10 min) Apex displacement (S:·) 
(!lg/1) 
Control Ischemia Control Jschemi~ 
0 103 :':" 10 ( 15} 26.!..2.2(9)h 86 !" 4 ( 14) 27 - 5 (!\) h 
125 5 (9) 23.::-0.3 {6)h 101 + 6 (9)" 19' 6 (6) h 
10 174::: 8 (11}" 25-2.4(8)h 71 . 3 ( 10) ,, 28 ' 6 (7) ~ 
30 182 -~ 11 {9)" 25"1.0(6} 0 41 -4 (9) a 26 • 9 (61 
100 146 .+: 10 (9)" 24:~ 0.3 (5) h 7 t. 2 {9) .• 23 . 6 (5) h 
Means + S.E.M. (n): "P<O.OS vs. 0 flg/1 (unpaired Hest): h P<O.OS vs. control (paired t-teH). 
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flow in the untreated hearts decreased by 60% 
( P < 0.00 1). During ischemia, flow in the presence 
and absence of nifedipine was comparable, about 
15 mljmin per g dwt. During reperfusion, 110\v 
again increased to control levels (fig. I). 
EXperiment 2 shows that even 3 ,u.gjl of drug 
acted as a vasodilator during the control period 
(table l). In this second experiment ischemia was 
induced with a pump. Coronary flow in untreated 
hearts diminished by 75% (P<O.OOI). Also in 
Expt. 2 ischemic flow \vas comparable for treated 
and untreated hearts. 
3.2. Apex displacement 
In Expt. I nifedipine at a concentration of 10 
J.tg/1 decreased apex displacement by 35% (P< 
0.01. fig. 1). Experiment2 shows that the negative 
50 
ADENOSINE 
SOLVENT 
NIFEDIPINE 
10 
0 .. '! 
"l ~10 
> 0 
HYPOXANTHINE 
0 
ISCHEMIA 
inotropic effect was dose~dependent (table 1 ). At 
100 J.tg/L nifedipine diminished contractility dur-
ing the control perfusion to 10% of the value 
observed with solvent (P < 0.001 ). During i.)chemia, 
apex displacement was about 25% of preperfusion 
values (P < 0.001). both in treated and untreated 
hearts. This means that ischemia induced a three-
fold increase (P < 0.02) in apex displacement. when 
a high dose of nifedipine (100 ,u.g/1) was present 
(table!). 
3.3. Biochemical changes 
Experiment 1 shows the release of adenosine. 
inosine and (hypo)xanthine during control perfu-
sion. ischemia and reperfusion (fig. 2). Purine re-
lease during the control period was 10 2.: 5 
nmoljmin per g dwt. At the end of the ischemic 
• 
INOSINE 
* * *: 
• 
ISCHEMIA 
Fig. 2. Nifedipine (1.0 /-lg/1) reduced the myocardial rele<1s~ of purine nucleosid"'~ tupper pan<'l) and oxypurinc' (lower p;illClJ. 
Conditions as in Expt. 1. see fig. L Means +S.E.M. (n=5). 6 P<0.05 V.>. solvent (unpair<'d Hc,t). • P<0.05 "· c:ontrul (paired t·lc,l 
with values at t=9 min). 
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Fig. 3. Nifedipine (e) reduced the myocardial release of lo.ctate. 
Condition~ as in Expt. L see fig. 1. Means .!.S.E.M. {n=5), 
6 P<0.05 v>. solvent (0). (unpaired Hest). ~ P<0.05 vs. 
control (paired t-test with values at t=9 min} 
period, purine release was 46 ± 17 nmoljmin per g 
dwt (P < 0.05 vs. control). Nifedipine ( 10 p:gjl} 
reduced this release by 75% (P < 0.05). 
These relatively mild ischemic conditions re~ 
suited in a lactate release which was 2.6 times 
higher than the control value (P < 0.02). This was 
completely abolished by 10 ,u.g/1 nifedipine (P < 
0.05, fig. 3). During reperfusion, purine and lactate 
production went down again but the hearts re-
leased more of these compounds in the untreated 
group (figs. 2 and 3). 
Experiment 2 shows that nifedipine reduced 
purine release during ischemia in a dose~depen­
dent way (fig. 4). Ischemia was more severe than in 
Expt. I. because flow was reduced to a larger 
extent (and heart rate was higher, see Baller et a!., 
1981). The highest dose of nifedipine, 100 flg/L 
prevented adenosine release during 10 min of 
ischemia by more than 90% (P < 0.02, fig. 5). This 
dose decreased the release of inosine. hy-po-
xanthine and xanthine during ischemia by 85% 
(P < 0.002). 75% (P < 0.05), and 64% (P < 0.05), 
respectively (data not shown). Figs. 4 and 5 also 
show that the solvent itself had an effect on purine 
production during the control period. Increasing 
the dose of nifedipine (and solvent) from 3 to 100 
200 
100 '::; 
! 
200 
' 
lDD j 
N I FED I PINE 
1D 
SOLVENT 
<. •O.D~)...J 
30 100 )JG/L 
CONTROL 
ISCHEMIA 
.0.0) j 
... 0.001--' 
Fig. 4. Nifedipine reduced purine release dose-dependently dur-
ing i~chemia. The ~urn of the purines adenosine. ino~ine. hypo-
xanthine and xanthine is shown. Conditiom a~ in Expt. 2. see 
table l. Means ::: S.E.M. {n = 4-9). P values vs. control (puired 
Hest) and vs. solvent (unpuired \-test) ure indicated. 
/--(g/1 doubled the release of purines (NS). The 
release of adenosine was even more dramatic: 
solvent increased it dose-dependently from levels 
< 1 nmoljlO min to 7-ll nmoljlO min (0.05 < P 
<0.10). 
In Expt. 2, differences in lactate release during 
the control period were only observed with 31--'g/1 
nifedipine: this induced a 42% decrease (P < 0.05, 
fig. 6). The nifedipine dose had to be increased to 
levels higher than in Expt. I to show an effect 
during ischemia: ten times more drug was needed 
to prevent lactate release in Ex pt. 2 (P < 0.00 I, 
please compare figs. 3 and 6). 
We were unable to measure a significant de-
crease in myocardial ATP content under the 
ischemic conditions of Expt. 2. However. adeny-
late energy charge decreased by about 15% due to 
ischemia (P < 0.02, table 2). This decrease was pre-
vented by 100 /--(g/1 nifedipine (P < 0.05 vs. 
solvent). 
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ISCHEMIA l1:i] 
~-o.oo1.J Ji ~j ~I 
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SOLVENT j 
l..O.OOI--' 
Fig. 5. Nifedipine reduced adeno~ine release from the is<.:hemi<.: 
heart dose-dependently. Conditions as in Ex pt. 2. see table I 
Means --'-S.E.M. (no=4-l 1), P values v~. control {pair<:d t-te£1) 
and vs. solvent (unpaired Hest) are shown. 
lO 
i: 20 
i 
' 10 
•0.05 
NIFEDIPINE 
10 
SOLVENT 
'-<0.001-' 
10 
J 
100 }JG/L 
CONTROL n 
ISCHEMIA eJ 
~ 
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Fig. 6. Nifedipine reduced myocardial lactate release from the 
ischemic heart dose-dependently. Conditions as in Expt. 2. see 
table 1. Means ::<:S.E.M. (n=4-ll). P values vs. control (paired 
!-test) and vs. solvent (unpaired !-test} are indicated. 
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TABLE 2 
hch..:mia-induced decrca'e of adenylate energy charge_ and 1t' 
preventwn by nifed!pine_ 'Sohent' refer" to a \'Chick volume 
corresponding to a nifedipine concentration of IOU f-'g, I_ Pcrfu-
~ion conditions a> in Ex pl. 2. ,;ee table I 
Addition 
Control bchemia 
None 0.890 + 0.007 0.793 ' 0.012 
(5} .• (7} h 
Solvent 0.896 . 0.004 0.761 I 0.029 
(4)' (4) J 
l'iif<:Jipine 10 .ug/1 0.1\89 ' 0.004 0.773 . 0.023 
{3)" (5) f 
100 .ug/1 0.897 1-0.007 0.1\64 I 0.024 
{4} (4) ~ 
Mean~ -•:S.E.M. (n): P-values, calculated with Jn unpaired 
t-test: u-h P<O.OOl: ,·-J P<0_02: c-r P<O.Ol: h-g P<0_02: J--~ P 
<0.05. 
4. Discussion 
A number of calcium antagonists reduce high-
energy phosphate breakdown during hypoxia. Al-
though these slow-channel blockers vary in th~ir 
mode of action (Opie, 1980: Henry'. 1980: Fleck-
enstein. 1980). nifedipine probably acts in a simi-
lar way. However, there are only' limited data 
supporting this view (Nayler et al.. 1980: Higgins 
et aL 1980; but see Ichihara et aL 1979). We 
decided to study the effect of nifedipine on the 
myocardial release of the AMP catabolites adeno-
sine, inosine and (hypo)xanthine. For that purpose 
we made isolated rat hearts ischemic for a period 
of a length comparable to the duration of an atrial 
pacing stress test in patients. We showed that 
breakdown of adenine nucleotides was indeed pre-
vented by nifedipine. The evidence is based on 
measurements of purine nucleosides and oxypu-
rines (figs. 2, 4 and 5), and adenylate energy charge 
(table2). 
In addition we found that the release of lactate, 
a marker of myocardial ischemia (see. for instance. 
Brachfeld, 1976: Starn and DeJong. 1977) was 
reduced by nifedipine (figs.3 and 6). Ichihara et 
a!. ( 1980) were unable to detect an effect of 
nifedipine on myocardial lactate release during 
ischemia in the dog. The reductions found in our 
experiments were not due to the negative inotropic 
action of nifedipine, because the drug did not 
affect contractility during ischemia (fig. 1 and ta-
ble I). Similarly, Perez et a!. ( 1980) found no 
nifedipine-induced depression of the mechanical 
activity of ischemic canine heart but, instead, they' 
observed a significant enhancement of its perfor-
mance. With the highest dose of nifedipine we 
found an increase Ill apex displacement (table I), 
concomitunt '>'-'ith a decrease in puri;-:e release 
(fig. 5). 
Atkinson ( 1977) has reviewed the activities of 
importarit regulatory· enzymes in vitro as a func-
tion of energy charge. With an increase in energy 
charge from 0 to L the regulatory enzy'mes in 
ATP-using sequences increase in activity and those 
which regenerate ATP decrease in activity. 
Nifedipine increased the energy charge to the levels 
necessary for the propa functioning of the heart 
(table 2). 
It is of interest that rat heart produces relatively 
large amounts of xanthine during ischemia (fig. 2: 
see De Jong, 1982). Xanthine oxidase, which con-
verts hypoxanthine to xanthine (and xanthine to 
urate) is reported to be absent from rat heart 
(Gandhi and Ahuja. 1979). or present in low 
amounts (Maguire et a!.. 1972). Because xanthine 
oxidase in heart and blood vessels has been im-
plicated as a causative factor in atherosclerosis 
(Carr et al.. 1975). further studies are clearly 
needed. 
Nayler et al. (1980) sho'>'-'ed that hearts from 
rabbits treated with nifedipine were protected 
against the ischemia-induced decline in the A TP-
generating and 0 2-utilizing capacity of the 
mitochondria. According to Nayler and Poole-Wil-
son (1981) no simple explanation for the protec-
tion afforded by calcium antagonists to hypoxic 
and ischemic heart muscle can be given at present. 
From our experiments we conclude that nifedipine 
prevents myocardial adenine nucleotide break-
down in ischemic rat heart. but the precise mecha-
nism remains to be solved. 
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E. HARMSEN, P.P. DE TOMBE and J.W. DEJONG. Synergistic effect of mfedipine and propranolol on adenosine 
(catabolite) release from ischemic rat heart, European J. Pharmacal. 90 (1983) 401-409. 
Both nifedipine a calcium antagonist. and propranolol a /3-adrenergic blocker, are used as protective agents of the 
ischemic myocardium. In the clinical setting, the combination of the two drugs is used succesfully although several case 
reports indicate potential dangers of the combination. For this reason we decided to study the combined effect of 
nifedipine and DL-propranolol in the isolated rat heart made ischemic for a short period of time. Apex displacement 
was taken as a measure of contractility. Release of the AMP catabolites adenosine, inosine. (hypo)xanthine and uric 
acid was used as a marker of ATP breakdown. Contractility during ischemia was not affected by the drugs. 
DL-Propranolol (30 or !50 !J-g/1) had no effect on ischemic myocardial purine release, while nifedipine (15 !J-g/1) 
reduced purine release during ischemia by 33% (P < 0.02). The combination of 15 p.g/1 nifedipine and 150 pg/1 
DL-propranolol decreased purine release by 53% (P < 0.005 vs. nifedipine). We conclude from these results that 
propranolol has a synergistic effect, adding to the beneficial action of nifedipine on ischemic myocardium. 
Calcium antagonist 
Purine nucleoside 
fi-B locker High-energy phosphates Oxypurine Ischemia Heart 
1. Introduction 
Pretreatment with nifedipine, a calcium 
antagonist, prevents excessive calcium accumula-
tion in the myocardial cell during ischemia and 
reperfusion. This probably ensures good ATP and 
creatine phosphate (CrP) levels and proper func-
tioning of the cell (Henry, 1980; Nayler et al., 
1980; Fleckenstein and Fleckenstein-Gruen, 1980; 
Watts et aL, 1980; Magovern et aL, 1981). Pro-
pranolol blocks the ,8-adrenoceptors of the heart, 
protecting the heart from adrenergic stimulation 
which causes 0 2 wastage and A TP and CrP deple-
tion (Opie et al., 1979; Manning et aL, 1981). Both 
nifedipine and propranolol are used in the clinic 
for treatment of angina pectoris. hypertension, 
and prevention of myocardial infarction (see, for 
* To whom all correspondence should be addressed. 
instance, Hugenholtz et aL, !981). In the last few 
years, the combination of the two drugs has also 
been used for several reasons: (I) The vasodilata-
tion and subsequent hypotension caused by 
nifedipine induces reflex baroreceptor activation 
and provokes ,8-adrenergic stimulation, which can 
be blocked with propranolol (Lederballe Pedersen 
et al., 1980; Joshi et aL, 1981; Landmark et al., 
1 982). (2) When nifedipine and propranolol are 
combined, the doses of each drug can be lowered, 
thus diminishing the side-effects (Ekelund and Oro, 
1979; Imai et aL, 1980; Lynch et al.. 1980; Dargie 
et al., 1981; Tweddel et al., 1981). (3) Cases with 
complicated angina are likely to be best treated 
with the combination, because nifedipine seems 
indicated for spasm-induced angina, while pro~ 
pranolol is more suitable for treating stable angina 
(Fox et aL, 1981; Moses eta!., 1981). 
However, a number of case reports indicate 
potential dangers, especially an excessive fall in 
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blood pressure, resulting in shock or even myocar~ 
dial infarction {Motte et aL 1980; Opie and White. 
1980: Staffurth and Emery'. 1981; Robson and 
Vishwanath, 1982). To our surprise the combina-
tion of these drugs had not been tested in ischemic 
animal heart. We studied the effect of nifedipine 
and DL-propranolol, alone or in combination, on 
ATP metabolism in isolated rat hearts. In our 
model, relatively mild ischemia during a short 
period of time was introduced to mimic the clini-
cal situation of exertional angina. The release of 
purine nucleosides and oxypurines was used as a 
measure of ATP catabolism. This has proven use-
ful in the isolated rat heart (Starn and De Jong, 
1977), the open-chested pig heart (De Jong et a!., 
1977) and patients with ischemic heart disease 
(Remme et al.. 1977; Fox et al.. 1979; Kugler, 
1979). 
Recently we have shown that nifedipine could 
depress purine release in ischemic hearts in a 
dose-dependent way (De Jong et al.. 1982). The 
present report shows that nifedipine decreases the 
release of ATP breakdown products, with DL-pro-
pranolol acting synergistically. 
2. Materials and methods 
2.1. Ischemic heart preparation 
Isolated rat hearts from male Wistar rats (292 
± 32 (S.D.) g) were retrogradely perfused accord-
ing to DeJong ( 1972) and DeJong et al. (1982). In 
short; the perfusion buffer (pH 7.4) contained 10 
mM glucose, 125 mM NaCI, 4.7 mM KCI. 1.35 
mM CaC1 2 , 20 mM NaHC03 , 0.4 mM NaH 2 P04 , 
I mM MgCl 2 • and was equilibrated with 95% 
0 2 + 5% C02 . Perfusion pressure was 72 mmHg 
(Statham pressure transducer, model P23D6, 
Gould Inc., Oxnard. CA). The temperature, mea-
sured in the cannula tip, was maintained at 37.0 ± 
0.5°C. Ventricles were paced at 4 V with 2 ms 
duration at 360 beats/min. To induce ischemia, 
flow was restricted with a model 2132 peristaltic 
pump (LKB, Stockholm, Sweden) to 2.5 mljmin. 
2.2. Chemicals 
All chemicals were analytical grade. Water was 
purified with the Milli-R04/MilliQ system (Milli-
pore Co., Bedford. MA). Nifedipine (in ampoules 
containing 0.1 g/1. supplied by Bayer AG, Lever-
kusen. FRG) and DL-propranoloi.HCl (in 
ampoules containing 0.1 gjl, purchased from ICI 
Chemicals, Macclesfield. UK) were dissolved in 
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the perfusion buffer. ]'..'ifedipine-containing solu-
tions were made and stored in alumina-wrapped 
glassware. The perfusion apparatus was made of 
brown-colored glass to prevent photolytic de-
gradation (Clark et al., 1981). 
2.3. Apex displacement 
Apex displacement was used as a measure of 
contractility (Starn and De Jong. 1977). It was 
measured with a displacement transducer (model 
7-DCDT-1010. Hewlett-Packard. Palo Alto. CA), 
fitted with a tampon steel hooked to the apex of 
the ventricle. and monitored with a Brush 2800 
recorder (Gould, Cleveland. OH). The displace-
ment observed 5 min after the start of the perfu-
sion before any drug was added was taken as 
100%. 
2.4. Prorocol 
The hearts were allowed to equilibrate with the 
perfusion Ouid for 5 min plus an additional 10 
min with medium containing nifedipine, DL-pro-
pranolol or both (preperfusion). The perfusate was 
then collected for 10 min (control) and 10 min of 
ischemia. The hearts were freeze-clamped at the 
end of the ischemic period. Two sets of experi-
ments were performed. In the first set, purine 
release from ischemic hearts was compared with 
the release from ischemic hearts treated with 30 
p.g/1 nifedipine, 30 p.g/1 DL-propranolol. or 30 
p.g/1 nifedipine and 30 ,u.gjl DL-propranolol. The 
second set of experiments was identical to the first, 
except for the concentrations of nifedipine and 
DL-propranolol. which were 15 and 150 p.g/1, 
respectively. 
2.5. Assay of purines 
Purines were assayed in a slightly modified 
version of the high-performance liquid chromatog-
raphy (HPLC) described by Harmsen et aL ( 1981 ). 
Two-hundred ,u.l of perfusate was injected on a 
,u.Bondapak C 18 column. The column was eluted at 
a rate of 3 mljmin with 0.07 M KH 2 P04 , pH 4.5, 
with methanol (30 ml added to l I buffer). Sam-
ples of perfusate were collected on ice. NaN 3 
(0.02% final concentration) was added to prevent 
bacterial purine breakdown. Analysis took place 
within 2 h. 
2.6. Analysis of myocardial adenine nucleotides 
The freeze-clamped heart was ground with 
liquid N2 and about 400 mg used for dry weight 
determination. The other part, about 600 mg, was 
mixed with 3.0 ml 0.75 M HC104 at liquid N 2 
temperature, thawed, centrifuged and the super~ 
natant fluid stored on ice. Analysis of myocardial 
high~energy phosphates in the extracts neutralized 
with KOH was also done by HPLC (Harmsen et 
a!., 1982). The elution profile of ATP, ADP and 
AMP from the ion~exchange column was used to 
calculate adenylate energy charge (A TP + 0.5 
ADP)/(ATP + ADP +AMP). Analysis took place 
within 6 h. 
2. 7. Statistical analysis 
Statistical analysis was performed with Student's 
t~test. P > 0.05 (two~sided) was considered not sig~ 
nificant (NS). Results are given as means ± S.E.M. 
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3. Results 
3.1. Flow 
Fig. demonstrates the vasodilator effect of 
nifedipine (15 ,ug/1 or 30 ,ug/1) during aerobic 
perfusion. Flow increased two~ fold (P < 0.005 vs. 
non~treated hearts). Apparently 15 ,u.g/1 nifedipine 
was enough to dilate the coronary arteries maxim~ 
ally. DL~propranolol had no effect on flow in both 
concentrations used. Ischemia was induced with a 
roller pump and resulted in a coronary flow of 2.5 
mljmin (13.5 mljmin per g dry weight i.e. flow 
reduction in the non~ treated heart was 75% (P < 
0.005)). 
3.2. Apex displacement 
Fig. 2 shows the negative inotropic properties 
I 
=NJFED:PJNE i5 ~g/1 
P=PROPRANOLOL 150 ~g/l 
CONTROL 
ISCHEMIA 
Fig. l. Influence of nifedipine and DL-propranolol on coronary now during control penod and ischemia. The drug was added 5 min 
after starting the perfusion. The average flow for 10 min fractions is presented. Ischemia was induced by means of a roller pump wuh 
a fixed flow of 2.5 mljmin. Heart rate was 360 bpm. perfusion pressure 72 mmHg. Means ± S.E.M. (n =5-9). • P < 0.05 vs 
non-treated rat hearts (- N, - P): v P < 0.05 vs. nifedipine-treated rat hearts ( + N. - P); e P < 0.005 vs. control period 
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of nifedipine during aerobic perfusion. Fifteen 
.ug/1 nifedipine induced a 25% decrease in apex 
displacement (P < 0.005 vs. non-treated hearts) and 
30 .ug/1 nifedipine a 60% decrease (P < 0.005 vs. 
non-treated). DL-propranolol showed no effect on 
aerobic contractility. When the the combination 
was infused, the negative inotropic effects found 
during the control period seemed only due to 
nifedipine. During ischemia, apex displacement 
was abcnt 40% of the aerobic values, in both 
treated and untreated hearts. This means that 
ischemia induced a 60% decrease in the non-treated 
and propranolol-perfused hearts (P < 0.005). With 
15 Jlg/l nifedipine (alone or with propranolol), 
ischemia caused the apex displacement to decrease 
by half (from 75 to 40%, P < 0.05) and with 30 
.ug;1 nifedipine (alone or with propranolol) no 
change in apex displacement due to ischemia was 
seen. 
12 0 
NeNJFEOIP:NE 30 JJ9/l 
P"PROPRANOLOL 30 ~g/l 
3.3. Purine release 
The release during aerobic perfusion was 0.4 
.umoljlO min per g dry weight. During ischemia, 
purine release was about 1.2 .umolj!O min per g 
dry weight (P < 0.005, see fig. 3). Nifedipine pro-
duced a dose-dependent decrease of the ischemic 
purine release (to 67 and 44% of this value for 15 
and 30 .ug/1, respectively). DL-Propranolol had no 
influence on purine release. However, the combi-
nation of 30 ,ug/1 nifedipine and 30 .ug/1 Dl-pro-
pranolol seemed to suppress the ischemic purine 
release better than either drug alone (NS). When 
the nifedipine concentration was decrea:>ed to 15 
Jlgjl and the propranolol concentration increased 
to 150 ,ugjl, the suppression of ischemic purine 
release was significantly greater than with nifedi-
pine (P < 0.05) or propranolol (P < 0.005) alone. 
Fig. 4 shows that nifedipine alone decreased 
12 0 
r.;~rJ!FEDIPINE 15 JJg/l 
P=PROPRANOLOL 150 J,Jg/l 
Fig. 2. Effect of nifedipine and DL-propranolol on apex displacement during aerobic perfusion and after 10 min of is<:hemia. The 
displacement before any drug was adcjed was taken as !00%. Means ± S.E.M. (n = 5-9). Experimental conditions. see legend to fig. 1. 
., p < 0.05 vs. non-treated rat hearts (- N, - P); " P < 0.05 vs. nifedipine-treated rat hearts ( + N, - PJ; • P < 0.005 vs. control 
period. 
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Fig. 3. Reduction of purine release by nifedipine and DL-propranolol during myocardial ischemia. Means ± S.E.M. (n = S-9). 
Conditions. see legend to fig. I. A= adenosine, I =inosine. H = hypoxanthine. X= xanthine and U"' uric acid. T" P < 0.05 vs. 
non-treated rat hearts (- N. - P}; 'V P < 0.05 vs. nifedipine-treated rat hearts ( + N. - P). 
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N=NlFEOJPINE 30~g/l 
P~PROPRANOLOL 30~g/l 
N=NIFEDJPJNE 15~g/l 
P=PROPRANDLOL l50~g/l 
Fig. 4. Reduction of adenosine release during ischemia. Means ± S.E.M. {n =5-9). ,. P < 0.05 vs. non-treated rat hearts {- N, - P}; " 
P < 0.05 vs. nifedipine-treated rat hearts ( + N, - P). 
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adenosine release (with 15 p.g/1 nifedipine by 47%. 
with 30 p.g/1 by 85%). Propranolol alone had no 
effect on adenosine release, whereas 150 ,u.g/1 pro-
pranolol and 15 ,ug/1 nifedipine decreased adeno-
sine release by 72% (P < 0.05 vs. non-treated; P < 
0.05 vs. nifedipine; P < 0.05 vs. propranolol). 
3.4. High-energy phosphates 
It can be seen in table 1 that nifedipine (30 
,u.g/1) significantly increased the ATP and CrP 
content, which seemed further augmented with 30 
,u.g/1 propranoloL Nifedipine 15 ,u.g/1 failed to 
protect high-energy phosphate levels but 150 ,ug/1 
propranolol increased CrP. although the energy 
charge did not change. Addition of nifedipine to 
the propranolol-containing buffer improved the 
energy charge to aerobic values. The latter were: 
ATP and CrP. 23.0 ± 0.4 and 22.9 ± 2.1 p.moljg 
dry weight, respectively, and energy charge 0.902 
± 0.003 (n ~ 4). 
The ischemic A TP and CrP values of non-
treated rat hearts were somewhat lower in the first 
set of experiments than in the second set (see table 
1 ). The only difference we noticed between these 
two groups was between the dry weight of the 
hearts (200 ± 4 vs 167 ± 4 mg. respectively, P < 
0.005). Rat body weights were comparable (289 ± 8 
vs. 298 ± 5 g). Seasonal variations between groups 
of animals could not be excluded. Because the 
effect of various concentrations of nifedipine and 
propranolol was evaluated within the sets of ex-
periments, conclusions may be drawn from each 
series of experiments. 
TABLE 1 
4. Discussion 
Ca antagonists e.g. nifedipine, and ,8-blockers 
e.g. propranolol. are thought to protect the heart 
under ischemic conditions. This supposedly en-
sures proper ATP and CrP levels in the heart, with 
good functioning of subcellular structures. The 
mode of action of these drugs is still rather ob-
scure. We studied their effect on myocardial ATP 
metabolism in a model in which the hemOdynamic 
variables were kept as constant as possible. 
4.1. N1jedipine 
Nifedipine is suggested to act by selective in-
hibition of Ca influx through the cell membrane. 
It supposedly uncouples electromechanical 
processes, resulting in a negative inotropic action. 
Nayler et al. (1980) found that during ischemia 
and reperfusion, nifedipine prevented excessive Ca 
overload, maintained A TP levels (but see lchihara 
et al., 1979), and preserved mitochondrial function 
and membrane structures. However, Church and 
Zsoter ( 1980) found no decrease of Ca influx in 
the mesenteric vein of the rabbit during nifedipine 
administration. They supposed an intracellular ac-
tion of nifedipine. Other authors suggested that 
beneficial effects of nifedipine were only due to its 
negative inotropic action (by lowering 0 2 con-
sumption through reduction of heart work and 
vasodilatation; see e.g., Fleckenstein and Flecken-
stein-Gruen, 1980). 
In our model, during aerobic conditions, 
nifedipine acted as a negative inotropic agent on 
ATP and creatine phosphate content, and energy charge of freeze~clamped perfused rat hearts. The hearts were perfused for 25 min 
aerobically and for 10 min of ischemia, as described in the Material and Methods section. The drugs nifedipine (Nif) andjor 
DL-propranolol (Prop) were added to the perfusion fluid 5 min after starting the perfusion.! and II refer to the first and second set of 
experiments, respectively. Means ±S.E.M. (n = 5-10)., P < 0.05 vs. none. 
Drugs Concentration ATP CcP Energy charge 
1-'g/1 JLmoljgdwt J.tmoljg dwt 
None 16.5 ± L2 13.6 ± 2.2 0.832 ± 0.022 
Nif 30 20.2±0.6 a 25.4±0.9 a 0.866±0.016 
Prop 30 18.5 ±0.8 15.7± 1.1 0.823±0.016 
Nif/Prop 30/30 22.4 ± 2.0 a 28.6 ± 3.6" 0.880±0.013 
II 
None 20.7±0.8 16.6±1.3 0.880 0.013 
Nif 15 21.3± 1.4 16.0± !.8 0.866 0.013 
Prop 150 22.1 ±0.7 21.5 ± 1.6 ll 0.875 0.007 
Nif/Prop 15/150 21.9±0.6 19.6±0.5" 0.901 0.010" 
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the heart (see fig. 2). The effect was dose~depen­
dent and confirmed our earlier results (DeJong et 
a!.. 1982). Vasodilatation seemed maximal at the 
)o\vest concentration used (15 ~J-g/L see fig. 1). 
whereas doubling the nifedipine concentration fur-
ther decreased contractility. This indicates that 
arterial smooth muscle cells are more sensitive to 
nifedipine than heart cells (see fig. 1). This is in 
accordance with findings of other authors (see, 
e.g., Fleckenst..:in and Fleckenstein-G!·uen, 1980). 
During ischemia, nifedipine had no effect on 
contractility in our preparation. Probably it can-
not interfere with electromechanical processes dur-
ing ischemia. However. despite its lack of negative 
inotropy during ischemia. nifedipine reduced 
adenosine (catabolite) release (figs. 3 and 4), with 
concomitant higher myocardial ATP and CrP levels 
(table 1). Furthermore the adenylate energy charge 
was better maintained (table I). 
Recently, Verdouw et a!. (1982) found that. 
after nifedipine treatment, there was a decrease of 
myocardial 0 2 consumption in pig hearts while 0 2 
demand was unchanged. Nayler et aL (1980) pro-
posed that mitochondrial Ca overload was pre-
vented, resulting in better preservation of function 
and preservation of myocardial ATP and CrP 
levels. Other possibilities are also conceivable. 
N!fedipine is likely to cause a shift from fatty acid 
to glucose oxidation (kttibara et al., 1979). Also 
several Ca (calmodulin)~dependent ATP-ases and 
-phosphorylases are possibly inhiblled (for a re-
view. see Stocklel. 1981). We conclude from our 
experiments that during ischemia, nifedipine shows 
ATP-sparing properties which are independent of 
the negative inotropic action of the dmg. Whether 
this effect- is caused by better or more economical 
AT!P production or by a decrease in ATP catabo-
lism. or both. is still unknovvn. The loss of the 
negat~ve ir.otropic properties of nifedipine remains 
intriguing. Recently Wein:ratib e: al. (1982) n:-
ported increases ic contractility during nifedipine 
administration to ischemic dog heart \vithout giv-
ing a satisfactory explanation. 
4.1. Propranolol 
DL-Propranolol protects the heart from the 
stimulatory actions of catecholamines. The latter 
increase oxygen consumption, and cause oxygen 
wastage. e.g .. due to a shift from carbohydrate to 
fatty acid oxidalion. Cyclic AMP is thought to 
mediate this action (Opie et aL 1979). It is thought 
that D- and L~propranolol stabilize membranes 
(Arnim and Weiman. 1981). 
In our model, DL-propranolol showed no effect 
on coronary flow and contractility (see figs. I and 
2). This suggests the absence of catecholamine 
release. Also no effect on ischemic purine release 
was seen. although a concentration of 150 p.g/1 
seemed to reduce CrP breakdown. The energy 
charge, however, was comparable with that in 
non-treated hearts. This is in accordance with find-
ings of Edoute et al. (1980) ai1.d Lubbe et al. 
(1980), who did not see a significant improvement 
of A TP levels during ischemia after propranolol 
infusion, although mitochondrial function 
improved slightly. Nayler eta!. (1980) found pre-
treatment of rabbits with propranolol effective for 
protection. However, in the intact animal ,8-block-
ade seems much more important In our model 
DL-propranolol did not show any effect on purine 
release. 
4.3. 1Vifedipine and propranolol 
The effects of the combination of drugs on flow 
and contractility can be ascribed to nifedipine. 
Although propranolol alone shows no effect on 
ischemic purine release, 150 p,gjl propranolol 
added to 15 ,u.gjl nifedipine gave a significant!;' 
lower adenosine (catabolite) release than did 15 
{lg/l nifedipine alone (see figs. 3 and 4). Also 
ATP. CrP and energy charge (table I} returned lO 
their aerobic control levels. We conclude from this 
observation that the ATP-sparing effect of nifedi-
pine can be augmented by propranolol. Also this 
synergistic effect of propranolol seems indepen-
der.t of contractility. i.e .. indeper.dent of clectro-
mechani.ccJ coupEng. Vv'e therefore assume tfwt the 
ATP-sparing effect is the resu:t of J. more eco-
r;omical A TIP metabolism. Especially ATP catabo-
lism (via ATP-ases and phospf:oryb~es) is con-
trolled by Ca (via activated calrr:odulir:) or cyclic 
AMIP. It seems possible that nifedipine. by ]O\\·er-
ing the internal free Ca concentration. activace~ 
cyclic A!VfP-depenC:en~ processes via compensa-
tory processes which are blocked v...'ith propranolol. 
'0/e conclude from our experiments that 
nifedipine alone or in combinatwn with pro-
pranolol prevents adenine nucleotide breakdown 
in ischemic rat heart. This effect seems indeper.-
dent of electromechanical coupling. Therefore these 
results suggest a direct effect of nifedipine on 
energy metabolism. which can be intensified by 
propranolol. The precise mechanism remains to be 
elucidated. Part of the beneficial effect of nifedi-
pine and propranolol administration in patients 
could be due to the effect we described. The 
negative side-effects of the combination of the 
drugs reported in the literature seem to be due 
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more to an excessive fall in blood pressure than to 
a direct negative effect on ~he metabolism of 
{ischemic) myocardium. 
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J. W. OEJ ONC, E. HARMSEN AND P. P. oETOMBE. Diltiazem Administered Before or During Myocardial Ischemia 
Decreases Adenine Nucleotide Catabolism. journal of Molecular and Cellular Cardiology (1984) 16, 000--000. 
Calcium antagonists potentially prevemATP breakdown, but literature data on this subjeCt are conflicting. We 
studied the effect of diltiazem on ATP catabolism in rat heart, perfused according to Langendorff. 
Administration of the drug took place either before or during ischemia, induced by lowering the perfusion 
pressure. The reduction in flow without di!riazem was 85%. We obsen.--ed a significantly (P < 0.001) !O\\'er 
production of purine nudeosides and oxypurines by the ischemic heart, when we gave di!tiazem in a dose 
range of 1 to 100 f.LM before ischemia. The highest drug concentration reduced purine release by 85%. Due to 
ischemia, myocardial adenine nucleotide content decreased by 40% (P < 0.00 l ); this was partially prevemed 
by 5 f.LM diltiazem (P = 0.04 v. untreated heam). The drug also effectiYdy reduced purine release, when 
applied five minutes after the induction of ischemia, but higher concentrations were needed. 
KEY WoRDS: ATP catabolism; Calcium antagonist; Creatine phosphate; Di!tiazem; Ischemia; Inotropic effect; 
Purine nucleosides; Oxypurines. 
Introduction 
Adenosine 5'-rriphosphate plays a central 
role in the maintenance of cellular integrity. 
A reduction in flow leads to increased cvwsolic 
calcium concentrations and gives ... rise to 
reduced ATP levels with loss of structure and 
function as a result [23]. Blockers of slow 
calcium channels presumably prevent this 
sequence of events [7]. Under a number of 
conditions, related to myocardial ischemia 
and reperl'usion, dilciazem is capable to 
presei\!e the ATP-generating capacity [3, 20] 
or to slow down ATP catabolism of the hean 
[3, 36]. Diltiazem protected (partially) the 
ATP content of hearts during the calcium 
paradox [I]. In some other studies diltiazem 
did not improve A TP metabolism, -..vhen an 
ischemic insult had already taken place [2, 22, 
35, 37]. We studied therefore in perl'used rat 
heart the effect of diltiazem on nucleotide 
breakdown, when the drug was administered 
either before or during ischemia. Purine 
effiux was routinelv used as an index of ATP 
catabolism [4, 26, J3]. 
• To whom requests for offprints should be addressed. 
Materials and Methods 
Preparation of ischemic heart 
Male Wistar rats {240 w 350 g), with free 
access to food and water, \'.'ere anesthetized 
with 30 mg sodium pentobarbital i. p. Hearts 
were rapidly removed and cooled in ice-cold 
saline. Retrograde perfusion of rhe aorta was 
immediatelv staned \Vith a modified Tvrode 
buffer as described before [5]. The buffer 
consisted of 128 mM NaCl, 4.70 mM KCl, 
1.35 mM CaCl2, 20.2 mM NaHC0 3, 0.42 
mM, NaH2P04, 1.0 mM MgCl2 and 10 mM 
D-glucose. The mixture \vas passed through a 
0.45 J.Lm filter and equilibrated with 95% 0 2 
co 5% C0 2. This resulted in a buffer pH of 
7.35 ± 0.05. Pacing frequency \Vas 300 beats/ 
min (4 V stimulation for 2 ms). Perfusion 
temperature (37°C) was measured in the 
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aortic canula \Vith a A-KC l probe connected 
to a DU-3 monitor (Ellab, Copenhagen, 
Denmark). Ischemia was induced by lowering 
the perfusion pressure from 72 mmHg to 
12 mmHg. 
Chemicals 
All chemicals \\'ere analytical grade. Water 
v.;as purified with the Millipore-Ro4/Milli-Q 
system (Millipore Co., Bedford, MA). 
Synthelabo (Brussels, Belgium) supplied 
d il tiazem, d-3-acetoxy-cis-2, 3-dih ydro-5- [ 2-
( dimeth ylam i no) ethyl]-2 -( p-methoxyphenyl)-
1 ,5-benzothiazepin-4(5H)-one HCl, as a 
solid. 
J\1yocardial function 
Apex displacement [JJ] or developed tension 
[24] was used as an indicator of lllfOCardial 
performance. The former was measured as 
described before [JJ]. The displacement, 
observed 5 min aher the start of the perfusion, 
v,.ras taken as 100%. A!ternativelv, tension 
development \•,ras monitored wid{ a P23Db 
transducer (Statham, Hato Rey, Puerto Rico), 
connected to the apex of the heart. Before 
ischemia the hearts were adjusted to a resting 
tension of about 12 g. 
CoronaT)' flow 
Mean coronary flow was measured by collec-
tion of perfusate during rhe last min me of 
normoxia, ischemia and reperfusion. 
Assay of purines 
Adenosine, inosine, hypoxanthine, xanrhine 
and urate were assayed with a slightly modified 
version of the HPLC method described before 
[10]. A J.i.Bondapak column (30 X 0.4 em, 
\!Vaters Assoc., Milford, MA) was eluted at a 
rate of 3.0 mVmin \.,.·ith 7 5mM KHzP04, 
pH 4.5, to which methanol (30 ml/1) had been 
added. The samples were mixed with NaN3 
(0.02% final concentration) to prevent 
bacterial purine breakdown. Perfusaces were 
kept on ice until analysis, which took place 
within 12 h. 
Assay of high-energy phosphates 
In a limited number of heans, adenine 
nucleotides and creatine phosphate were 
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determined as described before [11]. Data 
from these hearts are expressed per gram dl)' 
weight. The conversion factor to wet weiglu is 
0.15 to 0.20. 
Statistical anaLysis 
Analysis of variance was employed with rwo-
way classification; further evaluations were 
made using Schcffe's method for multiple 
comparisons [32]. P > 0.05 (C\vo-tailed) was 
considered not significant (NS). Results are 
expessed as means± S.E.M. 
One experiment out of 7 (0 fLM diltiazem) 
was rejected, because during ischemia and 
reperfusion apex displacement was nil, and 
purine release was about 3 7 nmol!min/g wet 
wt. These values were completely outside the 
range observed in the other experiments. 
According to the rejection rule of Anscombe 
and Tukey [32], with a 5% premium, the 
values of the experiment mentioned earlier 
were considered gross errors and rejected. 
Results 
Coronary flow 
Diltiazem increased coronary flow in comrol 
(normoxic) hearts dose-dependently (P < 
0.001; Fig. 1). One hundred micromolar 
diltiazem augmented coronary flow about 
twofold. The change in perfusion pressure 
from 72.0 ± O.l (O 12.4 ± 0.7 mmHg caused 
mvocardial ischen1ia: coronarv flow in hearts 
w(rhout diltiazem was reduced bv 85%. FlO\'>' 
in the presence of diltiazem duri;1g ischemia 
was comparable to that without drug (see Fig. 
1). Reperfusion pressure was 72.2 ± 0.1 
mmHg. It increased flows, but they were 
somewhat lower than the nonnoxic values (P 
< 0.001, sec Fig. 1). During reperfusion 
diltiazem increased coronary flow dose-
dependently{?< 0.001). The timeofdiltiazem 
administration (before or during ischemia) 
did not affect the coronary· flow observed 
during reperfusion. 
lvfyocardiaL function 
Diltiazem caused a decrease m apex 
displacement in nonnoxic control hcans 
(P< 0.00 1; Fig. 2). Analysis of variance showed 
that hearts (rcated with the two highest 
concentrations had a significantly smaller 
apex displacement than hearts perfused with 
25 
Control 
n ~ ,:< 
'""'·~ = . F 
. 
F, 
.. 
20 
15 
10 
5 
3 0 
; Lt_'_j';..,Lh_jec_m,o_[C!!J!IJ.C···JWI• LLCT!ljJJJ".·lllil1• uOrm!cc··:.~· !lilll_lC!11lJC.· .J· :Jl' :!1' _j 
20 Reperfus10n J 
"' 
~ 
I 
15 
=, "' I 
i 
I I 
,1]1 1/ I c 
10 
5 
0 
0 0.1 10 100 
pM dlihozem 
FIGURE I. Influence of diltiazcm on coronary flow in 
isolated hearts, perfused at a pressure of 72. mmHg 
(normoxic control and reperfusion) or 12 mmHg 
(ischemia). Open bars: no dihiazem; shaded bars: 
diltiazcm administered 10 min before ischemia; lurched 
bars: diltiazem given 5 min after the induCtion of 
ischemia. Normoxic control perfusion, ischemia, and 
reperfusion took place for 15 min each. Measurements 
were made at the end of each period. Means ± s.Dl 
{n = 6 for 0 fLM diltiazem, n = 4--5 for other experiments). 
For analysis of variance, sec tcxr. 
the other concemracions. Due to ischemia, 
apex displacement in hearts \vithout the drug 
decreased from 107 ± 6 ro 27 ± 8% (P< 0.002). 
In hearts treated with diltiazem up to 10 p..M, 
we found that the ischemic values ''Tre 
comparable for the various doses, regardless 
of the application time. The higher concentra-
tions, however, depressed the hearts signifi-
cantly. Apex displacement in untreated hearts 
recovered partially during reperfusion; there 
was no significant difference with normoxic 
control hearts (Fig. 2). With 10 and 100 /LM 
diltiazem, applied before ischemia, no 
significam differences were found during 
control, ischemia and reperfusion. \Yith the 
latter concentration, regardless of the 
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FIGURE 2. Effect of di!tiazem on apex d:splacement 
of isolated perfused beans. The ,.a)ue found 5 min after 
the stan of the perfusion (before any drug was given) was 
taken as 100%. Open bars: no diltiazem; shaded bars: 
diltiazem administered l 0 min before ischemia; hatched 
bars: diltiazcm giYen 5 min after the induction of 
ischemia. For other details, see legend to fig. I. 
application time, apex displacement through-
out the experiment was virtually zero. 
The variation m apex displacement, 
observed during ischemia, was considerable. 
In a second series of experiments, \Ve used 
therefore developed tension as a measure of 
myocardial function. Ten minutes after the 
starr of the perfusion, developed tension was 
about 28 g. Five micromolar diltiazem 
decreased this by 52% (P < 0.005, upper 
panel of Fig. 3). When the flow was reduced 
by 88%, developed tension decreased rapidly; 
hearts \Vithout diltiazem became arrhvthmic 
and ceased to beat after abom 15 ~1in of 
ischemia. Hearts, pretreated \vith the drug, 
did not show arrhythmias and developed 
1.2 ± 0.2 g tension until they were freeze-
clamped (after 30 min of ischemia, see Fig. 3). 
The differences becween treated and untreated 
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FIGURE 3. DcYcloped tension and purine release in 
normoxic control heans (a), and hearts made ischemic 
after 20 min perfusion (b and c). Hearts in group C 
received 5 fJ..)el diltiazcm 10 min prior w ischernia. J\·feans 
± 5-E-M. (n = 4). 
i.sclwmic beans were nor statistically sign if!~ 
cant, huwevcr. 
Purine release 
In normoxic control hearts, diltiazcm caused 
a dose-dependent release of purine nuclco-
sides. With analvsis of variance we found a 
significant (P < O.JOO l) difference for adenosine 
and inosine production with the various 
diltiazem concentrations (Fig. 4). With 100 
J.tM this release was tvvo to three times higher 
than in the untreated hearts. Diltiazem also 
increased the release of oxypurines 
[(hypo)xanthine and urate], but V·le did not 
observe statistically significant differences. 
Figure 5 depicts total purine release. The 
beans produced somewhat more purines 
during normoxia, when diltiazem \Vas used 
(P = 0.008), but no significant dose-
dependency was found. The drug effectively 
suppressed purine release during ischemia (P 
< 0.001). 'vVe observed an almost complete 
decrease in adenosine and inosine production 
with I 00 J.LM diltiazem, administered before 
ischemia (Fig. 6). Also the release of hypo-
xamhine, xanthine and urate diminished 
\Vith the higher diltiazem doses. Total purine 
release decreased 85% with the highest dose 
of diltiazem (Fig. 5). A similar picture emerged 
with dilriazem given when ischemia had 
already been present for some time, although 
the protective effect \Vas less (P = 0.02 u. pre-
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FIGURE 4. Release of purine 
nucleosides and oxypurines from 
isolated hearts, after 5 min preper-
fusion and I 0 min of perfusion with 
diltiazem at 72 mmHg (nonnoxic 
controls). Means± s.E.M (n ""6 for 0 
JJ.M diltiazem; n = 5 for other 
experiments). 
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FIGURE 5. Effect of diltiazem on the release of 
purines (adenosine, inosine, hypoxanthine, xanthine 
and urate) from isolated perfused hearts. Open bars: no 
dihiazem; shaded bars: diltiazem administered 10 min 
before ischemia; hatched bars: diltiazem given 5 min 
after the induction of ischemia. For other details, set' 
legend to Fig. 1. 
treatment, Figs 5 and 6). Diltiazem did not 
significandy affect the release of purine 
nucleosides and oxypurines during repe;{u-
51011. 
High-energ)' phosphates 
Myocardial ATP content decreased by 56% 
{P< 0.001, Scheffe's method) due .to 30 min 
ischemia (Fig. 7). If 5 J.I.M diltiazem had been 
present before the ischemic insult, this 
decrease was only 22% (P = 0.04 v. untreated 
hearts). Due to ischemia myocardial creatine 
phosphate decreased by 66% in untreated 
heans (P < 0.001), and by 48% when treated 
with 5 JJ.M diltiazem (P < 0.00 1; NS v. 
decrease in umreated hearts). The myocardial 
energy charge, (ATP + 0.5 ADP)/(ATP + ADP 
+AMP), decreased from 0.914 ± 0.003 to 
0.778 ± 0.14 due ischemia (P < 0.001). 
Pretreatment of the ischemic hearts \Vith 5 
p.M diltiazem improved the energy charge 
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FIGURE 6. Reduction of purine nucleoside and 
oxypurine release from ischemic hearts b:-' dihiazcm. 
e~·"·· diltiazem administered 10 min before 
ischemia; 0 --- 0 diltiazem added 5 min after induc-
tion of ischemia. Means± s u1. (n ""6 forO p..~1 diltiazcm; 
11"" 5 for other experiments). Other details arc g-iven in 
d1c legend to Fig. 1. 
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FIGURE 7. Content of ATP and creatine phosphate 
(CrP) in normoxic control heans (a), ischemic hearts (b), 
and ischemic hearts, prcueatcd \<;ith 5 f.LM diltiazem (c',. 
* P < 0.005 v. (a); D..P < 0.04 v (b). For derails, see Fig. 3. 
found in ischemic heans signiflcantly to 
0.881 ± 0.007 (P < 0.001). This value is not 
significantly' different from the energy charge 
in normoxic control hearts. 
Figure 8 shows that there was a good 
negative correlation between the myocardial 
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FIGURE 8. Negative correlation between myocardial 
adenine nucleotide content (ATP + AOP +AMP) and 
release of purines (adenosine+ inosine+ hypoxanthine 
+ xanthine + urate). 0 normoxic comrol hcans; • 
hearts, made ischemic for 30 min; A ischemic beans, 
pre[rea[ed with 5 J.H! diltiazem. 
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content or adenine nuclcotides and punnc 
release. [n the ischemic samples a lo\,. 
nucleotide content was found with a high 
release of purine nucleosides and oxypurincs. 
With 5 f.LYI diltiazem the values approached 
those of normoxic controls. 
Discussion 
When, due to lack of oxygen, the myocardial 
ATP content falls rapidly, AMP is formed, 
which can be broken down to adenosine, 
tnostne, and hypoxamhinc. These com-
pounds leave rhe cell before cell death occurs. 
Thev have been used as markers for mvo-
cardial ischemia [4, 8, 9, 17, 26, JJ]. Q~ite 
often d1e sum of these purines is taken w 
calculate myocardial adenosine production 
[14, 19, 28, .31]. However, the rat heart 
produces also substantial amounts of xanthine 
and urate [2 7, JO], because it contains xanthine 
oxidase [ 18, 30]. Therefore, we decided to 
monitor the myocardial release of the 
adenosine catabofites up to urate, as an index 
of mvocardial A TP breakdown; the relation-
ship bet\veen adenine nucleotide content and 
purine release from the ischemic hean is 
clearly depicred in Figure 8. From this study it 
is clear that xanthine and urate comprise a 
substamial fraction of the purines lea\"ing the 
heart. Urate makes up 62% of the purines 
released by normoxic tissue (Fig. 4), but the 
value drops to 18% during ischemia !Fig. 6) . 
This could indicate that xanthine oxidase 
operates under saturating conditions in the 
ischemic nwocardium. 
\Nc sho\;,ed earlier [5] that nifedipine, 
administered before ischemia, could prevent 
adenine nucleotide catabolism. In a prc-
liminar:r' study [6], a relatively low dose of this 
drug applied during ischemia was without 
effecr. \Vcishaar and Bing [ J 7] were unable to 
show a protective effect of diltiazem 
(administered 5 min prior to reperfusion) on 
myocardial ATP, although the creatine 
phosphate conrem increased. In this study 
carlv administration of diltiazem dimishcd 
isch.emic ATP breakdown considerablv, but 
creatine phosphate levels remained rel~tively 
low (Fig. 7). Diltiazem protected the myo-
cardial ener6'Y charge against an ischemia-
induced decrease. In addition, we observed 
that diltiazcm decreased dose-dependently· 
myocardial purine release lllOSI cffcuivcly, 
when the drug was given before isc\H~mia 
(Figs 5 and 6). Similarly, Takeo and Takenaka 
[J4] demonstrated that the isoproterenol-
induced breakdown of high-cncrt,'")' phos-
phates \Vas prcvcmcd dose-dependently by 
diltiazem. From the nifedipinc SLudy men-
tioned above [5], \•iith somewhat different 
ischemic conditions, and the pres em clata, \VC 
estimate that nifedipine is 30 times more 
potent than dlltiazem as a protective agent. 
The increased purine production during 
normoxia due tO dihiazem (Fig. 4) is puzzling. 
Diltiazem does not affect normal functioning 
mitochondria [20]. We would have expected 
the ATP-gencrative capacity to be adequate, 
especially if one considers the decreased 
mvocardial function. Possiblv, vasodilatation 
is "responsible for increased"' washout of the 
purines. In view of the fact that the higher 
diltiazem doses exceed those observed in 
human plasma [ 16], one 1night take the 
posture that the enhanced release of ATP 
metabolites during normoxia represents in 
part a non-therapeutic or toxic effect. 
The vasodilarory and negative inotropic 
properties of diltiazem, given to normoxic 
hearts, are clear from Figures 1 ro 3. These 
have been well-established by other studies 
[ 15,21, 29]. We found no corr~lation be(ween 
tnyoca.rdial function and purine production 
during ischelllia (sec, for instance, Fig. 3:1, so 
that it seems doubtful that the ATP-sparing-
c!Tecr of diltiazcnl, administered before 
ischemia, is due to a reduction in contractllitv. 
In anesthetized dog-s, dilitiazem nor nifcct"i-
pinc depressed ;ncchanical acrtvllv of 
ischemic hean; thev in fao signifi~antly 
enhanced its pcrfon;uncc [25]. Henry and 
\,Yah! [ 1 J] recently demonstrated that 
diltiazem acts dircctlv on cardiac muscle in 
the absence of rh~rthmic electrical and 
mechanical activltv. v\re conclude, like we did 
from earlier srudi~s \\'ith nifedipinc alone [5, 
6], or nifedipinc plus propranolol [ 12], that 
diltiazem presumably docs not protect by 
neganve tnotropy during myocardial 
ischemia. \Vc speculate that calcium 
antagonists reduce myocardial oxygen 
demand, thereby diminishing the effcet of 
flow impairment. 
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APPENDIX PAPER 8 
Enhanced ATP and GTP synthesis from hypoxanthine 
or inosine after myocardial ischemia 
EEF HARMSEN, PETER P. DE TOMBE, JAN WILLEM DE JONG, 
AND PETER W. ACHTERBERG 
Cardiochemical Laboratory (Thoraxcenter), Erasmus University, 3000 DR Rotterdam, The IV'etherlands 
HARMSEN, EEF, PETER P. DE TOMBE, .]At\' WILLE~ DE 
JONG, AND PETER \V. ACHTERBERG. Enhanced ATP and GTP 
synthesi~ from hypoxanthine or inosine after myocardial ~, .. 
chemia. Am. J. Physiol. 246 (Heart Circ. Physiol. 15): H37-
H4.3. 1984.-Increasing therapeutic use is made of purines for 
the treatment of ischemic heart disease, but little is known 
about regulatory mechanisms involved. Therefore we perfused 
isolated rat hearts with 0.02 mmol/l [8-"C]hy1)oxanthine or 
inosine. Under normoxic conditions about l% is taken up b) 
the heart and partially used for synthesis of ATP and GTP at 
a rate of 0.4 and 0.1 nmol- min-' -g dry we', respectively. After 
relatively mild ischemia (coronary How reduction of 70% for 20 
min), no increase in myocardial purine uptake i.s observed, but 
ATP and GTP synthesis rates are doubled (P < 0.001). D-
Ribose stimulates the hypoxanthine incorporation rate in nor-
moxie perfused rat hearts to 1.1 and 0.5 nmol- min __ , -g dry wt- 1 
for ATP and GTP, respectively, which is further increased 
duringpostischemic perfusion. About 80% of the [8-'·'C]inosine 
or [8-"C]hypoxanthine passes through the heart unchanged, 
while 15% is converted to (hypo)xanthine and uric acid. We 
conclude from these experiments that inosine and hypoxan-
thine incorporation into ATP and GTP is at least partly 
regulated by the availability of 5-phosphoribosyl-1-pyrophos-
phate. 
nucleotide biosynthesis; salvage; oxypurine; nucleoside; ribose; 
heart; rat 
IN THE AEROBIC HEART a critical balance exists between 
production of ATP and its utilization. If the heart be-
comes ischemic, this delicate balance is disturbed, and 
energy-rich phosphates are broken down to the nucleo-
sides and purine bases adenosine, inosine, hypoxanthine, 
xanthine, and uric acid. These apolar compounds can 
pass the cellular membrane and enter the bloodstream 
(2, 9). Because of this loss of purines, ATP levels will 
remain below control levels after reoxygenation (see, e.g., 
Ref. 18). To restore these adenine nucleotide pools three 
main pathways exist (Fig. 1}. I) In adenosine phospho-
rylation, adenosine is directly phosphorylated to AMP 
by adenosine kinase. The maximal incorporation rate in 
rat heart amounts to about 50 nmol-min- 1 -g dry wt- 1 
(16). This pathway is energetically economical. However, 
the adenosine concentration in blood is low, and this 
could be a restricting factor for adenosine phosphoryla-
tion. 2) In hypoxanthine salvage, hypoxanthine can be 
phosphorylated with 5-phosphoribosyl-1-pyrophosphate 
(PRPP) to form IMP (5, 12, 14, 22). IMP is a crucial 
0363-6135/84 $1.50 Copyright-:~: 1984 the American Physiological Society 
branching point between adenine and guanine nucleotide 
synthesis. In rat heart the hypoxanthine incorporation 
rate into ATP can amount to 3 nmol-min- 1-g dry wei 
(14) . .3) In de novo synthesis, purine nucleotides (adenine 
and guanine nucleotides) are also synthesized from small 
precursor molecules (among others, glycine, CO~l- In a 
10-step synthesis from PRPP, IMP is formed. De novo 
production rate of IMP in rat heart is about 0.1 nmol-
min-1-g- dry wt- 1 (24). This process is stimulated after 
anoxia, ischemia. and hypertrophy. As an explanation 
for this phenomenon. an enhanced synthesis of PRPP 
by acceleration of the hexose-monophosphate shunt has 
been proposed (24}. To bypass this shunt, ribose (a 
precursor of PRPP) can also be supplied (25). 
We decided to study the incorporation of [8- 1-1C]hy-
poxanthine into normoxic or postischemic rat hearts in 
the presence of o-ribose to investigate whether hypoxan-
thine incorporation is also PRPP dependent. Because 
inosine, a precursor of hypoxanthine, is used as a cardi-
oprotective and vasodilatory agent (4, 10, 11, 21, 231, [8-
1'1C]inosine incorporation rates in aerobic and postische-
mic rat hearts were also determined. :'vfammalian cells 
lack inosine kinase (22}; therefore inosine is converted 
to hypoxanthine and ribose-1-phosphate. Subsequently, 
part of the hypoxanthine is converted to IMP: ribose-1-
phosphate can serve as a precursor of PRPP. 
Hypoxanthine and inosine are incorporated not only 
into adenine nucleotides but also into guanine nucleo-
tides. To our knowledge no data about purine incorpo-
ration into myocardial guanine nucleotides have been 
published, although Swain et al. (20) recently im.-·esti-
gated the incorporation of 5-aminoimidazol-4-carbox-
amide riboside (AI CAR, an intermediate of the de novo 
pathway) in dog heart and found repletion of ATP and 
GTP levels. 
MATERIALS AND METHODS 
Perfusion protocol. Male Wist.ar rats [31.5 ± 34 (SO} 
g] were used. Hearts were removed and perfused as 
described earlier (3). The basic perfusion buffer (pH 7.4) 
consisted of (in mM) NaCl 125, KCl 4.7, CaCL 1.35, 
NaHC0,1 20, NaHzP0.1 0.4, MgCl~ LO, and o-glucose 10 
and was equilibrated with 35% 0~-5% C02• The perfusion 
pressure was 72 mmHg, mear.ured with a Statham pres-
sure transducer (model P2306, Gould, Oxnard, CA}. The 
hearts were paced at 300 beats/min, and the temperature 
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fiG. 1. Bio5ynthesis of ATP and GTP. PaOway I. adenosine phos-
phorylation; pathway 2, hypoxanthine salvage; p(nhway ,'3, de novo 
8ynthesis. ADA, adenosine deaminase IEC :J.5.4.4J; ADO, adenosine: 
AK, adenosine kinase (EC 2.7.1.20), A:vfPS. adenylosuccinate: HPRT. 
was 37.0 ± 0.5'C. 
The hearts were equilibrated with the buffer for 20 
min (period 1: aerobic perfusion). Then global ischemia 
was induced with a roller pump at a fixed f1ow of 2.5 mlj 
min (flow reduction by 65-73%-) for 20 min (period 2: 
ischemia), followed by 5 min of reperfusion (period 3: 
reactive hyperemia}. Hereafter perfusion took place for 
an additional 15 min (period 4: reperfusion) with 0.02 
mM [8) 4 C]hypoxanthine, 0.02 mM [8- 1 ~C]inosine, or 
0.02 mM [8- 14 C]hypoxanthine + 0.5 mM ribose (all dis-
solved in the perfusion fluid, radioactivity 5 ,..Ci/1). After 
period 4, hearts were perfused with basic perfusion me-
dium for 1 min to wash out the labeled substrates from 
the blood vessels. In the control group no ischemia was 
induced during period 2. 
Chemicals. All chemicals were analytic grade. Water 
was purified with the Milli-Ro4/Milli-Q system (Milli-
pore, Bedford, MA). [8- 14 C]hypoxanthine and [S.l-1C] 
inosine were supplied by Radiochemical Centre (Amer-
sham, Bucks., UK; sp act 50-60 Cijmol, diluted to 0.25 
Cijmol before use). 
Analytic methods. Samples were collected and stored 
on ice until analysis. No changes in purine composition 
of the perfusates were seen within the storage period, 
which was 12 hat the most. Adenosine(catabolites} Were 
assayed by a slightly modified version of the high-per-
formance liquid chromatography (HPLC) method de-
scribed by Harmsen eta!. (6). A 1-<Bondapak C1s column 
(Waters Associates, Milford, MA) was eluted at a flow 
rate of 3.0 mljmin with 15 mM KH2P04, pH 4.50, to 
which methanol (30 ml/1} had been added. Two hundred 
microliters of the coronary effluent were injected on the 
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hypoxnnthine phosphoribo~yhransfera~e me :2.4.~.8): [1\'0, inooine: 
1\"P. purine-nucleo~ide phosphorylase (EC ~.4.2. 1 J: PP,. pyrophnsphate: 
PRPP. phoHphoribosyl pyrophosphn1e: UA. uric acid: XAK. xanthine: 
X:V1P. xanthine-,']' -monopho~phate: XO. x<lnthine Gxidnse iEC 1.~.:1.21. 
system. Peaks were integrated (Varian CDS-111. Varian, 
Palo Alto, CAl and compared with standards. From 
radioactive samples the various HPLC peaks were col-
lected. Ten milliliters of Instagel (Packard Instruments. 
Downers Grove, IL) were added, and radioactivity was 
determined with a Packard Tricarb 26.50 liquid scintil-
lation counter. 
The perfusion experiment was terminated by freeze 
clamping the heart between two aluminum blocks pre-
cooled in liquid N~ (-190'C}. After being weighed, the 
heart was ground in a mortar, and about 0 .. 5 g was mixed 
with :3.0 ml 0.8 N HCIO., at -190'C. The other half was 
freeze dried to determine dry weight. The acid homoge-
nate was thawed and centrifuged at 4 'C. Two milliliters 
of the supernatant fluid were neutralized with about 200 
pl 6 N KOH. After centrifugation, 2.0 1-<l of the superna-
tant t1uid were used for the determination of nucleotides 
and creatine phosphate with HPLC according to Harm-
sen et al. (8). 
To determine 1'1C radioactivity in the ATP and GTP 
fractions, a fast, !socratic HPLC separation was devel-
oped. A Partisil-10-SAX column (Whatman, Maidstone, 
CK) was eluted at 3.0 ml/min with 0.42 l\1 KH2P04, pH 
4.20. One milliliter of neutralized heart extract was in-
jected. Fractions were collected and counted (Fig. 2}. In 
addition 50 ,..1 of this extract were counted to determine 
total 1·'C-radioactivity uptake in the heart. Values were 
corrected for blanks. He-counting efficiency was 85-90%. 
Coronary flow measurements. Mean coronary flow was 
measured by timed collection of perfusate in the periods 
described above. 
Statistical analysi~. For statistical evaluation, analysis 
2 
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Fu;_ 2 !socratic HPLC ~eparation oi' ATP and UTI' One milliliter 
ol- neutralized h~an extract wa~ in.iected on a Parti~il·S '\X column and 
elmed w1th a !1ow nl" :LO ml/min with 0.4~ m:>.1 KH,PO.,, pH 4.ZO 
of variance \vas used (2-way classification}: further com-
parisons \Vere made using Scheff&'s method for multiple 
comparisons (19). \Vhen only two means were compared, 
Student's unpaired t test was used. P > 0.0.5 was consid-
ered not significant INS). Results are given as means± 
SE. Three treatments {hy1Joxanthine, inosine, or h~'PO­
xanthine + ribose) were tested during two conditions 
(normoxia or reperfusion). Analysis of variance revealed 
that one experiment (hypoxanthine + ribose during nor-
mexia), in which the ATP and GTP biosynthesis rates 
were 4.43 and 0.83 nmol- min- 1 . g dry we 1 , respectively, 
contributed the major part of variance. The means± SD 
for all experiments (n = 26) were 1.06 ± 0.71 and 0.31 ± 
0.11 nmol- min- 1 • g dry we 1, respectively. According to 
the rejection rule of Anscombe and Tukey (see Ref. 19) 
with a premium of 5SL. the values of the experiment 
mentioned earlier were considered as gross errors and 
rejected. The recalculated biosynthesis rates for ATP 
and GTP for all experiments were 0.92 ± 0.19 and 0.29 
± 0.06 nmol- min- 1 • g dry wC 1, respectively (n = 25). 
RESCLTS 
In Fig. 3 mean coronary flows during the various 
periods are presented. During period 2, flow was re-
stricted to 13 ml-min-:.g dry wt-: (f1ow reduction of 
80%, P < 0.001 vs. control). In the first Ei min of reper-
fusion the average f1ow increased to above control level 
(levelS, reactive hyperemia; P < 0.001 vs. control), but 
in period 4 11ows in control and postischemic hearts were 
comparable. In preliminary experiments we investigated 
the time dependency of hy-poxanthine and inosine release 
during and after myocardial ischemia (Fig. 4). After 
induction of ischemia, inosine and hypox.9.nthine ap-
peared in the coronary eff1uent. However, within the first 
.')min of reperfusion (reactive hy-peremia, period 3) ino-
sine and hypoxanthine returned to control levels (<0.1 
,ul'vl). 
Total normoxic purine release (i.e., adenosine. inosine, 
hypoxanthine, xanthine, and uric acid) was about 20 
nmol-min- 1 -g dry we 1 {Fig. -5: period 2, control). This 
purine release was increased about six times during is-
chemia (P < 0.001 vs. control) and nine times during 
reactive hyperemia (P < 0.001 vs. control). During nor-
moxie perfusion 640:>.; of the purines released consisted of 
uric acid. but during ischemia this percentage fell to 28'ic. 
The percentages of the other purine compounds in the 
perfusate collected during normoxia were (with ischemic 
values in parentheses) adenosine 5 (11). inosine 17 (38), 
hypoxanthine 8 (1:3), and xanthine .S (9), respectively. 
8 CONTROL ISCHEMIA/ 
REPERFUSION 
WO 
period 1 perood 2 period 3 perood4 
F](;. :J. Coronary !low of normoxic and ischemic hearts, retrogradely 
perfused with a modified Tyrode solution, gassed with 95% 0,-5% CO,. 
at a perfusion pressure of i2 mmHg and a heart rate of .100 beats/mm. 
Ischemia was introduced with a roller pump at a fixed flow of 2.5 mlf 
min. /'eriod /,aerobic perfusion (0~20 min): period 2. ischemic period 
(20-40 mini: period 3. reactive hyperemia (40-4.~ min); and period 4, 
reperfusion (45-60 mini. In control hearts no flow reduction was used. 
Values are means± SE In= 4-6) . .t.. P < 0.001 vs. control It statistics). 
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FH .. !i. Tow! purine rele:~~e (adenosine+ ino~ine +hypoxanthine 
+ xantiline + uril' add) fmm i;;olated rat heart~. fJenod., 1-.'J ar<:• 
d\'l'med in legend of' Fig. :1. Values are mean~± SE In= 4 Gr . .A,!'< 
O.(llll v~- control it statistic~) 
In Table 1. the biosynthesis of ATP and GTP from 
O.OZ mM hypoxanthine or inosine is presented. Analysis 
of variance for hypoxamhine and inosine incorporation 
rates in the ATP fraction showed no significant inter-
action (P = 0.65) between the conditions normoxia and 
reperfusion on the one hand and the three treatments 
(infusion of hypoxanthine, of hypoxanthine + ribose, 
and of inosine) on the other hand. Thus the pattern for 
the three treatments was similar for normoxia compared 
with reperfusion. Incorporation rates during reperfm:ion 
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TABLE l. Uptake and incurporation rates of 
hypoxanthine and inosine 
~~-C--~~C .. ~~~ 
Addn""' ATP I.TP 
---·--~~-
!\/c,rm'JXIQ 
H\puxanthtne ti4 ± 1:2 11011''(1 liA ± 0.9 18'-;1 :2.0 ± 0.4 
H)p>Xdnthin~ fl:i ± ~~ illlO''c I lfi_(l::: Ll (lWc J i'i.:l:!: 0.4 
+ riiHJ>e 
ln<hine l 07 ± S I lOll'( I 7.:1 ± Ll (';'<:-;I :2.9 ± 0.4 (:J"·iol 
Hypoxanthin~ 
H\poxdtllh'tnf 
+ riho"e 
lnc,sine 
Rrpcr[u,,iun 
~H> ± 7 tlOil'il l-Ui± o .. s 05':;_J :J.9 = o.:J 1--1""1 
>n ± 1--1 11011':;, :2:2.:1 ± u 1'26':CJ 1:2 ± o:; t9<:-d 
\'alu~~ are mf'Uns ± SE in nnwl-1.5 min·· ·r: dry wt Ill- :l-61 
Fig-uru., Ill p"rentheses ar~ percent~ ol' total ''C-radiolabeluptake by 
ti>"~ue_ [8-''l'[hypoxanthine or [S-''C[inosine conversiiJn to ATP and 
(;TP cmd li)Jtclke oi' radioactivity were determined in o.cid extract~ oJ 
lr~fze-clamped heart>'. For ~tatistical analysis, ~ee text. 
were significantly (P < 0.0001) increased compared with 
the normoxic controls. Comparison of the three treat-
ments proved them to be statistically different (P < 
0.0001). In addition. by Scheff&'s method of multiple 
comparison the incorporation rates in the group treated 
with hypoxanthine + ribose were found to be different 
from the groups treated with hypoxanthine or inosine, 
the latter two not being different. Also the GTP incor-
poration rates showed no significant interaction (P = 
0.91) between normoxia/reperfUsion and the three treat-
ments. The significant differences paralleled those of the 
ATP incorporation rates. 
Besides incorporation into nucleotides, the other met-
TABLE 2. Metabolic fate of /8- 1 -1C}hypoxanthine 
and [8- 14 C}inosine 
Addnion 
Percer>t or Label infused 
"Mc,-,-"c,-,-o-,-"'-' 
dial up· 
take 
----······-·--·····---· 
lVCirmoxia 
Hypoxanthine 09 S2.7 G.!) 
±0.2 ±0.7 ±0.:2 
Hypoxanthine 0.9 0 .. ~ s:J.s .S.7 
+ribose ±0.1 :t:0.2 ±2.9 ;:;0.8 
lm>Ain~ 1.4 51.1 :3.8 :u 
:t:0.1 ±2.9 ±0.2 ±0.2 
Repcrfu.,iun 
Hypoxanthine 0.8 0.2 s:u 6.1 
±0.1 ±0.1 ±0.6 ±0.2 
Hypoxanthine 0.9 o .. ) s:J.2 7.0 
+ riho8e ±0.1 ±0.:2 ±2.:2 ±1.1 
Ino~ine 1..) 0 82.4 :J.R 2.4 
+0.1 +1.4 +0.2 ±0.2 
2.1 
±O.(i 
4.5 
±0.4 
7.:.1 
:<;0.1 
2.6 
±O .. S 
4.1 
±0.2 
1.1 
±0.1 
Valu~s {means± SEJ represem radioartivity recoYered in various 
high-pressure liquid chromatography fractions of perfusate. L"ptake is 
ralculared from '''C-radiolabel measured in extracb of freeze-clamped 
hearts. Data are expre~'ed ao percent of [8-''C]h~-poxanthine or [1\-
"C]inosine offered to heart., (n = 4-6). For statistical analyoi,, ~eP 
text. 
abolic fate of inosine and hypoxanthine \Vas conversion 
to xanthine and uric acid. V..-'e determined [8- 11 C]inosine 
or hypoxanthine conversion in the coronary effluent 
(Table 2). About 80% of both purines passed the heart 
unchanged and 10-15% were metabolized during a single 
passage through the coronary vasculature. About 0.8% 
of hy-poxanthine was taken up by the heart, whether or 
not ribose was added. On the other hand, [8- 1-1C]inosine 
uptake was about 1.5%, which is twice the hypoxanthine 
uptake (P < 0.001). Incorporation rates were comparable 
for hypoxanthine and inosine. During reperfusion. the 
uptake figures for these purines were comparable to the 
control values. In the statistical analysis of the uric acid 
data neither the interaction nor the reperfusion versus 
normoxic data were statistically significant (P = 0.16; P 
= 0.60, respectively). The three treatments, however, 
were significantly different (P < 0.0001): by Schefte's 
method of multiple comparison a significant difference 
(P < 0.001) existed between the group treated with 
inosine and the groups perfused with hypoxanthine in 
the presence or absence of ribose. Furthermore, perfusion 
with a mixture of ribose and hypoxanthine increased the 
uric acid release significantly (P < 0.0-5) compared with 
hypoxanthine infusion. 
Table 3 shows the data on energy-rich phosphates 
determined in freeze-clamped hearts. During ischemia, 
total adenine nucleotides (TAN), ATP, and creatine 
phosphate (CrP) fell (20, :30, and 50%, respectively). 
Two-way analysis of variance showed a borderline sig-
nificant interaction between normoxic and reperfused 
hearts with respect to TAN (P = 0.13) and ATP (P = 
0.06), i.e., the" decrease ofT A:t\ and ATP due to ischemia 
and reperfusion disappeared when 0.02 mM inosine was 
added to the reperfusion buffer. CrP during reperfusion 
showed an overshoot in all groups studied (P < 0.001. 
interaction 0.71). 
DISCUSSION 
Theoreticallv nucleotide synthesis rates from radiola-
beled purines s-hould be calc~lated on the basis of specd'ic 
activity of the intracellular purine compounds. However. 
we were unable to measure intracellular hypoxanthine 
and inosine concentrations. To overcome this problem. 
we assumed that the hypoxanthine and inosine concen-
trations in the heart cell were ref1ected by the concentra-
tions in the coronary effluent. As is shown in Fig. 4, S 
min after ischemia inosine and hypoxanthine concentra-
tions returned to normal values (<0.1 1-l:Yi). Therefore we 
concluded that within 5 min after ischemia, inosir.e and 
hypoxanthine concentrations in the heart cell had also 
returned to control values. which are low in heart (<1 
1-l:\1. see, e.g., Ref. 20). To minimize isotopic dilution. 
0.02 m:\1 [8-HC]hypoxanthine or -inosine were used. 
Hypoxanthine and inosine incorporation rates were 
about 0.4 nmol-min- 1 -g dry wC 1 into the ATP and 0.1 
into the GTP pool (8 and 2% of the t'C radioactivity 
accumulated in the heart, respectively; see Table I). In 
earlier experiments we showed that about 7:)% of [U-
' 
1Cjinosine (also labeled in the ribose ring) recovered in 
nucleotides was incorporated into the combined ATP 
and GTP pool both in normoxic and in reperfused hearts 
(7). Therefore we estimated that the total hypoxanthine 
and inosine incorporation into adenine and 1-.'lJanine nu-
cleotide;; amounts to about 0.7 nmol- min- 1 • g dry we 1 
during aerobic perfusion. After ischemia a twofold in-
crease in the incorporation rates of these purines into 
ATP and GTP i~ seen. The total amount of raciioactivitv 
taken up bv the heart is not changed, however. Thus th-e 
percentage. of hypoxanthine and inosine in heart, con-
TABLE :). CuncPntration.\' of high-mcrg\' phosphates 
"' 
freezp-c/amped cat hrarts 
·--------· ·-------· 
.'1ddi1wn TA:--.' AT!' All I' AJ\·11' (~TP CrP 
------
1Vurmuxi(l 
:-J<>ne ~IU :2:'..9 4-'~ IJ.:"i IHl ~7 .. 'i 
±l.O ±U ±o.:; ±0.2 ±0.1 ±2.:-\ 
H:-:pnxanlilin~ 21.-± 2:'..1 4.9 o.:J 1.0 :_l:LO 
±I. I ±1.2 ::c:O.G ±0.1 ±0.:1 ;:;2_(i 
H_vpoxanthin~ 2S.Ii 22.9 5.:1 0.:0 0.9 'lfl.l 
+ riho~~ ±J.G ±1.:1 ::c:0.4 ±0.1 ±0.1 :t::l.8 
lnosin€ 2().:1 2l.l 4.6 0.1 0.9 :22.:1 
±:!..1 ±l.fi ±0.6 ±0.2 ±0.1 ±UJ 
hchcmia 
I'\ on~ :2~.0 JG.fl ~-S u ll.7 1:U 
±2.1 ±2.6 ±1.1 ±O.G ±0.2 ±l.O 
Rcpafuswn 
None 2U li.G :1.4 0.5 0.7 44.9 
±J.:J ;:;1.2 ±O.:l ;:;0_2 ±0.:2 ±7.:) 
Hypoxamh'tn~ :!,',).~ l9.G :1.8 o.:; 0.8 44.:) 
±l.ll ±1.0 ±0.1 ±0.1 ±ll.l ±:1.7 
Hypoxanthine 24.!i 19 .. ~ 4.!'i ll . .'J 0.7 44.1 
+ ribose ±~.0 ±2.1 ±O.:l ±0.1 ;:;0.1 ±!J.2 
!nooine 26.7 22.:1 4.0 0.-1 11.9 :JI.S 
±1.2 ±0.9 +().:'. ±0.1 :::0.1 ±!.7 
Values ar~ meam ::': ::lE In "':1-6) in f1mol/g dry wt. Hearb were 
perfused as described in legend to Fig. :J. Ischemia refers to hean~ 
preperfused for 20 min. with an additional 20 min of i'chcmia For 
statistical anal_v~is. see text. TA:\1, total adenine nucleotides. 
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verted to ATP and GTP. is increased. The rest of the 
1
'
1C label is found in the fraction containing the nucleo· 
sides and oxypurines (see Ref. 8). We have not measured 
myocardial nucleosides and oxypurines, but we assume 
that more than SO% of the myocardial purine fraction 
consists of hypoxanthine (during hypoxanthine infusion) 
or inosine (during inosine in;Usion), as ref1ected by the 
perfusate concentration (see Table 2). If hypoxanthine 
and inosine were evenly distributed over the myocardial 
cells and extracellular space, intracellular hypoxanthine 
or inosine concentrations are estimated to be minimally 
15 1-1M. These concentrations are in the same order of 
magnitude as found in the perfusate. Therefore ATP and 
GTP biosynthesis is not limited by purine transport but 
is regulated intracellularly. According to Zimmer et a!. 
(24), the NADP-to-NADPH ratio decreases during and 
after ischemia, and the hexose·monophosphate shunt is 
accelerated. As a result of this process, ribose-S-phos-
phate levels are increased. which in turn increases the 
PRPP concentration. Because hypoxanthine phospho-
r):iation is PRP P dependent, this could give a reasonable 
explanation for increased salvage rates after ischemia. It 
is possible t.o bypass the hexose-monophosphate shunt 
by supplying ribose as a precursor for PRPP (2S). Indeed 
after ribose infusion, a significant increase in salvage 
rates is seen, which is further enhanced after ischemia. 
Namm (14) found that during normoxic perfusion 0.01 
m:VI inosine or hypoxanthine is incorporated into iso-
lated rat hearts at a rate of about 3 nmo\-min- 1 -g dry 
wC 1• Csing myocardial homogenates of the same species. 
Maguire et al. (1:3) measured hypoxanthine phosphori-
bosyltransferase (HPRT) activities with a maximal ini-
tial velocity (V,n,,l of about .. lQ 1-1mol-min- 1 -g dry wC 1• 
This is about 10,000 times higher than the salvage rates 
reported by Namm (14) or found in our experiments. 
Although an in vitro enzyme activity measurement can 
hardly be compared with in vivo activity. it seems that 
the hypoxanthine incorporation is not limited by the 
potentially available HPRT activity. Raivio et al. (15) 
have found a striking correlation between PRPP synthe-
sis and cellular phosphate concentration in human fibro-
blasts. ::vlyocardial PRPP synthesis could be regulated 
by phosphate concentration as well 
During hypoxanthine perfusion (with or without ri" 
bose) after ischemia, a slight C..JS) increase of TAN is 
seen. During posti.schemic inosine infusion, however, 
TAN and ATP are about 5 Mmoljg dry wt higher. ATP 
biosynthesis from [8-HC]inosine during reperfUsion is 
Ll nmol-min- 1 -g dry wC 1 (Table l), so TAt\ synthesis 
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will be about L'S. This i,; insufficient by far to account 
for the ob~erved total restoration. There are two other 
known pathways that could account for ATP biosyn-
thesis, namely t~denosine phosphorylation and de novo 
synthesis. Adenosine phosphorylation accounts maxi-
mally for .so nmol·min- 1 -g dry 'Wr 1 (14, 16). However, 
the adenosine concentration in the perfusate at the end 
of the ischemic period is about 1.2 pmol/1 and is lowered 
within ."i min of reperfusion to 0.04 >'mol/!. Therefore, 
under these experimental conditions, adenosine phos-
phorylation will be low because of lack of substrate. De 
novo synthesis in isolated rat hearts is 0.1 nmol- min- 1 • 
g dry wC 1 (2:3). This synthesis rate is PRPP dependent 
and is accelerated after ischemia. Whether de novo syn-
thesis is stimulated by inosine is unknown at this mo-
ment, but it seems unrealistic to assume that the resto-
ration of TAl\' and ATP is due to de novo synthesis. 
Bates et al. (1) postulated the existence of a pool of 
nonacid-extractable ATP, which under certain condi-
tions can be converted to acid-extractable ATP. It re-
mains to be seen whether this explanation is applicable 
w our results. 
During reperfusion an overshoot of creatine phosphate 
is seen (Table :3). In the model of Saks et al. (17) CrP 
serves as an "energy· carrier" from mitochondria to sites 
of utilization. In this scheme it is possible for the mito-
chondria to start producing energy' after mild ischemia, 
without direct utilization. For that reason, no CrP over-
shoot would be expected after severe ischemia, when the 
mitochondria are damaged (see Ref. 18). 
To our knowledge, this i~ the first report describing 
purine incorporation into the myocardial GTP pool, al-
though Swain et al. (20) recently reported restoration of 
GTP levels by de nO\'O synthesis in dog heart. It is 
interesting to see that the purine incorporation rate into 
GTP is about :25% of that of ATP, although the GTP 
content in heart is onlv about .5% of the ATP content. 
This indicates a faster ~ecoverv of GTP after ischemia. 
Our final conclusions are th-at hypoxanthine and ino-
sine are incorporated in botb the ATP and GTP pool in 
the heart. Tbis process is stimulated after ischemia and 
by ribose perfusion and is thereby dependent on myocar-
dial PRPP concentrations. Inosine especially seems to 
restore ATP levels, and this could (partly) explain its 
beneficial action. 
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